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ABSTRACT 
The use of core antigen (HBcAg) of hepatitis B virus (HBV) to present peptide 
epitopes to the immune system has been shown to enhance immunogenicity of the 
peptide epitopes. HBcAg fused to the first 8 amino acid residues of -galactosidase 
was exploited to serve as a carrier protein to present the epitopes from the S, preS 1 
and preS2 regions of HBV at its truncated C-terminus. The emergence of an HBV 
escape mutant carrying an amino acid substitution from glycine to arginine at amino 
acid residue 145 of the S domain suggests that it may be necessary to modify future 
HBV vaccines. The immunodominant region of HBsAg carrying mutant sequence at 
amino acid residue 145 was also fused to HBcAg. These HBcAg fusion proteins were 
expressed in E. coli and produced in high yields, and assembled into core-like 
particles morphologically indistinguishable from HBcAg itself. The largest multiple 
fusion protein, containing a dimer of the HBs (llll5 sequence as well as sequences 
from preS 1 and preS2 regions carried a total of 165 amino acid residues attached to the 
C-terminus of truncated HBcAg, and could still be accommodated in core-like 
particles. 
The HBcAg fusion proteins displayed similar HBc antigenicity and immunogenicity 
to the full-length HBcAg. Immunisation of rabbits with the HBcAg fusion proteins 
elicited T-cell-proliferative responses to HBcAg, HBsAg and preS 1 peptides. The T-
cell responses to HBcAg were much higher and more consistent than those to HBsAg 
or preS 1 peptide. The HBcAg fusion proteins induced antibodies against the 
corresponding peptides. The fusions carrying the immunodominant region of HBsAg, 
either wild-type or 91y 145 mutant with arginine, glutamic acid or lysine substitution, 
showed HBs antigenicity in the immunoblot analysis and the antigen-capture sandwich 
radioimmunoassay, albeit at a lesser extent, using two antibodies with different 
specificity. Furthermore, they elicited anti-HBs responses cross-reactive with wild-
type HBsAg. The addition of preS 1 and preS2 epitopes to the fusions carrying the S 
epitopes enhanced anti-HBs production. The ability of HBcAg to induce a strong 
HBcAg-specific T-cell response in the context of multimeric B-cell epitopes may 
xi 
explain the carrier effects of HBcAg particles. The results indicate the potential value 
of these HBcAg fusion proteins as vaccines against wild-type HBV and its variants. 
xl' 
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CHAPTER 1: INTRODUCTION 
1.1 	General 
The discovery of Australia antigen in human serum by Blumberg et aL (1965) and the 
subsequent demonstration of the association of Australia antigen with hepatitis B led 
to the identification and characterisation of hepatitis B virus (HBV) (Dane et al., 
1970). HBV was thought to be a unique virus different from viruses of other families 
until 1978, when Summers et aL (1978) found a similar virus which caused 
hepatocellular carcinoma (HCC) accompanied by a particular form of hepatitis with 
degenerative and regenerative changes in woodchucks. Now Hepadnaviridae include 
HBV and the hepatitis viruses of the woodchuck (WHV), ground squirrel (GSV) 
(Marion et al., 1980), tree squirrel (TSHV) (Feitelson et al., 1986), Peking duck 
(DHBV) (Mason et al., 1980), and heron (HHBV) (Sprengel et al., 1988). Less well 
documented findings in other rodents, marsupials, and cats suggest that other 
hepadnaviruses may have been detected. The host range of Hepadnaviridae is narrow, 
in fact strikingly species-specific. HBV appears to infect only humans in nature. 
However, productive infections have been established experimentally in higher 
primates. Hepadnaviridae also exhibit tropism for hepatocytes although viral DNA 
sequences have been detected in small quantity in cells other than hepatocytes, such 
as peripheral blood leukocytes (Laure et al., 1985) and bone marrow (Elfassi et aL, 
1984). They share similar virion size and ultrastructure, antigenic structure, and 
molecular as well as biological features (reviewed by Ganem and Varmus, 1987). 
Their unique features include an unusual genome structure and mechanism of viral 
DNA replication which involves reverse transcription. 
1.2 	Clinical aspects of HBV infection 
Hepatitis B is a common disease representing a major worldwide health problem, 
which is especially serious in Southeast Asia and Africa. The infection may lead to 
a chronic carrier state and may progress to chronic liver disease including HCC, a 
major cause of death from cancer throughout the world. Perinatal spread from an 
infected mother to her offspring represents the most important mechanism for 
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maintenance of HBV carriers in endemic areas of the world. Parenteral transmission 
is one of the principal modes of spread of hepatitis B in non-endemic areas. The 
sources include blood, blood products and contaminated needles and other instruments. 
Since HBV surface antigen (HBsAg) can be detected in almost every body fluid, such 
as saliva, tears, seminal fluid, vaginal secretions and breast milk, in HBV-infected 
individuals, contact-associated transmission may occur. 
1.2.1 Acute and chronic hepatitis 
The course of HBV infection varies widely in different individuals, which depends on 
the host immune response, rather than on the virus itself, since HBV is not cytopathic 
to the hepatocytes. In addition to the inapparent or subclinical infections, patients may 
develop anicteric or icteric hepatitis. Patients may recover completely, progress to 
chronic hepatitis, or, in very rare cases, develop fulminant hepatitis, in which massive 
sections of the liver are destroyed and is often fatal. Acute infection in adults is 
usually self-limited, but 5-10% of infected individuals become carriers (i.e. chronically 
infected). The carriers are identified by the persistence of HBsAg and anti-HBc for 
at least 6 months. The carrier state is more likely to be established following 
childhood infection. The HBsAg carriers may be divided into two groups. Those that 
are HBeAg and virion positive have been shown to be highly contagious. Those that 
are HBeAg and virion negative and anti-HBe positive have low infectivity. Chronic 
infection can be associated with nearly normal liver function, or may lead to the 
development of chronic persistent hepatitis (CPH), chronic active hepatitis (CAH), 
cirrhosis and HCC. 
1.2.2 Hepatocellular carcinoma 
Several lines of evidence support the connection between chronic HBV infection and 
HCC. 1) The epidemiologic evidence is the geographical coincidence between a high 
prevalence of HBV infection and a high incidence of HCC. Geographic areas with 
the highest incidence of HCC are also areas where HBV infection is common and 
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where persistent HBV infections occur at the highest frequency. 2) The incidence of 
HCC is much higher in HBV-infected humans, woodchucks, ground squirrels and 
Chinese ducks than in uninfected members of the species. A large, prospective study 
in Taiwan has shown the incidence of HCC to be more than 100- to 200-fold higher 
in HBsAg-positive than in HBsAg-negative individuals (Beasley et al., 1981), and a 
prospective study in Japan yielded a similar result. Further evidence of a link comes 
from animal studies. More than 90% of woodchucks infected with WHV at birth died 
of HCC within 2-3 years (Popper et al., 1987). 3) Almost all HBV-related HCCs 
harbour integrated viral DNA, often in multiple copies. In some cases, tumours are 
clonal with respect to these insertions, indicating that integration of viral DNA 
precedes or accompanies the transforming event (Tanaka et al., 1988; Hino et al., 
1989). 
Although the molecular mechanisms leading to oncogenesis are still not understood, 
evidence supporting the direct or indirect contribution of HBV DNA to HCC has 
accumulated. Integrated viral DNA contains extensive deletions and rearrangements, 
which are different for each integrated viral sequence, indicating that integration is a 
random event. There is no evidence that the HBV genome contains viral oncogenes. 
HBV does not appear to activate known proto-oncogenes by the integration of viral 
sequences in the flanking host DNA although there are certain exceptions. However, 
in animal models, it has been demonstrated that WHV contributed to neoplastic 
transformation through insertional activation of cellular proto-oncogenes, eg. c-myc 
and N-myc (Hsu et al., 1988; Fourel et al., 1990). Besides the activation of cellular 
proto-oncogenes, integration of viral DNA can lead to deletions and rearrangements 
of cellular DNA at sites of integration. These events could also contribute directly to 
growth deregulation. Transactivation of cellular genes by the truncated products of 
integrated HBV PreS 2/S genes (Kekule et al., 1990) and by HBxAg (see Section 
1.5.4), and long-term storage of the three HBV envelope glycoproteins (Chisari et al., 
1989) have been proposed as causative or contributory factors in RB V-associated 
oncogenesis. 
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Finally, HBV may also contribute indirectly to oncogenesis, for infection generally 
results in hepatocyte necrosis, which may trigger a host response marked by chronic 
inflammation, fibrosis and hepatocyte regeneration. This regenerative hyperplasia 
expands the population of cells at risk of subsequent genetic alterations that further 
deregulate cell growth. Therefore, the host immune responses to HBV infection which 
lead to the destruction of infected hepatocytes and trigger these changes may 
contribute to oncogenesis. It is tempting to speculate that HBV DNA may contribute 
both directly or indirectly to HCC in vivo. 
13 	Virión structure 
1.3.1 Ultrastructure 
The structure of the hepatitis B virion in presented in Figure 1.1. The virion was first 
observed under the electron microscope in 1970 as a spherical particle approximately 
42 nm in diameter (Dane et aL, 1970), with an electron-dense, spherical inner core 
With a diameter of approximately 27 nm surrounded by an envelope approximately 7 
nm in thickness. In addition to the virion, or Dane particle, which is found in the 
liver and blood of acutely infected individuals, there are more numerous particulate 
forms that bear viral surface antigen (HBsAg) in the serum of infected hosts. These 
are small spherical particles with a diameter of 22 nm and filamentous forms 22 nm 
wide and varying in length. They are considered to be incomplete viral envelope 
forms. The core particles, or nucleocapsids, which can be released from the virions 
by detergent treatment, bear the viral core antigen (HBcAg), the viral e antigen 
(HBeAg) in a cryptic form, the viral DNA, DNA polymerase activity, and a protein 
kinase activity that phosphorylates HBcAg. The core particle occurs uniquely in the 
liver early in acute infections. The HBeAg, first detected as a soluble antigen in 
serum of HBV-infected patients (Magnius and Espmark, 1972), is closely associated 
with the core and its antigenic reactivity. The HBcAg can be converted into HBeAg 
by proteolytic degradation under dissociating conditions (MacKay et al., 1981a). 
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Figure 1.1 Structure of HBV. (A) The Dane particle consists of an envelope (HBsAg 
and host-derived lipid) and a core particle containing the HBcAg, which surrounds the 
partially double-stranded viral genome and DNA polymerase/reverse transcriptase. (B) 
The subviral particles, spherical and filamentous forms, are composed solely of 
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13.2 Genome structure 
The HBV genome is a partially double-stranded, circular DNA molecule of about 3.2 
kb with a molecular mass of about 2 x 106  (Figure 1.1; Kaplan et al., 1973; Robinson 
et al., 1974; Summers et al., 1975). The complete, long strand serves as template for 
viral transcription and is thus termed the minus strand (Pasek et al., 1979). The long 
strand is not a closed circle having a nick at a unique site. The position of the 5' end 
of the short strand, or termed the plus strand, is fixed, but its 3' end is variably 
situated (Summers et al., 1975). The single-stranded gap varies from 20-50% of the 
circular length. The circular structure is maintained by base-pairing of the 5' ends of 
the two strands over a length of 200 to 300 nucleotides (Sattler and Robinson, 1979; 
Delius et al., 1983). An endogenous DNA polymerase activity can fill in the single-
stranded region of the short strand. The 5 ends of both strands of DNA are not able 
to be phosphorylated with polynucleotide kinase (Gerlich and Robinson, 1980) because 
a protein and an oligonucleotide are covalently attached to the 5' end of the long 
strand and the short strand, respectively. Within the overlap or "cohesive end" region, 
there are two 11-base direct repeats, called DR1 and DR2, which play an important 
role in viral DNA replication (see Section 1.7). 
1.4 	Genome organisation 
The complete nucleotide sequences of cloned DNAs of HBV have been determined 
(Pasek et al., 1979; Galibert et al., 1979). There are four translational open reading 
frames (ORFs), utilising all three translational phases, in HBV which are all encoded 
by the minus-strand DNA (Figure 1.2). The four ORFs are termed C, P, S and X. 
The P region overlaps within all the other three. In effect, the minus strand is read 
one-and-a-half times. The HBV isolate (HBV 130) used in this work is 3182 bases 
in length and the beginning of the coding sequence for HBcAg was selected as 
number 1 in nucleotide sequence (Burrell et al., 1979; Pasek et al., 1979). The same 
numbering system is used in this work described here. Galibert et al. (1979) used the 
unique target sequence for restriction endonuclease EcoRI as number 1, which is 
Figure 1.2 Genetic organisation of the HBV genome. Open reading frames in three 
translational phases are indicated by heavy lines. Transcriptional control regions are 
denoted by boxes and are abbreviated as follows: SPI, preS 1 promoter, SPII, preS 2/S 
promoter; CP, core promoter, enhiXP, enhancer/X promoter; enhil, enhancer II. (Data 
from Pasek et al., 1979; Schaller and Fischer, 1991). 
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located within pre S region. However, in the sequence of HBV130, this EcoRI site 
does not exist, and in fact of 22 HBV DNA sequences in the EMBL and GENBANK 
databases, only 5 carry an EcoRI site. To convert the numbering system of Pasek et 
al. to that of Galibert et al., add 1900 to numbers less than 1283 and subtract 1282 
from numbers greater than 1282. 
The four ORFs of HBV are the following: 
The C ORF, encompassing nucleotides 1 to 549 of the HBV sequence, encodes 
HBcAg. The C ORF is also preceded by a short upstream in-phase ORF, termed pre-
C ORF, encompassing nucleotides 3096 to 3182 of the HBV sequence, which could 
encode a larger HBcAg-related polypeptide which is relevent to the formation of 
HBeAg. 
The P ORF, encompassing nucleotides 407 to 2902 of the HBV sequence, encodes 
DNA polymerase, or reverse transcriptase. 
The S ORF, encompassing nucleotides 1437 to 2114 of the HBV sequence, encodes 
HB5Ag. Upstream of S ORF is an in-phase reading frame (ORF preS) with two 
conserved in-phase initiation codons that can direct the synthesis of two additional 
HBsAg-related proteins. These codons subdivide the preS region into two functional 
subregions, termed preS 1 and preS 2, encompassing nucleotides 948 to 1271, and 1272 
to 1436 of the HBV sequence, respectively. 
The X ORF encodes HBxAg, encompassing nucleotides 2656 to 3117 of the HBV 
sequence, which has a transactivating function. 
1.5 	Viral polypeptides 
1.5.1 Core (Nucleocapsid) proteins with HBcAg and HBeAg specificities 
The HBcAg, comprising 183 amino acids with a molecular weight of 21 kD, is the 
single polypeptide found in virion core, which consists of approximately 180 subunits 
of HBcAg in an icosahedral structure (Onodera et al., 1982). Free HBcAg is confined 
to infected hepatocytes. In contrast,. HBeAg, which has a molecular weight of 16 kD, 
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is structurally related to HBcAg and is often present in the bloodstream of HBV-
infected patients mainly as soluble dimers (Tedder and Bull, 1979). HBeAg was first 
identified in the serum of individuals infected with HBV (Magnius and Espmark, 
1972) and is an important serological marker for HBV infection. High titres of 
HBeAg in the serum are correlated with high levels of virus replication (Imai et al., 
1976; Werner et al., 1977), and therefore high infectivity (Nielsen et al., 1974; Okada 
et al., 1976). Seroconversion to anti-HBe is indicative of viral clearance. However, 
the biological role of HBeAg remains enigmatic. HBeAg in the serum exists in free 
forms as well as in association with IgG and serum albumin (Takahashi et al., 1978) 
resulting in considerable physical heterogeneity (Tedder and Bull, 1979). 
The presence of HBeAg in the core of Dane particles in a cryptic form was 
demonstrated by treatment of serum-derived core particles with pronase, SDS, 
chaotropic agents or by sonication or centrifugation in CsC1 (Budkowska et al., 1979; 
Takahashi et al., 1979; Ohori et al., 1979). MacKay et al. (1981a) also showed that 
HBcAg, produced in E.coli, can be converted into HBeAg by proteolytic cleavage 
under dissociating conditions, thereby demonstrating that no other HBV protein was 
the source of HBeAg. The nature of the conversion of HBcAg to HBeAg was further 
defined by Takahashi et al. (1983) who determined the C-terminus of HBeAg to be 
33-35 amino acids upstream of the C-terminus of HBcAg by amino acid sequencing, 
suggesting that HBeAg represents a part of HBcAg. 
HBeAg was detected to contain two subspecificities, HBeAg/1 and HBeAgI2, by 
immunodiffusion. HBeAg/1 was usually more stable than HBeAgI2 (Tedder and Bull, 
1979; Yamada et al., 1979). The monomeric forms of HBeAg displayed only 
HBeAg/1 antigenicity, while the polymeric forms exhibited HBeAgI2 antigenicity, as 
treatment of HBeAg with both SDS and 2-mercaptoethanol abolished HBeAg/2 
antigenicity (Matsuda and Ohori, 1988). Two distinct antigenic determinants on 
HBeAg were also demonstrated by monoclonal antibodies (MAbs) designated as "a" 
and "b" (Imai et al., 1982) or "a" and "n" (Ferns and Tedder, 1984). Salfeld et al. 
(1989) also mapped antigenic determinants of HBeAg, one linear (HBe1) and the other 
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conformational (HBe2) (see Section 4.5). Whether the two distinct antigenic 
determinants on HBeAg described by different authors are the same remains unclear. 
HBcAg and HBeAg are encoded by two different mRNAs which have slightly 
different 5' ends and therefore contain different in-frame initiation codons which are 
referred to as the core and the pre-core AUGs. Synthesis of the HBcAg starts at the 
second initiation codon, ie. core AUG, and the resulting protein is located in the 
cytoplasm and the nuclei of the cells. It self-assembles into virus capsids and is 
exported from the cells as part of a virus particle. The region between these 2 
initiation codons, which are eighty-seven nucleotides apart, is termed pre-core region. 
The larger "pre-core" protein is encoded by the larger mRNA and therefore contains 
an extra 29 amino acids encoded by the pre-core region, termed pre-core (pre-C) 
sequence, at its N-terminus. The first 19 amino acids of the pre-C sequence act as a 
signal sequence for secretion and therefore directs the pre-core protein into the 
secretory pathway. 
At least two different proteolytic events are involved in the maturation of HBeAg. 
The first proteolytic event removes the signal peptide from the pre-core protein, which 
is mediated by the signal peptidase located in the lumen of the endoplasmic reticulum 
(ER) and results in the formation of a precursor protein, P22 (Bruss and Gerlich, 
1988; Garcia et al., 1988). The second proteolytic event removes the C-terminal 
domain of about 34 amino acids of P22 and converts it to the 16-kD HBeAg which 
occurs in a post-ER compartment, most likely the Golgi apparatus, and eventually 
HBeAg is released from the hepatocytes (Ou et al., 1986; Standring et al., 1988; 
Wang et al., 1991). The processing protease is probably a cellular enzyme, aspartyl 
protease (Jean-Jean et al., 1989). Suggestions that the protease is of viral origin came 
from the observation that the sequence near the N-terminal region of HBcAg contains 
a conserved motif, i.e. LLDTAS for most HBV subtypes, very similar to the protease-
like sequences, which is involved in Gag processing in retroviruses (Miller, 1987). 
On the basis of this finding, a model was proposed that HBeAg would be generated 
by self-cleavage of HBcAg at the C-terminus by the protease activity of the HBcAg. 
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However, mutational deletion of the putative active sites of this protease did not 
impair the processing (Nassal et al., 1989), suggesting that the protease is not of viral 
origin. 
A variety of mutants with defects in pre-core region were detected in the sera from 
anti-HBe positive patients, but not from HBeAg positive carriers (Carman et al., 1989; 
Tong et al., 1990; Okamoto et al., 1990). In fact, in the original HBV isolate used 
for the expression of HBcAg in E. coli (Burrel et al., 1979), this pre-core mutant was 
cloned and sequenced (Pasek et al., 1979). The emergence of pre-core defective 
mutants also provides evidence to support the view that the pre-core sequence plays 
an important role in the synthesis and secretion of HBeAg. On the other hand, the 
detection of these naturally occurring preC-deficient mutants prevailed as hosts 
seroconvert from HBeAg to anti-HBe, suggesting that pre-core region might not 
required for HBV replication (Okamoto et al., 1990). Indeed, it has been shown that 
mutational ablation of pre-core translation has no effect on viral replication, assembly 
and infectivity in DHBV (Schlicht et al., 1987) or in WHV (Chen et al., 1992a). 
Since about two thirds of the pre-core sequence spanning amino acids 10-29 is singly 
coded, mutants in this region would be able to survive, as the coding capacity for the 
other viral polypeptides is not affected. The pre-core region is conserved in all animal 
hepadnaviruses. However, the reason why expression of pre-core region has been 
retained in viral evolution remains an enigma. 
Nucleocapsid formation in vivo involves the correct assembly of three viral 
constituents: HBcAg, the polymerase and the pregenome RNA. No major cellular 
proteins have been detected in the core particle. However, in vitro, HBcAg self-
assembles to 27 nm core-like particles when expressed in E. coli and the recombinant 
HBcAg is morphologically and immunologically identical to natural HBcAg (Burrell 
et al., 1979; Stahl et al., 1982; Cohen and Richmond, 1982). HBcAg can also be 
expressed in a wide range of systems (Gough and Murray, 1982; Kniskern et al., 
1986; Roossinck et al., 1986; Clarke et al., 1987). However, the E. coli expression 
system is the simplest and the most popular method, which has been exploited for the 
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production of large quantities of HBcAg for research and diagnostic uses (Stahl et al., 
1982). The nucleic acid and all other viral proteins are not required for this assembly 
in vitro. The addition of heterologous sequences to the N-terminus of HBcAg does 
not affect such assembly (Clarke et al., 1987; Stahl and Murray, 1989). 
HBcAg consists of two structurally and functionally distinct domains. The sequence 
from the N-terminus to amino acid position 144 is by itself sufficient for particle 
assembly, at least at high protein concentrations present in heterologous expression 
systems, eg. E. coli (Gallina et al., 1989; Stahl and Murray, 1989; Birnbaum and 
Nassal, 1990). The C-terminal 34 amino acids contain 16 arginine residues, 14 of 
which occur in 4 clusters. This C-terminal sequence has been termed the protamine-
like region, implying that it is involved in nucleic acid binding. 
Addition of heterologous sequences to the N-terminus of HBcAg does not impair 
particle formation. Stahl et al. (1982) synthesized HBcAg in E. coli as a fusion 
protein with the first eight amino acid residues of 3-gaIactosidase fused in frame to 
HBcAg in which the first two N-terminal residues were deleted. Clarke et al. (1987) 
reported the expression of major immunogenic epitopes from foot and mouth disease 
virus (FMDV) fused to the N-terminus of HBcAg, which carried a total of 30 amino 
acid residues from foreign sequences. These fusion proteins still assembled into core-
like particles. 
The assembly of core-like particle is also unimpeded by the addition of peptide 
sequences to the C-terminus of the truncated HBcAg consisting of amino acids 3-144, 
implying that the protamine-like C-terminus of HBcAg is not critical for particle 
formation (Stahl and Murray, 1989). It has also been shown by deletional analysis 
that the first 144 amino acids of HBcAg are sufficient for assembly in E. coli (Gallina 
et al., 1989). In addition, the truncated P16 polypeptide linked by disulphide bonds 
into dimers and assembled into the particle by noncovalent interaction; while in the 
authentic HBcAg particles, additional disulphide bonds, presumably between the C-
terminal cysteines of the protamine-like regions, further stabilise the structure and 
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convert it into a covalently closed lattice (Gallina et al., 1989). Birnbaum and Nassal 
(1990) also demonstrated that HBcAg deleted from the C-terminus to amino acid 
residue 164, 149 or 144 also formed particles when expressed in E. coli. However, 
the presence of the basic C-terminus greatly enhanced encapsidation of nucleic acid 
and appeared to play a crucial role in capsid stability via protein-nucleic acid 
interactions (Birnbaum and Nassal, 1990). 
Since the basic C-terminal domain of HBcAg is dispensable for assembly and both 
HBcAg and HBeAg contain the regions which are needed for core particle formation, 
the failure of HBeAg to form particles may be due to the additional amino acids, ie. 
pre-core sequence. Indeed, it has been demonstrated that the pre-core sequence not 
only mediates the secretion but also determines the structural and aggregational 
properties of HBeAg. When 'the pre-core sequence was replaced with an unrelated 
signal sequence in the pre-core protein, it still entered the secretory pathway and was 
efficiently processed, but secreted as assembled particles (Schlicht and Wasenauer, 
1991). Furthermore, the remaining ten amino acids within the pre-core sequence 
attached to the N-terminus of HBcAg after processing has recently been shown to 
determine the non-particulate nature and the antigenicity of HBeAg (Wasenauer et al., 
1992). 
It has been presumed that the C-terminal region of HBcAg has DNA-binding activity 
because of the resemblance of its amino acid sequence to that of protamine. Indeed, 
Petit and Pillot (1985) demonstrated that HBcAg purified from liver has nonspecific 
DNA-binding activity. Furthermore, HBcAg produced in E. coli has also been shown 
to bind both DNA and RNA (Matsuda et al., 1988; Gallina et al., 1989; Hatton et al., 
1992). However, there are conflicting reports concerning the importance of the 
protamine-like domain in mediating nucleic acid binding. HBeAg partially purified 
from serum bound to HBV DNA (Matsuda et al., 1988), while recombinant HBeAg, 
consisting of amino acids 1-144 of HBcAg and 6 amino acid residues from a linker 
sequence, but lacking the ten amino acid residues of the pre-core sequence, did not 
(Gallina et al., 1989). It is possible that some of the differences in amino acid 
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sequence between natural HBeAg and the recombinant HBeAg can account for this 
discordance. In addition, since the HBeAg from serum was only partially purified, the 
DNA binding might perhaps involve another compartment. 
Assembly of replication-competent HBV nucleocapsid required the interaction of the 
HBcAg, the product of the viral P gene and the RNA pregenome. It has been shown 
that the protamine-like region of HBcAg is essential for efficient RNA pregenome 
encapsidation (Birnbaum and Nassal, 1990). Recently, Hatton et al. (1992) dissected 
the nucleic acid-binding capabilities of the protamine-like region of HBcAg and 
demonstrated that the first arginine repeated sequence motif (Repeat I) spanning amino 
acids 150-157 was the minimal region required for RNA binding and packaging, but 
did not bind DNA, while the three other repeats bound DNA much more efficiently 
than RNA. Nassal (1992) also showed that the arginine-rich region in HBcAg was 
essential for proper interaction with nucleic acid, but only half of the C-terminal 
region spanning to amino acid 164 was sufficient for RNA pregenome encapsidation 
with an efficiency similar to that of the full-length HBcAg. In addition, the C-
terminal region from amino acids 165 to 173 was required for proper genome 
replication (Nassal, 1992). In contrast, sequence beyond amino acid 164 was not 
required for the formation of enveloped virions, suggesting that nucleocapsid 
envelopment is independent of the presence of a mature DNA genome (Nassal, 1992). 
The arginine-rich C-terminus of HBcAg has also been shown to resemble the nuclear 
localisation signals for several viral and cellular proteins (Kalderon et al., 1984; Lyons 
et al., 1987). Viral nucleocapsids can be detected in the nucleus of HBV-infected 
hepatocytes (Ray et al., 1976; Chu and Liaw, 1987). However, localisation of HBcAg 
expressed in cultured mammalian cells has been demonstrated in the nucleus 
(McLachlan et al., 1987), cytoplasm (Ou et al., 1989; Yeh et al., 1990), or both 
(Roossinck et al., 1986). Ou et al. (1989) showed that the HBeAg precursor protein 
P22, if expressed without the preceding signal sequence, was transported into the 
nucleus very efficiently; while HBcAg, on the other hand, was detected mostly in the 
cytoplasm in mammalian cells. Although the pre-core sequence consisting of the C- 
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terminal ten amino acids, which remains after cleavage of the signal sequence, is 
important for nuclear transport of P22, it does not contain a nuclear localisation signal 
(Yeh et al., 1990). Nevertheless, the arginine-rich domain contains a signal for 
nuclear translocation of P22 (Yeh et al., 1990). Since HBcAg is localised in 
cytoplasm in their expression system, but contains the arginine-rich domain, the 
authors argue that the ten C-terminal region of the pre-core sequence, contained in 
P22, is also required in mediating nuclear localisation. Deletion and point mutational 
analyses of HBcAg, which is localised in nucleus in this expression system, revealed 
that the first and the last clusters of the arginine residues within the arginine-rich 
domain represent distinct and independent nuclear localisation sequences (Eckhardt et 
al., 1991). The significance of these nuclear localisation sequences in HBcAg to the 
HBV life cycle is not yet clear. 
Core particles purified from mature virions contain a protein kinase activity (Albin and 
Robinson, 1980). This kinase activity can phosphorylate HBcAg in the core particles. 
Incubation of core particle with y- 32P ATP leads to phosphorylation of HBcAg on 
multiple serine and threonine residues, but not of HBeAg (Roossinck and Siddiqui, 
1987). The pre-core protein derivative, P22, can also be phosphorylated in cells, while 
the mature HBeAg, which is converted from P22 by proteolytic cleavage, is not 
significantly phosphorylated (Yeh and Ou, 1991). Because HBcAg isolated from 
DHB V-infected hepatocytes is phosphorylated and that isolated from mature DHBV 
virion is not, it has been speculated that phosphorylation of the core protein regulates 
the maturation of the virion (Pugh et al., 1989). However, the role of this 
phosphorylation in HBV infection and replication has not yet been elucidated. 
1.5.2 Polymerase 
The P ORF occupying 80% of the genome is thought to code for the DNA 
polymerase, or reverse transcriptase, associated with Dane particles (Kaplan et al., 
1973) because its sequence shares homology with sequences in the poi genes of 
retroviruses (Toh et al., 1983). Direct evidence supporting this possibility was shown 
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by the expression of P-gene-encoded sequences in E. coli in the form of fusion 
proteins. The fusion proteins were found to have reverse transcriptase activity, and 
cross-reacted with sera from HBV-infected chimpanzees (McGlynn and Murray, 1988), 
indicating that P gene product is expressed during the viral life cycle. Antibody to 
synthetic peptides with sequences derived from the P-gene sequence was also shown 
to immuno-precipitate reverse transcriptase activity in detergent-disrupted HBV virions 
(Bavand etal., 1989). Furthermore, Weimer et al. (1990) demonstrated that antibodies 
against the RNase H domain of the P protein (see below) are early markers of 
infection and a signal of ongoing virus replication and decreasing titres indicate the 
decline or end of active virus production. Due to the low abundance in the virions, 
this putative protein, however, has not been isolated and fully characterised. The 
results from Bartenschlager and Schaller (1992) suggest that there are very few, 
possibly only one, P protein (polymerase) molecules per core particle. Direct evidence 
has shown that the P-gene product is contained in the nucleocapsid as an unprocessed 
90kD protein and it can perform its function as a multidomain polypeptide without 
requiring proteolytic processing (Barterschlager and Schaller, 1988 and 1992). 
From the results of structural and mutational analyses of the P protein, as well as 
sequence comparison with other reverse transcriptase genes, the P-gene product has 
been divided into four domains from the N- to the C-terminus: the terminal protein 
('I'P) serves as the primer of the minus DNA strand, a spacer region, the reverse 
transcriptase, and the RNase H domain (Barterschlager and Schaller, 1988; Radziwill 
et al., 1990). The P-gene product is required in addition to HBcAg for viral 
pregenome encapsidation (Bartenschlager et al., 1990; Hirsch et al., 1990). 
Furthermore, the intact P-gene product, ie. multiple domains of the P protein, is 
indispensable for RNA encapsidation in HBV (Bartenschlager et al., 1990; Blum et 
al., 1991) and in DHBV (Chang et al., 1990; Chen et al., 1992b). 
Terminal protein (TP) attached to the 5 end of the minus strand of the genome has 
been identified to be encoded by the P gene in DHBV (Barterschlager and Schaller, 
1988; Bosch, et al., 1988) and in HBV (Radziwill et al., 1990). It has been. 
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demonstrated further that the TP domain located in the N-terminus of the P protein 
is responsible for this DNA linkage (Barterschlager and Schaller, 1988; Bosch et al., 
1988). After the TP domain binds to a specific, short target sequence located near the 
5 end of the pregenomic RNA (Bartenschlager et al., 1990), reverse transcription is 
initiated (Barterschlager and Schaller, 1988; Radziwill et al., 1990). Mutations in the 
three functional domains within the P gene drastically reduced endogenous DNA 
polymerase activity (Radziwill et al., 1990). The RNase H domain is responsible for 
degradation of the RNA component in the hybrid molecule of viral RNA pregenome 
and minus-strand DNA (Radziwill et al., 1990). 
1.5.3 Envelope proteins (surface antigen) 
HB5Ag (surface antigen) is present both in the envelope of intact virions and as free 
circulating subviral particles. The 22-nm HBsAg particles isolated from the sera of 
HBV-infected patients are complex macromolecular assemblies, containing about 75% 
protein, 25% lipid, and N-linked carbohydrate. One lipoprotein particle contains about 
100 HBsAg polypeptide monomers. HB5Ag assembly is classically believed to occur 
in the ER. However, recently, by using immunocytochemical and biochemical 
approaches, the results support a model in which rapid dimer formation of HBsAg, 
catalysed by protein disulphide isomerase (PDI), occurs in the ER, and is followed by 
transport of dimers to a pre-Golgi compartment where the absence of PDI and a 
different lumenal environment allow the assembly process to be completed (Huovila 
et al., 1992). HBsAg comprises three envelope polypeptides, the major, or small (S), 
the middle (M) and the large (L) proteins. All three envelope proteins exist in two 
forms differing in the extent of glycosylation. They are encoded in a single ORF and 
initiate at three separate in-phase initiation codons spaced at intervals of 108 (or 119, 
depending on subtype) and 55 codons, but terminate in the same stop codon. The 
segments downstream of the three initiation codons are termed the preS 1 and preS, 
regions and the S gene (Machida et al., 1984; Heermann et al., 1984). The two 
larger polypeptides could be detected in all three mammalian hepadnaviruses, 
including HBV, WHV and GSV (Heermann et al., 1984; Wong et al., 1985; Persing 
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et aL, 1986a). The avian hepadnaviruses, DHBV, also contain a preS region with 
multiple in-frame AUGs, but only one unglycosylated 36-kD preS protein has been 
detected (Pugh et al., 1987). 
Among the three envelope proteins, the major component is the S protein; it is also 
often called HBV surface antigen (HBsAg), as it was originally thought to be the only 
viral antigen present on the subviral particle by early immunological studies. The 
major protein is 226 amino acids in length and is encoded by the S gene. It exists in 
two forms, non-glycosylated (P24) and glycosylated (GP27), which possesses a 
complex N-linked glycan at asparagine residue 146 (Peterson, 1981). The middle 
protein is coterminal with the small protein, having 55 additional amino acids (called 
preS2) at the amino terminus (Stibbe and Gerlich, 1983; Machida et al., 1984). It is 
a glycoprotein present in two forms, GP33 and GP36, according to the extent of 
glycosylation; GP33 contains one glycan at amino acid 4 of the preS 2 domain and 
GP36 is additionally glycosylated within the S domain (Stibbe and Gerlich, 1983). 
The large protein is also coterminal with the small and the middle proteins, having an 
additional 108 or 119 amino acids (called preS 1) at the N-terminus of the middle 
protein (Heermann et al., 1984). The large protein is also present in a glycosylated 
(GP42) and a non-glycosylated (P39) form. In addition to glycosylation, both P39 and 
GP42 are acylated at their N-terminal glycine residue with myristic acid (Persing et 
al., 1987). The preS 1 and preS 2 regions carry specific immunological determinants, 
which are discussed in detail in Chapter 5. 
The S protein is a major component in the virion envelope, the filamentous and the 
spherical subviral particles. The middle and large proteins are quantitatively minor 
components of the circulating pool of S-related antigens, with the middle protein 
accounting for about 5%-15% of the total, and the large protein representing only 
about 1%-2% or even less of the total (Heermann et al., 1984). The 22-nm spherical 
particles may consist of the S protein alone or the S and the middle proteins, but 
without the large protein. The proportions of the three envelope proteins differ in the 
different forms of HBsAg particles and appear to vary at different stages after 
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infection. 
Which of the three S proteins performs the attachment function to hepatocytes and 
initiates infection is not clear. It has been proposed that the preS 2 domain possessed 
a polymerised human serum albumin (pHSA) binding site (Machida et al., 1984), 
which may play a role in the attachment of HBV to hepatocytes using pHSA as a 
linker molecule (Pontisso et al., 1989a). However, it has not yet been shown 
experimentally that pHSA mediates uptake of HBV to hepatocytes. It also appears 
that hepatocyte cultures do not express a pHSA receptor in vitro. A further 
attachment site of HBV has been found in the preS 1 domain, located between amino 
acid residues 21 and 47 (in subtype with 119 residues of the preS 1 sequence), 
suggesting an important function of this attachment site in the viral pathogenesis 
(Neurath et al., 1986; Pontisso et al., 1989b). Indeed, antibody against this attachment 
site is virus neutralising (Neurath et al., 1989; Thornton et al., 1989). Nevertheless, 
the hepatocyte receptor for HBV is not yet identified. Recent findings have suggested 
a role of interleukin 6 receptor (Neurath et al., 1992), transferrin receptor (Franco et 
al., 1992), or IgA receptor (Pontisso et al., 1992) in mediating HBV-hepatocyte 
interaction. 
The major S protein contains all the information required for 22 nm particle assembly 
and secretion. Eukaryotic cells transfected with DNA fragments bearing only the S 
gene produce morphologically normal 22-nm particles. Effective synthesis of the S 
protein has been achieved in S. cerevisiae (Valenzuela et al., 1982; Murray et al., 
1984) and in some animal cells (Dubois et al., 1980; Laub et al., 1983). This property 
has been exploited to produce highly immunogenic HBsAg particles in yeast as HBV 
vaccines (McAleer et al., 1984; Murray et al., 1984). Unlike the HBsAg purified 
from serum, the recombinant S protein is unglycosylated, indicating that glycosylation 
is not required either for particle assembly or for immunogenicity. However, synthesis 
of the S protein in prokaryotic cells, eg. E. coli, was less successful, as the yields were 
low (MacKay et al., 1981b). The S protein contains three hydrophobic regions (Stirk 
et al., 1992). The first and the second domains are known to harbour topogenic signal 
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sequences, termed signals I and II, that direct the transmembrane orientation (Eble et 
al., 1987). Mutational analysis of the three hydrophobic domains showed that they 
also played important roles in the subviral particle assembly and secretion (Bruss and 
Ganem, 1991a). 
Eukaryotic cells expressing the middle protein assemble and secrete 22-nm particles 
that were indistinguishable from those found in serum (Dubois et al., 1980; Imamura 
et al., 1987) or reduced in size by 30% compared to those containing only the S 
protein, suggesting the middle protein can affect subunit packaging and, therefore, the 
nature of the assembled particle (McLachlan et al., 1987). Mammalian cells 
transfected with cloned HBV DNA have been reported to express both the middle and 
the S proteins organised into mixed particles of 22 nm diameter (Persing et al., 1985). 
Interestingly, the preS 2 domain itself lacks functional signal sequence activity and its 
translocation across the ER membrane is mediated by downstream signals within the 
S domain (Eble et al., 1990). This unusual behaviour had previously only been 
identified in experimental fusion proteins constructed in vitro. 
Unlike the two other envelope proteins, the large protein alone cannot form particles. 
When expressed alone, it remains bound to the cell membrane (Cheng et al., 1986; 
Imamura et al., 1987; McLachlan et al., 1987). Moreover, when the large and the S 
proteins are synthesized in the same cell, the secretion of 22-nm particles is blocked 
(Persing et al., 1986b; Ou and Rutter, 1987). The over-accumulation of retained large 
protein aggregates can be harmful to the host cells. It has been demonstrated that 
overexpression of the large protein gene in transgenic mice caused accumulation of 
filamentous envelope particles in hepatocytes, followed by cell damage and the 
development of liver cancer (Chisari et al., 1989). These results suggest that the preS 1 
domain of the large protein contains signals that promote intracellular retention of the 
protein. Mutational analysis in the preS 1 region of the adw2 subtype (with 119 amino 
acid residues) led Kuroki et al. (1989) to postulate an ER retention signal located in 
the preS 1 amino acids 6 to 19. Since this region of the large protein is myristylated, 
ER retention might be attributable to the affinity of this hydrophobic fatty acid for the 
21 
ER membrane. Investigation of the role of myristylation in the large protein in 
secretion has led to divergent results. Single and double mutations of the myristic 
acid attachment sites did not lead to secretion of the protein (Kuroki et al., 1989). 
However, similar studies employing the ayw subtype (with 108 amino acid residues, 
lacking 11 residues at the N-terminus) indicated that the block of secretion could be 
partially overcome by mutation or deletion of the myristylation site, and creation of 
a myristyl attachment site in the small protein impaired the secretion of the subviral 
particles but not their intracellular assembly (Prange et al., 1991). The discrepancy 
of the result might be attributable to the different sequence between the two subtypes 
at their N-terminus. 
The role of the three envelope proteins in the formation of Dane particles has been 
addressed. By transfecting hepatoma cells with mutant HBV genomes affecting the 
large, middle or S proteins, Ueda et al. (1991) showed that all three proteins were 
indispensable for the formation of Dane particles. However, the role of the middle 
protein in virion formation is disputed. Similar studies indicated that the large and S, 
but not the middle proteins were necessary for virion production (Bruss and Ganem, 
1991b). A naturally-occurring HBV mutant unable to produce the middle protein has 
been shown to be competent in replication, virion formation and secretion (Fernholz 
et al., 1991). The overexpression of the large protein inhibits virion release, while ER 
retention of envelope proteins mediated by the large protein and the myristylation of 
the large protein are not required for Dane particle formation and release (Bruss and 
Vanem, 1991b). In the virion budding, the envelope proteins must interact, directly 
or, indirectly, with HBcAg. The interaction between the nucleocapsid and the envelope 
proteins in the formation of the virion and its budding is not yet clear. For example, 
which regions of HBcAg interact with which region of HBsAg? How do the core 
particles trigger budding? 
1.5.4 HBXAg 
The X ORF could encode a polypeptide which contains 154 amino acids and is termed 
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X (HBxAg) because the function of its product during viral infection is unknown. The 
X-gene product is expressed during viral infection. A 1-kb or 0.7-kb X-specific 
mRNA has been detected in mammalian cells transfected with the complete HBV 
genome or with a fragment of the HBV genome containing X ORF (Cough, 1983; 
Saito et al., 1986). Antibody to synthetic peptides with sequences derived from the 
X gene has been used to detect a protein in some HBV-infected liver biopsies, HCC 
tissues (Moriarty et al., 1985) and in cultured cells transfected with the HBV genome 
(Pugh et al., 1986). HBxAg has also been detected by indirect immunofluorescence 
or immunohistochemical staining in hepatocytes from HBV-infected livers (Katayama 
et al., 1989), hepatoma cell lines containing integrated HBV DNA (Chisaka et al., 
1987), and cell lines transfected with the complete HBV genome (Pugh et al., 1986). 
Synthetic peptides representing segments of HBxAg and fusion proteins synthesized 
in E. coli with X-gene-encoded sequences have also been used to identify anti-X 
antibodies in the sera of some HBV-infected patients (Kay et aL, 1985; Weber et al., 
1988), indicating that the X sequence is expressed at some stage during viral infection. 
HBxAg-specific T-cell response has also been detected in patients with acute, and less 
frequently with chronic HBV infection (Jung et al., 1990). In vivo, HBxAg is 
probably expressed only in very low amounts and thus far all attempts to visualise it 
by immunoblotting or other biochemical techniques have failed. 
The X genes of HBV, WHV, and GSHV have been shown to encode proteins that 
transactivate transcription from a very wide array of target promoters (reviewed by 
Rossner, 1992). HBxAg is capable of stimulating the expression of genes under the 
control of autologous as well as other viral and cellular regulatory sequences, eg. 
Simian virus 40 (SV40), Rous sarcoma virus and human immunodeficiency virus 
(HIV), MHC class I, MHC class II, n-interferon and c-myc (Zhou et al., 1990; Hu et 
al., 1990; Twu and Schloemer, 1987; Seto et aL, 1988; Twu and Robinson, 1989; 
Siddiqui et al., 1989). 
Colgrove et al. (1989) showed that transient transfection of human hepatoma cells 
with the complete HBV genome containing a frameshift mutation in the X ORF 
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resulted in a decrease in the level of all viral mRNAs. Human hepatoma cell lines 
transfected with a plasmid containing the transcription units for the preS 2 and surface 
(preS2/S) mRNAs and a frame shift mutation in the X mRNA also greatly reduced 
HBsAg secretion (Rossner et al., 1990). These results suggest that the transactivating 
activity of HBxAg in vivo may contribute to the high level of HBsAg expression 
observed in the course of natural infection. 
Several cellular regulatory sequences have been demonstrated as targets for 
transactivation by HBxAg, which may explain certain physiological conditions 
associated with HBV infection. The elevated expression of MHC class I and class II 
antigens on the surface of hepatocytes during HBV infection may both be attributable 
to transactivation of the regulatory region of the genes that encode these antigens by 
HBxAg (Hu et al., 1990; Zhou et al., 1990). As a result, the aberrant expression of 
MHC class I and class II antigens may influence the clinical course of the HBV 
infection. 
Speculations exist as to the potential role of HBxAg in hepatocarcinogenesis. HBxAg 
coding sequence isolated from HBV integrates associated with HCC (Wollersheim et 
al., 1988) or chronic hepatitis (Takada and Koike, 1990) maintained the capacity to 
transactivate, and a consequent aberration in the expression of a cellular gene involved 
in regulation of cellular proliferation may contribute to the development and/or 
maintenance of HCC. The more direct evidence linking HBxAg with HCC has been 
obtained through the use of HBV X-gene transgenic mice. Kim et al. (1991) showed 
that the induction of HCC in two lines of transgenic mice harbouring the X gene 
under control of its own promoter/enhancer complex. In contrast, transgenic mice 
carrying the X gene under control of the human a-1-antitrypsin regulatory region did 
not develop a pathological reaction (Lee et al., 1990). 
Because HBxAg stimulates a striking variety of promoters that do not share a common 
cis-regulatory element and it does not bind to DNA (Siddiqui et al., 1987; Faktor and 
Shaul, 1990), it has been speculated that HBxAg acts indirectly through cellular 
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pathways. Recently, Kekule and colleagues (1993) showed that HBxAg uses a tumour 
promoter signalling pathway for transactivation. HBxAg elicits an elevation of 1,2-
diacylglyceral(DAG), the endogenous protein kinase C (PKC) activator, and 
subsequently activates PKC, which results in activation of the transcription factor AP-
1 (Jun-Fos). As a result, HBxAg transactivates through binding sites for AP-1 and 
other PKC-dependent transcription factors. Since the PKC signalling pathway also 
mediates cell transformation by tumour-promoting agents, this mechanism of gene 
regulation might also account for the oncogenic potential of HBxAg. However, the 
mechanism by which HBxAg causes an increase in DAG is still unclear. The preS 2/St 
may also participate in the transcriptional control of viral gene expression via the same 
cellular pathway (see Section 1.8.2). 
1.6 	HBV variants 
The adaptive immune response usually protects vertebrate hosts against virus 
infections either through neutralising antibody responses or virus-specific T cells. 
Some viruses may persist in the host despite an immune response by hiding in 
privileged sites, such as brain, ganglion and cornea (eg. herpes simplex virus), or by 
changing patterns of cytopathogenicity, growth kinetics or tissue tropisms. Other 
viruses escape by down-modulating viral antigen, MHC gene products, by inducing 
immunosuppression (eg. HIV), by changing neutralising determinants (eg. influenza 
virus) or by changing T-cell epitopes recognised by cytotoxic T cells (eg. HIV). 
Immune selection occurs not only with antibodies, which has been well documented 
in influenza virus as antigenic drift, but also with cytotoxic T cells. In a transgenic 
mouse model of lymphocytic choriomeningitis virus (LCMV) infection (Pircher et al., 
1990) and in HIV-infected individuals (Phillips et al., 1991), the cells harbouring 
viruses with mutated T-cell epitopes were not recognised by cytotoxic T cells any 
more, hence were not destroyed resulting in the survival of the viruses. 
The strategy of HBV genome replication involves the reverse transcription of an RNA 
intermediate. Such a process is highly susceptible to point mutation due to the lack 
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of proof-reading enzymes for correcting errors in duplication. Therefore, HBV is 
prone to mutations. In persistent HBV carriers, it is conceivable that mutations could 
occur at any sequences of HBV DNA, with a frequency proportional to the length of 
time the host harbours the virus. A mutant HBV may survive so long as the mutation 
does not interfere with virion formation. 
1.6.1 Surface variants 
A new type of HBV variant, named HBV 2, has been detected in Senegal (Coursaget 
et al., 1987). The HBV2 displays different HBc antigenicity from that of HBV. After 
the loss of HBsAg, neither anti-HBc nor anti-HBs becomes detectable. Although 
HBV2 and HBV share common epitopes of HBsAg, as the HBV 2 reacts with anti-HBs 
in conventional tests for HBsAg, vaccine-induced anti-HBs does not protect against 
HBV2 infection, suggesting that the a determinant of HBsAg (see Section 1.9.1) might 
change in HBV2. The presence of HBV 2 might partly account for the high proportion 
of HBsAg(+) and anti-HB5(-) individuals in some chronic carriers. Wands et al. 
(1986) also found a variant which shares some HBsAg epitopes with HBV, but is only 
detected by a particular monoclonal anti-HBs antibody radioimmunoassay. 
Chimpanzees infected with this long-incubation variant were not protected by prior 
immunisation with HBsAg. Another mutant with a single amino acid change in the 
C-terminus of HBsAg has been reported in a patient in whom the only HBV marker 
was HBV DNA detected by polymerase chain reaction (PCR) (Thiers et al., 1988). 
Whether these mutants are capable of infecting hepatocytes or/and influencing the 
severity of the liver disease is not known. 
In HBV vaccination programmes, infants born to HBV mothers receive anti-HBs 
immunoglogulins and HBsAg vaccines. Approximately 95% of the vaccinees were 
protected, while the others did not develop an anti-HBs response or became infected 
in spite of adequate passive and active immunisation. Recently, a vaccine-induced 
escape mutant that expresses an altered a determinant of HBsAg has been reported 
independently in such infected children who responded well to the vaccine (Carman 
26 
et aL, 1990; Harrison et al., 1991; Fujii et al., 1992; Okamoto et al., 1992). In most 
cases, there was only a transient appearance of HBsAg in the patient's serum followed 
by the appearance of anti-HBc and anti-HBe, as would be expected in acute infection. 
However, acute hepatitis occurred in a few cases, as persistent rises in transaminases 
were detected (Carman et al., 1990; Fujii et al., 1992). 
Molecular analyses of the mutant revealed a point mutation from G to A resulted in 
an amino acid substitution from glycine to arginine at amino acid 145 of HB5Ag 
(Carman et al., 1990; Harrison et al., 1991; Fujii et al., 1992). HBsAg in patient's 
serum may be detected by some but not other commercial kits (Fujii et al., 1992). 
The mutation site is located within the immunodominant a region. The binding of the 
mutant to MAbs specific to this region was much reduced (Carman et al., 1990). 
These results suggest that the mutation has resulted in a conformational change 
affecting one or several epitopesin the region of the a determinant. These antigenic 
changes are not surprising, as arginine is a much larger residue than glycine and is 
charged. The mutant, therefore, was more hydrophilic than the wild type and a new 
HB5Ag specificity may be present. Interestingly, the same mutant has also been found 
in two of three liver transplant recipients who were given monoclonal anti-HBs to 
prevent reinfection of the homograft but who became viraemic during therapy 
(McMahon et al., 1992). Although the children bearing this gly 145 HBsAg mutant 
seldom have disease, the mutant is infectious and can cause hepatitis in chimpanzees 
(Ogata et al., 1993). Recombinant HBsAg carrying gly 145—'arg produced in yeast is 
not able to bind to'anti-HBs (Waters etal., 1992). Thus, it is conceivable that current 
HB5Ag vaccine might not protect against infection with this mutant. The emergence 
of the 91y 145 mutant has implications for vaccine development. 
Although other mutations have been found in the a determinant, these do not seem to 
be important (Moriyama et al., 1991; McMahon et al., 1992). The substitution of 
threonine or isoleucine for asparagine at codon 126 of the S gene has been found in 
HBV-vaccinated children in a family (Okamoto et al., 1992). The mutation was 
associated with a significant decrease in the antigenicity of some determinants on the 
27 
S protein as measured by MAbs. The same mutation was observed in 12 of 17 clones 
of DNA obtained from their mother before the mother-to-child transmission. This 
suggests a selective advantage of the mutant over the wild-type HBV under immune 
pressure. 
The g1y 145 mutant has emerged under pressure generated by anti-HBs antibody, both 
vaccine induced and therapeutic. Although first found in Italy (Carman et al., 1990), 
this escape mutant has since been reported elsewhere, eg. the Far East, England, and 
the USA. However, there are no data on how far such a virus has spread within the 
vaccinated population or the general population. The prevalence of such mutation is 
also little known. This information is necessary to assess the need to change vaccine 
components. In addition, mutants unable to produce the middle S protein have been 
documented (Femholz et al., 1991; Raimondo et al., 1991; Santantonio et al., 1992). 
These findings may have important implications for the usefulness of diagnostic preS 
protein assays and for the efficacy of new vaccines containing preS proteins. 
1.6.2 Pre-core variants 
The observation that some patients in the South Mediterranean and the Far East had 
HBV DNA measurable in their sera by dot-dot hybridisation but were negative for 
HBeAg (Bonino et al., 1981; Chu et al., 1985) led to the discovery of a mutant that 
was incapable of synthesizing the pre-core protein from which HBeAg is derived 
(Carman et al., 1989). A mutant with a single substitution in the second last codon 
(codon 28, TQG—TG) of the pre-core region, converting tryptophan 28 to a stop 
codon, hence preventing translation of the pre-core protein, was found in sera from 
anti-HBe(+) and HBV DNA(+) patients with chronic hepatitis. The translation of 
HBcAg is not affected. Thus these patients can have continuing viraemia in the 
absence of circulating HBeAg. The emergence of the pre-core defective mutant has 
implications for the use of anti-HBe as a serological marker for viral clearance. 
Okamoto et al. (1990) also reported that various mutants occurred in the pre-core 
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sequence, including point mutations to convert tryptophan 28 to a stop codon or abort 
the initiation codon, as well as deletion and insertion to induce frameshifts, were 
found in sera of persistent carriers, along with seroconversion to anti-HBe(+). Among 
them, the same pre-core mutant changing trp 28 to a stop codon as described by Carman 
et al. (1989) was the commonest and was found in 16 of 18 (89%) anti-HBe(+) 
carriers studied (Okamoto et al., 1990). These mutations leading to pre-core region 
defects were rarely observed in persistently infected HBe(+) individuals or in patients 
with acute hepatitis after they had seroconverted to anti-HBe (Okamoto et al., 1990). 
Santantonio et al. (1991) also indicated high prevalence, 33 out of 42 (79%) cases, 
and heterogeneity of the pre-core mutants in anti-HBe(+)IHBV DNA(+) patients with 
chronic hepatitis in the Mediterranean areas. Patients may also harbour a mixture of 
the wild-type and the mutant viruses during the early seroconversion phase (Okamoto 
et al., 1990; Brunetto et al., 1991; Santantonio et al., 1991). Gunther et al. (1992) 
showed that several different pre-core mutants emerged from HBe(+) carriers who 
seroconverted to anti-HBe(+) during interferon treatment. However, the emergence 
of these pre-core mutants was not correlated to the outcome of treatment with 
interferon (Gunther et al., 1992; Xu et al., 1992). 
It is believed that hepatitis is due to immune-mediated killing of hepatocytes and that 
HBcAg/HBeAg is an important target. As the host develops immune responses to 
HBeAg, hepatocytes secreting HBeAg would be subjected to immune elimination, 
whereas hepatocytes incapable of secreting HBeAg would escape it. This kind of 
immune selection may explain how pre-core-defective HBV replaced non-defective, 
wild-type HBV along with seroconversion to anti-HBe in persistent carriers. The 
studies of the relations between HBV heterogeneity and course of chronic infection 
in 145 HBsAg(+) carriers indicated that the pre-core defective mutant could be found 
in any phase of HBV infection (Brunetto et al., 1991): in 27% of immunotolerant 
carriers, in 67% of patients with chronic hepatitis (immunoelimination phase) and in 
17% of carriers with latent infection. These results suggest that the presence of 
mutant HBV can be independent from the pressure of immunoelimination. However, 
immunoelimination appears to determine a positive selection of the mutant. 
The pre-core defective mutants have been suggested to cause severe forms of hepatitis 
in several clinical settings. This mutant was described in diagnosed sera of 8 out of 
9 HBeAg(-)/anti-HBe(+) patients but in none of 6 HBeAg(+) patients who had 
fulminant hepatitis B (Carman et at., 1991). However, whether patients with 
fulminant hepatitis were infected, ab initio, with the pre-core defective mutant or have 
this mutant early in the course of the infection under an unusually potent immune 
selection could not be determined. In Japan, the pre-core defective mutant was found 
in all 7 patients with fulminant hepatitis but in none of 10 patients with acute, self-
limited hepatitis B (Omata et al., 1991). In addition, the outbreaks of fulminant 
hepatitis in nosocomial infections (Liang et al., 1991) as well as in maternally and 
sexually transmitted cases (Terazawa et at., 1990; Yotsumoto et al., 1992) have also 
been ascribed to pre-core defective mutants. In these cases, it has been suggested that 
infection ab initio with the pre-core defective mutants causes a more severe hepatitis 
than that associated with the emergence of the mutant during HBeAgfanti-HBe 
seroconversion (Kosaka et al., 1991; Liang et al., 1991). Yoshiba et al. (1992) 
reported reactivation of the pre-core defective mutant leading to fulminant hepatitis 
in three HBeAg(-)/anti-HBe(+) carriers following intensive cytotoxic chemotherapy 
for tumours. 
It seems too early to claim that the pre-core defective mutant causes fulminant 
hepatitis, as a cause-effect relationship has not been established yet. The humoral 
response to HBcAg, particularly to HBeAg, is capable of inhibiting the cytotoxic T-
cell killing of hepatocytes (Mondelli et al., 1982; Pignatelli et al., 1987). Therefore, 
in those patients infected ab initio with a pre-core defective mutant, the absence of 
HBeAg would allow the cytotoxic T cells (CTL) to destroy infected hepatocytes in an 
unrestricted way. However, this hypothesis does not explain the finding that fulminant 
hepatitis also occurs in HBe(+) patients infected with wild-type HBV. The alternate 
hypothesis is that the patient may be genetically predisposed to mount a very strong 
immune response against the HBe(+) wild-type virus, resulting in fulminant hepatitis 
and rapid selection of the mutant. 
The extremely high prevalence of the pre-core defective mutant bearing the codon 28 
non-sense mutation may be attributable to the following reasons. First, the mutation 
occurs in the sequence TGGGG; all of the Gs have been documented to be mutated 
to A, an example of mutation at hot-spots. Secondly, Tong et al. (1992) showed that 
the two naturally occurring pre-core mutation with stop codons in the 28th or 2nd 
codon had no perceptible effect on viral DNA replication, while the other eight 
artificial pre-core stop codon mutants were partly or completely defective in DNA 
replication. Because the pre-core sequence is largely overlapped by the pregenomic 
encapsidation signal (Junker-Niepmann et al., 1990) which is required for RNA 
packaging, the nonsense mutation in the other codons caused the impairment of this 
signal resulting in lack of packaged pregenomic RNA. The replication capability of 
the HBV pre-core defective mutant with a stop codon in the 28th codon has been 
demonstrated (Tong et al., 1991a and 1991b). Furthermore, DHBV mutants defective 
in the pre-core region can also infect susceptible ducks (Chang et al., 1987; Schlicht 
et al., 1987). 
1.6.3 Core variants 
Wakita et al. (1991) described a long span of in-frame deletions (105-183 bp) in the 
middle of the C gene detected in 7 out of 11 chronic hepatitis patients but not in 
asymptomatic carriers of HBV. The expected HBcAg or HBeAg carries deletions of 
amino acids located within 63-132 amino acids from the N-terminus of HBcAg. 
Recently, a cluster of changes in 18 amino acids (codons 84-101 from the start of the 
C gene) has also been found in 15 (with CAH and cirrhosis) of the 20 chronic 
hepatitis cases, whereas only mild liver disease (CPH) was found in the 5 patients 
without mutation (Ehata et al., 1992). 
The mutation region may contain antibody binding sites (colucci et al., 1988; Salfeld 
et al., 1989) and T helper (Th)-cell epitopes which have been identified in mice 
(Milich et al., 1987b). Although CTL epitopes within HBcAgIHBeAg have not been 
- precisely identified, they could be located close the antibody binding sites since anti- 
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HBc and anti-HBe have been shown to inhibit the CTL response in vitro (Mondelli 
et al., 1982; Pignatelli et al., 1987). These results suggest that the region with 
substitution or deletion found in these core mutants contains the major target of CTL. 
However, the question may be raised whether the mutations are the result of 
immunological pressure or they affect the pathogenesis of hepatocellular injury in 
chronic hepatitis or primarily evoke lymphocyte attack. The association of these core 
mutants with hepatocellular injury awaits to be clarified. 
1.7 	Genome replication 
The mechanism of the HBV genome replication is strikingly different from that of 
other DNA viruses. It involves a reverse transcriptase step first indicated by the 
findings of Summers and Mason (1982) with DHBV-infected duck livers, and 
confirmed later for HBV (Miller et al., 1984a and 1984b) and other hepadnaviruses 
(Lien et al., 1986; Seeger et al., 1986). The model for replication of the 
hepadnaviruses is based on that proposed by Summers and Mason (1982), Lien et al. 
(1986) for DHBV and by Seeger et al. (1986) for GSHV replication. The replication 
of the hepadnaviral genome involves several steps (Reviewed by Robinson and 
Marion, 1988; by Blum et al., 1989; and by Seeger et al., 1991) as illustrated in 
Figure 1.3. 
1) Conversion of open circular DNA to covalently closed circular DNA (cccDNA) 
within the nucleus of infected hepatocytes. In Peking ducks 6-16 hr after DHBV 
infection, cccDNA can be found in the liver, which precedes other viral RNA and 
DNA intermediates (Mason et al., 1983; Tagawa et al., 1986). The formation of 
cccDNA further involves several steps: a) removal of the covalently bound terminal 
protein (TP) and the terminal redundant sequence, termed "r", from the 5' end of the 
minus-strand DNA; b) ligation of the 5' and 3' ends of minus-strand DNA; c) removal 
of the RNA primer from the 5' end of plus-strand DNA; d) completion of the plus-
strand gap; e) ligation of the 5 and 3' ends of plus-strand DNA. The cccDNA 
accumulates in the nucleus where it serves as a template for transcription of mRNAs 
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Figure 1.3 Replication of the HBV genome. (A) Relaxed circular virion DNA is 
converted into ccc DNA. (B) Pregenomic RNA initiates ca. 5 nucleotides upstream of 
DR1 and terminates near a polyadenylation signal downstream of DR1, creating 
terminally redundant ends. (C) Primed by terminal protein (TP), minus-strand DNA 
synthesis begins at the copy of DR1 close to the 3 end of pregenomic RNA and 
proceeds to the 5 end of the RNA template, leading to a ca. 9 nucleotide-long 
terminal redundancy, termed "r", while at the same time the pregenomic RNA is 
degraded by RNase H. (D) Plus-strand DNA synthesis is primed by an RNA oligomer 
bearing a copy of DR1. The RNA primer derived from the 5' end of pregenomic 
RNA transported to the DR2 region of the minus-strand DNA. (E) Plus-strand DNA 
synthesis proceeds to the 5 end of minus-strand DNA is necessary for the 
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and pregenome RNA, the template of new DNA genomes by reverse transcription 
(Summers and Mason, 1982; Miller and Robinson, 1984; Tagawa et al., 1986). 
cccDNA is then amplified not only from infecting viral DNA as described above but 
also through de novo synthesis by reverse transcription (Tuttleman et al., 1986; Wu 
et al., 1990). cccDNA levels in persistently infected hepatocytes in vivo have been 
estimated at various values, ranging from 3 to 50 copies per nucleus (Summers et al., 
1990). The low copy numbers suggest that amplification of cccDNA in natural 
infections occurs at the early stage of the infection and the size of the pool of 
cccDNA may be limited by specific control mechanism. Summers and colleagues 
(1990) showed that the viral envelope proteins are required for regulation of cccDNA 
amplification. 
Transcription of minus-strand cccDNA by host RNA polymerase to generate a 3.5-
kb RNA, the pregenomic RNA. That cccDNA prepared from cloned viral DNAs are 
infectious in vivo supports the notion that cccDNA is the template for the transcription 
of the pregenomic RNA (Will et al., 1982; Seeger et al., 1984). This RNA contains 
terminally redundant ends (termed "R") and three copies of an 11-bp direct repeat 
(DR), which contains signals important for minus- and plus-DNA synthesis. DR1 is 
located at both the 5 end and near the 3' end, while a third copy of the repeat, termed 
DR2, is located upstream of DR1 close to the 3 end of pregenomic RNA (Buscher 
et al., 1985; Enders et al., 1985). 
Encapsidation of pregenomic RNA. The RNA pregenome is transferred to the 
cytoplasm and packaged along with the newly-synthesized viral DNA polymerase 
(reverse transcriptase) into core particles in which reverse transcription occurs. A 
sequence located near the 5 end of the RNA pregenome encompassing the last two-
thirds of the pre-core region and the beginning of the C gene has been identified as 
a cis-acting element, termed pregenome encapsidation signal (e), for RNA packaging 
(Junker-Niepmann et al., 1990). The P protein containing all functional domains is 
required as a structural component for RNA pregenome packaging, as known 
enzymatic activities of the P protein are not involved in the packaging reaction 
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(Bartenschlager et al., 1990). In addition, the protamine-like C-terminus of HBcAg 
is important for RNA packaging (Gallina et al., 1989; Birnbaum and Nassal, 1990). 
Synthesis of minus-strand DNA by reverse transcription of pregenomic RNA 
(Mason et al., 1982; Summers and Mason, 1982). DNA synthesis is initiated at DR1 
near the 3' end of the RNA template, as the 5' end of minus-strand DNA is mapped 
to the DR1 sequence at the 3' end of pregenomic RNA (Seeger et al., 1986; Seeger 
and Maragos, 1990). Terminal protein (TP) covalently attached to the 5 end of 
minus-strand DNA is believed to serve as a primer for synthesis of minus-strand DNA 
(Gerlich and Robinson, 1980; Molnar-Kimber et al., 1983), and is encoded by the P 
gene (Barterschlager and Schaller, 1988; Bosch et al., 1988; Radziwill et al., 1990). 
The RNA template is degraded by viral P protein (RNase H domain) as DNA 
synthesis proceeds (Radziwill et al., 1990). 
Synthesis of plus-strand DNA by copying the minus-strand DNA. Synthesis of 
plus-strand DNA is primed by an RNA oligomer (with 17-18 nucleotides), which is 
donated from the 5 end of the RNA pregenome and bears a copy of DR  (Lien et al., 
1986; Seeger et al., 1986). The RNA primer is transposed to the DR2 region of the 
minus strand and primes the synthesis of plus-strand DNA (Lien et al., 1986; Seeger 
et al., 1986). When the 3 end of the elongating plus-strand DNA reaches the 5' end 
of the minus-strand DNA template, it must switch template to the 3 end of the minus-
strand DNA forming a circular molecule. The 3' end of the new plus strand 
dissociated from the 5 end of the minus strand contains a sequence complementary 
to the short terminal redundancy (r) of the minus strand. This complementary 
sequence in the plus strand could then base-pair with r at the 3 end of the minus 
strand, resulting in circularisation of the DNA and positioning of the 3' end of the 
minus strand for use as the template for continued elongation of the plus strand. The 
failure of plus strand to proceed to full-length may be attributable to the constraining 
of viral polymerase within the viral core. 
During the process of minus- and plus-strand DNA synthesis, the core particle are 
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assembled into mature virions by coating with post-translationally modified HBsAg 
and then exported from the hepatocytes in the blood stream. 
1.8 	Viral transcription 
HBV genome replication involves the reverse transcription of an RNA intermediate, 
termed pregenomic RNA. Therefore, viral transcription has a dual function: the 
synthesis of the RNA pregenome, which serves as a template for genome replication, 
and the synthesis of mRNAs for viral protein synthesis. It appears that the cccDNA, 
the first viral DNA form detected after infection and the only form found in the 
nucleus, is the template for viral transcription which is carried out by host RNA 
polymerase II. 
1.8.1 The HBV transcripts 
Four different transcripts which can be divided into two species, genomic and 
subgenomic, have so far been identified (reviewed by Blum et al., 1989; and by 
Schaller and Fischer, 1991). All of these RNAs are unspliced with the same polarity 
and are polyadenylated at a common 3' terminus (Figure 1.2). The genomic 
transcripts are greater than one genome-unit in length (3.5 kb) and serve as template 
for viral DNA synthesis as well as for the pre-C, C and P gene products (Will et al., 
1986 and 1987). Their synthesis is liver-specific (Will et al., 1987) and controlled by 
the core promoter (or genomic promoter), which has been identified within the 150 
nucleotides upstream of the genomic RNA start site with no "TATA-box" homology 
(Yaginuma and Koike, 1989). The core promoter directs the synthesis of two closely 
related subsets of genomic transcripts which have been designated according to their 
functions as pre-core mRNA and C mRNA/pregenome. The slightly shorter C 
mRNA/pregenome is synthesized more abundantly than the pre-core mRNA and is the 
messenger for HBcAg and the DNA polymerase (Ou et al., 1990). Furthermore, after 
assembly into nucleocapsid containing pregenomic RNA and viral DNA polymerase 
surrounded by the core proteins, this RNA becomes the template for reverse 
transcription to synthesize the viral DNA genome. The slightly longer pre-core 
mRNA is the messenger for the pre-core protein which is the precursor of HBeAg. 
The pre-core mRNAs are not packaged into nucleocapsids (Enders et al., 1987; Will 
et al., 1987; Nassal et al., 1990). Expression of the 3.5-kb transcript has been 
observed only in hepatic cell lines infected with HBV or transfected with its DNA 
(Will et al., 1987). Therefore, it seems likely that liver-specific host factors are 
required for genomic RNA transcription. 
The subgenomic transcripts consist of three species with 2.4, 2.1 and 0.9 kb in length, 
among which the 2.1-kb mRNA is the most abundant detected in the acutely infected 
liver. The 2.1-kb mRNAs (or the preS 2/S transcripts) are heterogeneous in size and 
are the templates for the synthesis of the S and the middle proteins specified by the 
same reading frame (Cattaneo et al., 1983 and 1984). A longer RNA is the messenger 
for the middle protein, while several shorter RNAs with similar length, which initiate 
from different position, are the messengers for the S protein. Synthesis of these 2.1-
kb mRNAs is also controlled by a single promoter, termed the preS 2/S promoter 
(Raney et al., 1989). This promoter also lacks a "TATA-box" sequence, instead, the 
DNA sequence upstream of the preS 2/S mRNA start sites contains homology to GC-
rich elements of the SV40 late promoter (Cattaneo et al., 1983). The 2.1-kb PreS 2/S 
transcripts have been detected in several transfected cell lines derived from non-
hepatic tissues, suggesting that expression of these transcripts is not particularly tissue-
or species-specific (Laub et al., 1983). However, it is possible that expression of the 
transcripts might be substantially more efficient in hepatocytes. 
The 2.4-kb mRNAs (or the preS 1 transcripts) are the templates for the synthesis of the 
large protein (Will et al., 1987). The preS 1 promoter contains a "TATA box" 
sequence found in most eukaryotic promoters, which is highly liver-specific 
(Antonucci and Rutter, 1989) and displays much lower activity than the preS 2/S 
promoter (Cattaneo et al., 1984; Yaginuma et al., 1987; Raney et al., 1990). 
From its map position, a polyadenylated transcript of about 0.9-kb in length is a 
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candidate for a mRNA for X-gene expression. Gough (1983) demonstrated a 1.0-kb 
transcript which appeared to map to the X region in HBV-transfected rat cells. In 
human cells transfected with HBV, a 0.7-kb transcript which coded for X protein was 
also identified (Saito et aL, 1986). In woodchucks with acute or chronic WHV 
infections, an X-region-specific transcript of approximately 0.65 kb was found 
primarily in the nucleus of hepatocytes (Kaneko and Miller, 1988). However, the X 
transcript has not been identified during the course of HBV infections. The 
production of this mRNA seems to be drastically repressed under conditions 
supporting viral replication. Apart from the core, preS 2/S, and preS 1 promoters, the 
fourth promoter element, the X promoter, located upstream from the X gene which 
directs transcription of a heterologous reporter gene has been identified (Siddiqui et 
al., 1987; Treinin and Laub, 1987). 
1.8.2 The regulation of viral transcription 
Besides the four promoters, which direct the synthesis of the four different transcripts, 
and the single polyadenylation site, two enhancer elements have been identified in the 
HBV genome (Figure 1.2). One is located as a part of the X promoter overlapping 
the 3 end of the P gene, which is generally known as the enhancer and has been 
recently designated enhancer I (Shaul et aL, 1985), and the other is located 
downstream of the enhancer I and immediately upstream of the core promoter 
overlapping the 3' end of the X gene, and is designated enhancer II (Yee, 1989). 
Transcription from all HBV promoters is increased in the presence of the enhancer I 
(Hu and Siddiqui, 1991). The enhancer I is also able to stimulate heterologous 
promoters, eg. the herpes simplex virus thymidine kinase promoter (Antonucci and 
Rutter, 1989; Yee, 1989) and the SV40 early promoter (Shaul et al., 1985; Chang and 
Ting, 1989) There are disparate results concerning the liver specificity of the 
enhancer I (Elfassi, 1987; Chang and Ting, 1989; Patel et al., 1989; Yee, 1989). In 
contrast, the enhancer II functions exclusively in a liver-specific manner, thus it is also 
termed liver-specific enhancer (Yee, 1989; Yuh and Ting, 1990). 
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Negative regulatory elements within the HBV genome have been detected. It has been 
shown that a negative regulatory element within the preS 1 coding region could down-
regulate transcription from the preS 1/S promoter (De-Medina et al., 1988; Bulla and 
Siddiqui, 1989). Another negative regulatory element, a silencer element, located 
within the X ORF and near the core promoter has also been found to down-regulate 
the activity of the core promoter, and the SV40 early promoter in an orientation-
independent, but a position-dependent, manner (Gerlach and Schloemer, 1992). 
Viral transcription is also regulated by viral gene products. It has been shown that 
HBxAg is capable of acting as a transcriptional transactivator of a wide range of 
homologous and heterologous transcriptional regulatory sequences of viruses and 
various cellular genes (Reviewed by Rossner, 1992). HBxAg regulates transcription 
from the HBV core promoter/enhancer (Colgrove et al., 1989; Siddique et al., 1989), 
the preS2/S promoter/enhancer (Colgrove et al., 1989; Rossner et al., 1990), the preS 1 
promoter/enhancer (Raney et al., 1990; Rossner et al., 1990), and the X 
promoter/enhancer (Siddiqui et al., 1989). In addition, it has been demonstrated that 
a 3'-truncated preS 2/S region of integrated HBV DNA expressed in a human hepatoma 
cell line and tissue encoded a C-terminally truncated middle surface protein (MHBs), 
which exerted a transcriptional transactivator function (Kekule et al., 1990; Lauer et 
al., 1992). This transactivation phenomenon is at least in part linked to the protein 
kinase C signalling pathway (Natoli et al., 1992). This mechanism has recently been 
demonstrated to be used by HBxAg for transactivation (Kekule et al., 1993). 
1.9 Immune response to HBV 
Immune response to HBV antigens plays a major role in determining pathological 
sequelae in acute and chronic HBV infection. The serological profiles of acute and 
chronic disease states are presented in Figure 1.4. Termination of the HBV infection 
occurs with the disappearance of HB5Ag and the appearance of anti-HBs. The 
presence of HBsAg (and perhaps preS)-specific cell-mediated immunity might be 
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Figure 1.4 The serological profiles during acute and chronic HBV infection. 
Variations in the time at which the various markers appear in individual cases are 
indicated by dash lines. (Adapted from Murray, 1987). 
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addition to the cellular immune responses for clearance of infected hepatocytes, 
neutralising antibodies are required to prevent spread of released virions to uninfected 
liver cells. The establishment of the chronic carrier state could be regarded as a 
failure to mount appropriate immune responses to HBV infection. It is generally 
accepted that the pathogenesis of chronic HBV infection is immunologically mediated 
and not due to direct cytopathic effects of the virus. T-cell responses to HBcAg on 
the surface of infected hepatocytes play an important role in the pathogenesis of liver 
damage in chronic HBV infection (Mondelli et al., 1982). 
1.9.1 Immunology of HBsAg 
The antigenic specificities of HBsAg are complex. All HBsAg preparations possess 
the dominant, group-specific determinant a and two pairs of subtype determinants d 
or y and w or r which are, for the most part, mutually exclusive. Therefore, four 
HBsAg serological subtypes are generally encountered, namely, adw, adr, ayw and 
ayr. However, isolated cases of unusual HBsAg subtype determinants, such as awr, 
adwr, adyw, adyr and adywr, have been reported (Okamoto et al., 1987; Yamanaka 
et aL, 1990). The "compound" subtype may be due to phenotypic mixing either by 
co-infection of hepatocytes with one original subtype and the mutant strain induced 
by point mutation which leads to subtype conversion or by double infection of 
hepatocytes with two HBV strains of different subtypes, which might be introduced 
to HBV carriers in early stages while immune responses are immature, or to those 
who are immunocompromised (Yamanaka et al., 1990). The HB5Ag subtypes are 
unevenly distributed around the world and have provided useful markers for 
epidemiologic studies. 
The a determinant of the S region has been located between amino acid residues 138 
and 149 (Prince et al., 1982), as well as 139 and 147 (Bhatnagar et al., 1982) by 
peptide epitope mapping and antigenic prediction approaches. An additional a 
determinant has also been identified with a disulphide induced cyclic peptide 
corresponding to residues 122 to 137 of HBsAg (Dreesman etal., 1982; Ioflescu-Matiu 
41 
et al., 1983). The a determinant is composed of more than one epitope since panels 
of non-crossreacting a-specific monoclonal antibodies exist (Swenson et al., 1988). 
The majority of the a epitopes are conformationally sensitive and likely to be 
discontinuous. The spatial arrangement of the antigenic region appears to be stabilised 
by cystine bridges. Cyclisation of peptides corresponding to the a region through 
cysteine residues 124 and 137 (Dreesman et al., 1982) or 139 and 147 (Brown et al., 
1984) results in increased antigenicity. It was also shown that the replacement of 
cysteines 124 and 147 by serines drastically reduced or eliminated antigenicity and 
proline residue 142 was required for the display of full antigenicity (Ashton-Rickardt 
and Murray, 1989a). In contrast, cysteine 121 can be changed to serine without 
affecting antigenicity (Antoni and Peterson, 1988). Antibodies to the a determinant 
provide protection against infection by any of the HBV subtypes (Szmuness et al., 
1982). Some of the antibodies to the a determinant have been shown to be capable 
of neutralising both ad and ay subtypes of HBV (Iwarson et al., 1985a). 
Extensive studies on the immunogenicity of three forms of HBsAg and on the 
regulation of the immune response 'to them have been carried out in inbred mice by 
Milich and his colleagues. Antibody production and T-cell response, including 
HBsAg-specific T cell proliferation and interleukin-2 (IL-2) production, to the S 
protein are regulated by at least two immune response (Ir) genes mapping in the I-A 
and I-C subregions of the H-2 locus (Milich and Chisari 1982; Mulch et al., 1985a). 
HBsAg high-responder and non-responder haplotypes have been identified. Multiple 
T cell recognition sites on HB5Ag, dependent on the H-2 haplotype of the responder 
strain, have also been recognised (Milich et al., 1985c). Furthermore, the T cell 
recognition sites do not necessarily overlap with B cell recognition sites (Milich et al., 
1985c). Different B-cell as well as Th-cell epitopes of S, preS 1 and PreS 2 regions are 
recognised in different inbred strains (Milich and Chisari, 1982; Mulch et al., 1986b 
and 1987a). 
The preS2 antigen is more immunogenic than the S antigen in terms of antibody 
production in vivo with respect to the effective immunisation dose and the magnitude 
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as well as the time of onset of the primary immune response (Milich et al., 1985d). 
The preS2 antigen also appears to be more immunogenic than the S antigen at the T -
cell level in terms of in vitro T-cell activation, including the effective priming dose, 
the magnitude of the T-cell response, and the quantitative in vitro dose-response curve 
(Milich et al., 1985b). Furthermore, the immune response to preS 2 . antigen is 
regulated by H-2 linked genes distinct from those regulating the immune response to 
S antigen, such that immunisation with preS 2 antigen of mice responsive to preS 2 
antigen but non-responsive to S antigen can circumvent non-responsiveness to the S 
antigen. Therefore, the preS 2 antigen appears capable of generating Th-cell activity 
that can induce S-region as well as preS 2-region antibody production, thereby 
circumventing non-responsiveness to the S region (Milich et al., 1985b and 1985d). 
Although the antibody response to the preS 2 region is largely group-specific (Milich 
et al., 1986b and 1990c), the preS 2-specific T-cell response is highly subtype-specific 
(Milich et al., 1990a). 
Similar characteristics have been described for the immune response to preS 1 antigen. 
The genetic regulation of anti-preS 1 antibody production can be independent of the 
anti-S and anti-preS2 regions, as immunisation with HBsAgfP39 particles containing 
the preS 1 region can bypass non-responsiveness to the S and preS 2 regions in terms 
of antibody production (Milich et al., 1986a). Therefore, although the production of 
antibody to the three regions of HBsAg is independently H-2-restricted, preS 1- and 
preS2-specific T cells can provide functional help not only to B cell clones of the 
corresponding antigen specificity, but also to S region-specific B cell clones. Other• 
results suggest that antibodies to preS 1 and preS 2 are virus-neutralising (Neurath et al., 
1985). These results argue that inclusion of the preS region may augment the 
effectiveness of future HBV vaccines by providing a more immunogenic HBsAg 
particle and by decreasing the incidence of genetic non-responsiveness. If the human 
T cell response to preS 2 is focused on the subtype variable C-terminal region, which 
is the case in murine T cell recognition (Milich et al., 1990a), there may be a case for 
including both major subtypes of HBsAg/P33 in preS 2-containing vaccines, whereas 
the preS2-containing vaccines currently in clinical trials are composed of a single 
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HBsAg subtype (Tron et al., 1989). However, so far there is no clinical evidence to 
prove that the preS 2-containing vaccines are superior to the S protein-containing 
vaccines. 
The S protein bears B-cell determinants important for the induction of a protective 
immune response in man. Both individuals who recover from an acute HBV infection 
and those who respond properly to the HBsAg vaccine produce significant amounts 
of anti-HBs antibodies. On the other hand, patients with chronic HBV infections and 
non-responders to the vaccine produce little, if any anti-HBs. Indeed, the HBV 
vaccine produced from plasma-derived HBsAg and treated with pepsin in its 
manufacturing contains no preS 1 or preS 2 region but only S region, as does the vaccine 
produced in yeast containing only the S coding sequence (Murray et al., 1984). 
In the course of acute HBV infection, the appearance of anti-preS antibodies precedes 
anti-S antibody. The antigenic determinants of preS 2 appear to be linear, as they are 
resistant to reduction of disulphide bonds (Neurath et al., 1984). The disulphide bond-
independent determinants on the preS 2 region may be more easily mimicked by 
peptide analogues than "conformational" determinants on the S region. The protective 
role of anti-preS antibody is supported by chimpanzee-challenge experiments. The 
complete preS 2 region or a synthetic peptide derived from it has been shown to confer 
protective immunity in chimpanzees (Itoh et al., 1986; Emini et al., 1989; Thornton 
et al., 1987 and 1989). A synthetic peptide derived from the preS 1 region (preS 12-
47) also elicits antibodies protective against HBV infection in chimpanzees (Neurath 
et al., 1989; Thornton et al., 1989). 
In humans, T cell sensitisation to HBsAg in acute and chronic HBV infection is 
usually undetectable and when measurable is expressed transiently and at low level 
(Ferrari et al., 1986 and 1990). Vento et al. (1987) evaluated prospectively the T cell 
sensitisation to HBV antigens from the preclinical phase of acute hepatitis. The first 
detectable response in terms of T lymphocyte migration inhibitory factor (T-LIF) 
production (about 1 month before the first evidence of liver damage) was directed to 
44 
preS2 determinant, followed by the appearance of T cell sensitisation to HBcAg and 
finally to HBsAg. These T cell responses became undetectable shortly after the 
clinical symptoms. After recovery, T cells were again responsive to HBsAg and preS 2 
antigen, whereas sensitisation to HBcAg was no longer detectable. Mishra et al. 
(1992) also showed the presence of T cell response in terms of lymphocyte 
proliferation against the S (124147) peptide during early acute hepatitis. This response 
was suppressed during late stages followed by partial reversal during recovery. The 
decline in T cell responsiveness during the late acute phase of hepatitis may be due 
to immunosuppression (Barnaba et al., 1985) and persistence of the same may also be 
involved in the development of chronicity. Ferrari et al. (1990) found positive 
lymphocyte responses to the envelope proteins, which although low, were almost 
equally distributed in the different groups of patients studies [HBeAg(+) CAH, anti-
HBe(+) CAH, or chronic asymptomatic carriers] and the S-, preS 1-, and preS 2-specific 
T cells were simultaneously elicited. The T cell response to HBsAg in vaccine 
recipients has been investigated. Celis et al. (1984) showed that the PBLs from most 
of the vaccinees did not proliferate to a great extent to HBsAg in vitro. However, the 
lymphocyte proliferation to HBsAg could be substantially increased with some of the 
non-responding individuals if their peripheral blood lymphocytes (PBLs) were 
maintained in culture in the presence of HBsAg and IL-2. Since production of anti-
HBs antibody is T-cell dependent (Roberts et al., 1975), T cell sensitisation to HBsAg 
plays an important role in the clearance of HBV. 
1.9.2 Immunology of HBcAg and HBeAg 
Despite the fact that HBcAg is an internal component of the virion, high-titred anti-
HBc antibodies are regularly produced by virtually 100% of HBV-infected individuals. 
Furthermore, anti-HBc of 1gM class appears early in acute hepatitis B, before anti-
HBs, and 1gM and IgG anti-HBc can persist with slowly decreasing titres for many 
years. In contrast, anti-HBe antibody may not develop or may appear at various times 
after the appearance of anti-HBc, and its presence is correlated with viral clearance. 
Although HBcAg and HBeAg are structurally related and highly cross-reactive at the 
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T-cell level (Milich and McLachlan, 1986; Milich et al., 1988b), they are serologically 
distinct and the immune responses to them appear to be regulated independently. 
In the murine system, Milich and McLachlan (1986) demonstrated that HBcAg can 
induce antibody response via both T-cell-dependent and T-cell-independent pathways. 
In contrast, anti-HBe production is T-cell-dependent. Anti-HBc antibody production 
and the HBcAg-specific T cell response are all influenced by similar H-2-linked-genes 
(Milich et al., 1987b). The anti-HBc response is significantly greater than the anti-
HBsAg response in all strains of mice and no non-responder strains have been 
identified. Multiple, but distinct, T-cell sites on HBcAg are also recognised by 
individual inbred strains of mice (Milich et al., 1987b). Agretopic (residues binding 
to MHC molecules) and epitopic (residues binding to T-cell receptors) residues within 
a dominant T-cell determinant of the HBcAg have been demonstrated in a certain 
haplotype of mice (Milich et al., 1989). This murine model predicts that a human 
outbred population would exhibit similar complexity, and individuals may recognise 
distinct T-cell sites in the context of their specific HLA genotypes. Although neither 
anti-HBc nor anti-HBe antibody is virus-neutralising, vaccination with HBcAg can 
confer protection against HBV infection in chimpanzees (Murray et al., 1984 and 
1987; Iwarson et al., 1985b). Milich et al. (1990b) investigated the consequences of 
in utero exposure to HBeAg on HBcAgIHBeAg-specific immune responses by using 
HBeAg-expressing transgenic mice as a model. The HBeAg transgenic mice were 
tolerant to both HBeAg and HBcAg at the T-cell level. They did not produce 
antibody to HBeAg, but did produce anti-HBc in vivo and in vitro. The finding that 
in utero exposure to HBeAg renders T cells non-responsive to HBeAg as well as to 
HBcAg may be relevant to the mechanisms of T-cell tolerance in human HBV 
infection because HBeAg is more likely than HBcAg to traverse the placenta. 
The studies by Milich et al. (1987c) demonstrated that HBcAg-specific T cells are 
capable of providing Th-cell activity for anti-S, anti-preS 1 and anti-preS 2 antibody 
production provided HBcAg and these envelope proteins are present within the same 
particle or entity. This fact may explain the mechanism of protection by HBcAg in 
46 
chimpanzees (Murray et al., 1984). Furthermore, these HBcAg-specific Th cells were 
shown to induce anti-HBs production in HBsAg-non-responder mice (Milich et al., 
1987c). These studies describe a mechanism for circumventing HBsAg non-
responsiveness in which the only requirement was that HBcAg and HBsAg be present 
within the same particle, eg. HBV. A similar result was obtained by using a Th-cell 
epitope from HBcAg, instead of HBcAg itself, as a T-cell carrier moiety. A synthetic 
peptide composed of a Th-cell epitope from HBcAg and a B-cell epitope from HBsAg 
can elicit production of anti-peptide antibody, that is cross-reactive with the native 
HBsAg (Milich et al., 1988a). These results indicate the potential use of HBcAg or 
HBcAg-specific Th-cell epitopes as carrier moieties for a multivalent vaccine against 
HBV and other infectious agents. Moreover, HBcAg was shown to function 
efficiently as an immunologic carrier moiety for DNP (dinitrophenyl) hapten in 
euthymic as well as athymic mice in contrast to conventional carrier proteins (Milich 
et al., 1988a). Therefore, the T-cell-independent nature of HBcAg may be exploited 
to advantage for vaccine development for use in individuals who are T-cell 
compromised. 
In chronic HBV infection, Vento et al. (1985) showed that T lymphocytes from 
patients with chronic HBV infection were able to produce T-LIF in response to 
HBcAg but not to HBsAg. Ferrari et al. (1986) demonstrated that peripheral blood 
T cells bearing the CD4 (helper/inducer) phenotype from patients with chronic HBV 
infection were sensitised by HBcAg. The intrahepatic, infiltrating lymphocytes, which 
may be more representative of events occurring at the site of HBV antigen synthesis 
and cellular injury, contain functionally competent Th cells and CTLs that are specific 
for HBcAg and are capable of regulating each other's activities (Ferrari et al., 1987a 
and 1987b). 
There is accumulating evidence that HBcAg is a major target for a specific cell-
mediated immune response during chronic HBV infection. HBV-infected hepatocytes 
may be destroyed in vitro by autologous peripheral blood T cells and that killing is 
inhibited by anti-HBc but not by anti-HBs antibodies (Mondelli et al., 1982; Naumov 
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et al., 1984). A reduction of T cell cytotoxicity against autologous hepatocytes similar 
to that obtained with anti-HBc antibodies has also been observed using monoclonal 
anti-HBe antibodies (Pignatelli et al., 1985). Further evidence in support of HBcAg 
as the primary target antigen comes from immunofluorescence studies showing that 
cytoplasmic/membranous distribution of HBcAg is associated with CAll compared to 
a nuclear distribution of HBcAg in patients with CPH, while membranous HBsAg is 
present in both CAR and CPH (Chu et al., 1987), suggesting that the immune system 
may recognise HBcAg and thereby contribute to pathology by eliminating some cells 
expressing HBcAg and replicating virus. However, it is not clear whether HBcAg is 
also the target for recognition by CTL during acute hepatitis B. It was shown that 
monoclonal anti-HBc antibodies were able to inhibit cytotoxicity by approximately 
50% in acute hepatitis infection (Mondelli et al., 1987). The remaining activity which 
was not inhibited by anti-HBc antibodies presumably was due to natural killer cells 
which have been shown to be active during the course of acute HBV infection 
(Chemello et al., 1986). These results suggest that HBcAg can also be a major target 
for recognition by CTL during acute infection. 
1.10 Vaccine development 
Conventional vaccines based on inactivated or attenuated infectious agents have some 
disadvantages. With inactivated vaccines there is always the need to ensure that the 
product no longer contains any live organisms. Moreover, the handling of large 
volumes of virulent organisms is a hazard to the personnel involved. With attenuated 
vaccines the disadvantages include the possible presence of adventitious agents in the 
cells or medium used for production, the hazard of reversion to virulence, and the 
need for storage at low temperature. These factors encouraged the development of 
new vaccines based on recombinant DNA technology, the best example of which is 
the HBV vaccine based on the S protein produced in yeast. In fact, the first hepatitis 
B vaccines were prepared from plasma of asymptomatic HBV carriers using purified 
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at present. The drawback of the difficulty to propagate HBV in vitro has prevented 
the development of conventional vaccines from virus propagated in cell culture. Since 
HBsAg has been proved to elicit neutralising or protective antibody as shown by 
serological surveys and experimental transmission studies in human volunteers and 
chimpanzees, purified HBsAg particles isolated from HBV carriers have been 
developed as vaccines. The plasma-derived vaccines have been shown to be safe and 
effective (Szmuness et al., 1980) and have been widely used throughout the world. 
However, the source of HBsAg is relatively limited and is not uniform, and extensive 
purification procedures and safety testing are required, but HBsAg can now be 
produced in yeast on a large scale for use as a vaccine in humans (Murray et al., 
1984). 
The use of synthetic peptides for vaccination is one alternative which is vigourously 
being explored. The synthetic vaccines contain a relatively small peptide or peptides 
shown to constitute epitopes of the organisms which elicit a protective immune 
response. Since they can be chemically synthesized in unlimited quantities and do not 
contain infectious agents, they might prove to be the vaccines of choice if found 
sufficiently efficacious. Since the dominant B-cell epitopes on the S protein are 
discontinuous, it has proved difficult to mimic them by linear synthetic peptides. This 
problem is partially overcome by using cyclic peptides generated by intramolecular 
disulphide bond formation between cysteine residues present in the peptides 
(Dressman et al., 1982; Brown et al., 1984). Successful mimicking of determinants 
of the S protein using synthetic peptides has been reported (Prince et al., 1982; 
Dressman et al., 1982; Brown et al., 1984). Since enhancement of the 
immunogenicity of the preS region of HBsAg has been demonstrated in mice (Milich 
et al., 1985b and 1985d), and the peptides derived from the preS 1 or preS 2 are 
protective against HBV infection in chimpanzees (Itoh et al., 1986; Emini et al., 1989; 
Neurath et al., 1989; Thornton et al., 1987 and 1989), it is suggested that the 
inclusion of the B-cell epitopes from the preS region into S protein-based HBV 
vaccines might broaden the repertoire of anti-HBV-specific antibodies elicited by 
active immunisation. 
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The first crucial step in raising protein-reactive anti-peptide antibodies that can provide 
protective immunity is identification of the protein fragment(s) comprising B-cell 
epitope(s). The only exact way to identify B cell epitopes is to understand the three-
dimensional structure of antigens or of antigen-antibody complexes. However, 
because such studies are difficult to carry out, many attempts to predict B-cell epitopes 
have been made. Because the antigenic determinants recognised by B cells can be 
either continuous or assembled topographic sites (discontinuous) and their location has 
been related to accessible, hydrophilic and mobile structures on the antigen, most 
predictive methods for B-cell epitopes are based on selecting amino acid sequences 
typical of such features (Hopp, 1986), such as hydrophilicity (Hopp and Woods, 
1981), t3-turn propensity (Chou and Fasman, 1978), and acrophilicity (Hopp, 1986). 
The acrophilicity scale was derived by visual observations to determine the frequency 
of occurrence of the amino acids in highly exposed locations on the surface of 
proteins. In contrast to the hydrophilicity scale, which is based on the water solubility 
of the amino acids, the acrophilicity scale is, for the most part, a size scale. Some 
computer programmes containing relevant algorithms for prediction of B-cell epitopes 
have also been developed (Menendez-Arias and Rodriguez, 1990). Practical 
approaches to defining B-cell epitopes on a specific protein have concentrated largely 
on immunising laboratory animals with synthetic peptides predicted as described 
above, and seeking antibody reactivity with the native protein. Recently, libraries of 
random peptide sequences were constructed in filamentous phages and screened to 
identify peptides that specifically bind to known antibodies or other proteins (Scott 
and Smith, 1990; Devlin et al., 1990). The epitopy library may provide a simple, 
inexpensive alternative to chemical synthesis of peptides for mapping B-cell epitopes, 
and has the advantage of being completely unbiased. 
It was generally believed that, because of their small size, peptides would behave like 
haptens and would therefore require coupling to a large "foreign" protein carrier, such 
as bovine serum albumin, keyhole limpet haemocyanin (KLH) or thyroglobulin, to 
enhance their immunogenicity. Thechoice of appropriate carriers and the method of 
peptide-carrier linkage are of primary importance. Tetanus toxoid (TI) has been 
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employed in many studies because it has been used for human vaccination for many 
years without side effects. Moreover, because most humans have been immunised 
with Ti', the response against a synthetic peptide conjugated to IT carrier should be 
improved by the pre-existence of an anti-carrier immunity. However, epitopic 
suppression could occur as demonstrated by Schutze et al. (1985). A peptide with 
helper, but not suppressor function within Ti' has been identified and may circumvent 
epitope-specific suppression (Edinger et al., 1990). Other carrier systems have been 
explored, such as liposomes (Garcon and Six, 1991), lipids (Goodman-Snitkoff et al., 
1991; Schild et al., 1991) and some integral membrane proteins isolated from E. coli 
(Croft et al., 1991). 
In fact, synthetic peptides can be highly immunogenic in their free form if they 
contain not only a B-cell epitope but also a Th-cell epitope. The 141-160 peptide 
from VP1 of FMDV is a good example of such a peptide. In its unconjugated form, 
this peptide is capable of eliciting a neutralising antibody response that will protect 
experimental animals against infection (Francis et al., 1985 and 1987a). Mice 
immunised with a peptide from Sendai virus nucleoprotein, which was recognised by 
the C1'Ls of the mice were protected against lethal virus challenge (Kast et al., 1991). 
Similarly, when Schulz et al. (1991) injected a T-cell epitope from the nucleoprotein 
of LCMV as a free synthetic peptide, protection was demonstrated by inhibition of 
viral replication in mice spleens, which correlated with CD8(+) LCM V-specific CFLs. 
If, however, a free peptide is a poor immunogen or produces an immune response that 
is genetically restricted, an appropriate Th-cell epitope, either from a foreign protein 
or from the same molecule as the B-cell epitope, may be added. Francis et al. 
(1987b) demonstrated that H2d  mice, which are poor or non-responders to the 141-
160 peptide of FMDV, can be converted into responders by adding foreign Th-cell 
epitopes from ovalbumin or sperm whale myoglobin to the FMDV peptide sequence. 
A synthetic immunogen comprising an HBcAg Th-cell epitope (P120-140) and an 
HBsAg B-cell epitope from the preS 2 region (P14-21) elicited anti-peptide antibody 
production which was cross-reactive with the native envelope protein (Milich et al., 
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1988a). It was also shown that the peptide consisting of a Th-cell epitope and a B-
cell epitope from human rhinovirus also elicited good anti-peptide and antiviral 
response and may overcome the non-responsiveness of mice to the B-cell epitope 
alone (Francis et aL, 1989). The drawback of inclusion of Th-cell epitope is that it 
is necessary to characterise and incorporate additional Th-cell epitopes in order to 
broaden the potential of Th-cell recognition in an outbred population. In identification 
of Th-cell epitopes, generally, in vitro assays of T-cell proliferation in response to 
component proteins, protein fragments and peptides are required to identify appropriate 
sequences (Livingston and Fathman, 1987). Furthermore, it seems that universal Th-
cell epitopes for each species should be sought. 
However, there are two published algorithms that appear to improve the chances of 
selecting appropriate peptide sequences with T-cell epitopes from the primary 
sequence of a protein. The first, proposed by DeLisi and Berzofsky (1985), suggests 
that T-cell epitopes tend to be amphipathic structures, i.e. molecules that possess 
opposed hydrophilic and hydrophobic domains, which are frequently on opposite faces 
of an a-helix. The second method, proposed by Rothbard and Taylor (1988), is based 
on amino acid sequence patterns found to be associated with T cell antigenicity. 
Computer programmes for prediction of T-cell epitopes are now available (Menendez-
Arias and Rodriguez, 1990). 
An alternative approach to presentation of peptide epitopes to the immune system is 
the linkage of the potential B-cell epitopes to larger carrier molecules which may, or 
may not, possess their own Th-cell epitopes. Research has focused on methods of 
polymerising peptides or conjugating them to large immunogenic carrier proteins. 
Problems with these methodologies include the introduction of chemicals that are 
undesirable in vaccine preparations. A number of approaches have been developed 
to overcome these drawbacks. Tam (1988) has shown that, by building the peptide 
of interest onto a framework of lysine residues so that eight copies instead of one are 
present, the product elicits a much greater response than the monomeric form. This 
system, termed multiple antigenic peptide (MAP) system has been proved useful for 
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synthetic peptides derived from FMDV (Francis et al., 1991), Schistosoma mansoni 
(Wolowczuk et al., 1991) and HIV (Nardelli et al., 1992) etc. The diepitope MAPs 
containing both the a and the preS 2 determinant of HBV induced high-titre antibodies 
reactive to the a synthetic peptide and the S protein, as well as to the middle proteins 
(Tam and Lu, 1989). Another system has been developed for the efficient attachment 
of a synthetic peptide to a reassembled rotavirus nucleocapsid without using additional 
chemical reactions (Frenchick et al., 1989). Yet another promising approach is the use 
of recombinant DNA technology to engineer coding sequences for small peptide 
sequences fused to the genes for larger proteins. The presentation of viral epitopes 
on the surface of particulate structures has been explored, so that the epitopes are 
repeated over the entire surface of the particle and may therefore resemble the virion 
structure from which they were derived. Several approaches have been made in this 
direction, particularly the use of self-assembling particles from either Ty protein from 
yeast (Adams et al., 1987), HBsAg (Delpeyroux et al., 1986) or HBcAg (Clarke et al., 
1987; Stahl and Murray, 1989; Francis et al., 1990). 
The use of HBcAg to present peptide epitopes offers several advantages. HBcAg can 
be synthesized in E. coli, where it spontaneously self-assembles into characteristic 27 
nm particles (Burrell et al., 1979) and can be expressed in a wide range of systems 
(Clarke et al., 1987; Kniskem et al., 1986; Roossinck et al., 1986). From the studies 
by Milich and his colleagues as discussed earlier, HBcAg is known to be highly 
immunogenic, due to the presence of a number of well-defined Th-cell epitopes, its 
ability to function as a T-cell independent antigen, and its polymeric nature. 
Furthermore, both the N- and the C-termini of HBcAg can be replaced, to some 
extent, by foreign epitopes without affecting the self-assembly properties. A study 
using FMDV VP1 peptide 141-160 fused to the N-terminus of HBcAg and expressed 
via vaccinia virus demonstrated that the immunogenicity could approach that of 
inactivated FMDV particles (Clarke et al., 1987). Stahl and Murray (1989) reported 
construction of several fusion proteins in which coding sequences for different 
epitopes from HBV S and preS proteins and from the envelope protein of HIV were 
linked to C-terminus of the first 144 residues of HBcAg. These fusion proteins are 
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produced in high yields in E. coli, assemble into core-like particles, and are good 
immunogens. 
1.11 Aims of this study 
Although currently used HBV vaccines based on HBsAg have proved to be effective 
and safe, 2-5% vaccinees fail to respond to them, or show little or no seroconversion. 
In addition, in patients on routine haemodialysis and those with immunodeficiencies, 
the efficiency of the vaccine was as low as 50% (Sanchez et al., 1983; Stevens et al., 
1984). The emergence of a vaccine escape mutant, which carries an amino acid 
substitution from glycine to arginine at amino acid 145 of HBsAg (Carman et al., 
1990; Harrison et al., 1991; Fujii et al., 1992) suggests that it may be necessary to 
modify future HBV vaccines. An ideal HBV vaccine should provide protection in 
those who do not respond to HBsAg or become infected with antigenic variants. Since 
preS regions are believed to play a role in viral entry into the hepatocytes (Machida 
et al., 1984; Neurath et al., 1986; Pontisso et al., 1989a) and anti-preS antibodies are 
virus-neutralising (Itoh et al., 1986; Emini et al., 1989; Neurath et al., 1989; Thornton 
et al., 1987 and 1989), one approach would be the inclusion of the neutralising 
epitopes from preS 1 and preS2 domains. Another approach would be the addition of 
the sequence of HBsAg from the mutant virus to induce antibodies with a different 
specificity to confer immunity against the mutants. 
HBcAg was shown to be an extremely efficient immunogen in terms of T cell 
activation and antibody production (Milich et al., 1987b) and its T-cell independent 
nature may be exploited to advantage for vaccine development for use in T-cell 
compromised individuals (Milich and McLachlan, 1986). Although anti-HBc antibody 
is not virus-neutralising, vaccination with HBcAg can confer protection against HBV 
infection in chimpanzees (Murray et al., 1984 and 1987; Iwarson et al., 1985b). 
Murine experiments showing that HBcAg-primed T cells can provide Th-cell recall 
memory for antibody production to envelope proteins may well explain the protection 
of chimpanzees against HBV infection by HBcAg vaccination. Furthermore, HBcAg- 
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speciflcTh cells were shown to induce anti-S antibody production in mice that did not 
respond to HBsAg (Milich et al., 1987c). Studies in mice also indicated that the 
production of antibody to preS 1, preS 2 and S regions of HBsAg is independently H-2-
restricted, preS 1- and preS2-specific T cells can provide functional help not only to B-
cell clones of the corresponding antigen specificity, but also to B-cell clones specific 
for S region; thus attachment of the Th-cell epitopes from preS 1 or preS2 to the S 
protein can circumvent non-responsiveness to the S region (Milich et al., 1985b, 
1985d and 1986a). Therefore, the problem that some vaccinees and patients do not 
respond to the S protein could perhaps be circumvented using the response to HBcAg, 
preS1 or preS2 through multivalent vaccines. The use of HBcAg to present peptide 
epitopes to the immune system has been shown to enhance immunogenicity of peptide 
epitopes (Clarke et al., 1987; Stahl and Murray, 1989). HBcAg could be exploited 
to serve as a carrier moiety to present S, alone or with mutant sequences, preS 1 and 
preS2 epitopes from the envelope proteins with the aims of creating a multivalent 
vaccine which may elicit a broader repertoire of protective antibodies. 
In this study, epitopes from preS 1, preS2 and S regions of the envelope proteins were 
fused to truncated HBcAg to create HBcAg fusion proteins carrying preS 1 and preS 2 
epitopes with or without the immunodominant a determinant of HBsAg, in the N- or 
C-terminal regions of HBcAg. Another series of HBcAg fusion proteins carrying the 
immunodominant epitope of HBsAg were also constructed in which g1y 145 was 
replaced by arginine, to mimic the reported escape mutant, glutamic acid or lysine. 
In addition, the wild-type a region was combined with the g1y 145 mutant sequence of 
HBsAg in HBcAg fusion proteins carrying in addition to one mutant and one wild-
type sequence of HBs (1111 the preS 1 and preS 2 epitopes. 
The antigenicities of these HBcAg fusion proteins were examined in terms of their 
reaction with anti-HBc and anti-HBs antisera. The humoral and cellular immune 
responses of rabbits and mice to these HBcAg fusion proteins were compared. To 
explore further the specificity of the antibody to the HBcAg fusion proteins, antisera 
to the, native HBsAg and to the HBcAg fusion proteins were compared. The results 
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not only provide information on the immunological aspects of the HBcAg fusion 
proteins carrying the envelope epitopes from HBV, but also shed light on the design 
of HBV vaccines based on HBcAg particles. 
56 
CHAPTER 2: MATERIALS AND METHODS 
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2A MATERIALS 
2A.1 Suppliers of laboratory reagents 
Restriction endonucleases: 
Boehringer Mannheim GmbH: Mannheim, Germany 
GIBCO BRL Life Technologies: Paisley, Scotland 
New England Biolabs Inc.: Beverly, Massachusetts, U.S.A. 
Pharmacia LKB Biotechnology: Milton Keynes, U.K. 
Modifying enzymes: 
Alkaline phosphatase, E. coli DNA polymerase I (Kienow large fragment), 
Mung bean nuclease, Sequenase version 2.0 DNA polymerase, Thermus 
aquaticus (Taq) DNA polymerase, T4 DNA ligase, T4 DNA polymerase, T7 
DNA polymerase. 
Boehringer Mannheim GmbH 
GIBCO BRL Life Technologies 
Northumbria Biologicals Ltd: Cramlington, U.K. 
Pharmacia LKB Biotechnology 
United States Biochemical Co.: Cleveland, U.S.A. 
Standard laboratory reagents: 
BDH Chemicals Ltd: Poole, U.K. 
Calbiochem-Novabiochem Co.: La Jolla, U.S.A. 
Fisons Chemicals: Loughborough, U.K. 
GIBCO BRL Life Technologies 
ICN Flow Limited: Rickmansworth, U.K. 
Sigma Chemical Co.: Poole, U.K. 
Reagents for bacterial media: 
Becton-Dickinson U.K. Limited: Oxford, U.K. 
Difco Laboratories: East Moseley, U.K. 
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Reagents for lymphocyte culture: 
GIBCO BRL Life Technologies 
ICN Flow Limited 
Pharmacia LKB Biotechnology 
Sera-lab: Sussex, U.K. 





Sheep anti-mouse Ig, 'I-labelled whole antibody 
Donky anti-rabbit Ig, 'I-labelled whole antibody 
Amersham International plc.: Aylesbury, U.K. 
Specific activity 
- 3,000 Curies/mmole 
1,000 Curies/mmole 
5 Curies/mmole 
- 2,400 Curies/mmole 
- 1,800 Curies/mmole 
Antibiotics: 
ampicillin - Beecham Research Laboratories: Brentford, U.K. 
penicillin G - Sigma Chemical Co. 
streptomycin - Sigma Chemical Co. 
tetracycline - Sigma Chemical Co. 
Sera: 
Anti-mouse IgG (sheep) precipitating serum 




Scottish Antibody Production Unit (SAPU): Lanarkshire, U.K. 
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Detection kits for radioimmunoassays (RIAs): 
AUSRIA II 125 diagnostic kit 
AUSAB diagnostic kit 
Abbott Laboratories: Chicago, U.S.A. 
2A.2 Media 
2A.2.1 Bacterial media 
Luria broth (LB): 
Difco Bacto-tryptone, 10 g 
Difco Bacto-yeast extract, 5 g 
NaCl, 5 g 
per litre adjusted to pH 7.2. 
Luria agar: 
As Luria broth with 15 g per litre Difco agar. 
Terrific broth: 
Difco Bacto-tryptone, 12 g 
Difco Bacto-yeast extract, 24 g 
glycerol, 4 ml 
per 900 ml mixed with 100 ml sterile solution of 0.17 M KH 2P041  0.72 M 
K2HPO4 after autoclaving 
M9 Minimal agar: 
Difco Bacto Agar, 15 g 
10 x M9 salts, 100 ml 
glucose, 20% (v/w), 20 ml 
Vitamin 13 1, 1 mg/ml, 10 ml 
MgSO41  0.1 M, 10 ml 
CaCl2, 0.1 M, 10 ml 
ME 
per litre. 
10 x M9 Salts: 
Na2HPO4, 60 g (0.423 M) 
KH2PO4, 30 g (0.220 M) 
NaCl, 5 g (0.086 M) 
NH4C1, 10 g (0.187 M) 
per litre. 
Top-layer agar: 
Difco Bacto agar, 10 g 
Trypticase, 10 g 
NaCl, 5 g 
per litre. 
2 x YT: 
Bacto-tryptone, 16 g 
Bacto-yeast extract, 10 g 
NaCl, 5 g 
per litre. 
Antibiotics: 
Ampicillin to a final concentration of 100 pg/ml or tetracycline to 10 ug/ml 
was added to media immediately prior to use when required. 
2A.2.2 Lymphocyte culture medium 
RPMI-1640 medium was supplied by GIBCO BRL Life Technologies as 10 
x concentrate medium and buffered with NaHCO 3 (10 mM) and HEPES (20 
mM). It was supplemented with L-glutamine (2 mM), -mercaptoethanol (2-
ME, 5 x iO M) and foetal calf serum (FcS, 5%) for lymphocyte culture. 
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2A3 Solutions 
20 x SSC: NaCl, 3 M; tn-sodium citrate, 0.3 M; pH 7.0 
50 x TAE: Tris-HC1, 2 M; glacial acetic acid, 1 M; EDTA, 50 mM; pH 8.0 
10 x TBE: Tris-HC1, 0.9 M; boric acid, 0.9 M; EDTA, 20 mM; pH 8.0 
TE: Tris-HC1, 10 mM, pH 8.0; EDTA, 1 mM 
Sequencing TE: Tris-HC1, 10 mM, pH 8.0; EDTA, 0.1 mM 
STE: Tris-HC1, 10 mM, pH 8.0; EDTA, 1 mM; NaCl, 150 mM 
PBS: K2HPO4, 8 mM; KH2PO41  1.5 mM; NaCl, 150 mM 
Low-Tris buffer (LTB): Tris-HC1, 20 mM, pH 7.9; NaCl, 20 mM; 
EDTA,lmM 
PCA: 25 parts redistilled phenol: 24 parts chloroform: 1 part iso-amylalcohol 
CA: 24 parts chloroform: 1 part iso-amylalcohol 
Scintillation fluid: 2,5-diphenyloxazole (PPO), 6 g; 
1,4-bis(5-phenyloxazol-2-yI)benzene (POPOP), 0.05 g; 
toluene, 1 litre 
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2A.4 Bacterial strains 
NAME GENOTYPE REFERENCE 
RB791 ara, E(lac-pro), strA, thi, Brent & Ptashne (1981) 
lacZEtMl5 
DH 5ct supE44, Hanahan (1983) 
AlacU169(4801acZM'f15), 
hsdRl7, recAl, endAl, 
gyrA96, thi-1 
NM522 hsdL5, A(lac, pro), supE, Gough & Murray (1983) 
dii, F[proAB, lacZEM15, 
lacP] 
BMH 71-18 mutL mutL::TnlO, t(lac, pro), Kramer et al. (1984) 
supE, th4 F7proAB, 
lacZMvulS, lacP] 
XL1Bluer supE44, hsdRl7, recAl, Bullock et aL (1987) 
endAl, gyrA46, thi, relAl 
lac, F[proAB, lacP, 
lacZLM15, TnlO(tef)j 
TG1 supE, hsdE5, dii, i(lac- Gibson (1984) 
proAB), F [traD36, 
proAr, ladq, lacZMvflSj 
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2A.5 Plasmids 
NAME DESCRIPTION REFERENCE 
pHBcS(l1l .. 1 This plasmid contains the coding Stahl & Murray (1989) 
sequence for a fusion protein of 
-galactosidase (1 /HBc(3 . 144) 
/HBS(llllS 	under control of the 
tac promoter. 
pHBcS(lI1 .. 1 Similar to pHBcS(lll. l . Contains Stahl & Murray (1989) 
HBs(1ll .
1 
	instead of HBs(lll . 156). 
pHBcPreS l(120)  Similar to pHBcS(llllS . Contains Stahl & Murray (1989) 
PreS l(l) instead of 
pHBcPreS l(l Similar to pHBcS (1l1l5 . 	Contains Stahl & Murray (1989) 
PreS l(1 . 3 	instead of HBs (1l1 . 1S . 
pHBcPreS 2 Similar to pHBcS (11l . l5 . 	 Contains Stahl & Murray (1989) 
PreS 1 	instead of HBs(lll . 1S . 
pHBcX Similar to pHBcS (11l15 . 	Contains Rossner (1991) 
HBs(111 ..120) and HBx(11$4) instead 
of HBs(111.15. 
pHinG2 E. colilS. cerevisiae shuttle vector. Murray et al. (1984) 
Allows expression of HBsAg in S. 
cerevisiae under control of yeast 
PHOS promoter. 
pHinG2145R Similar to pHinG2. Carries an K. Murray (personal 
amino acid substitution from communication) 
glycine to arginine at amino acid 
145 of HBsAg. 
PT 
2A.6 Oligonucleotides 
NAME SEQUENCE 5-3' COMMENTS 
M13-20 GTA AAA CGA CGG Bacteriophage M13 
CCA GT universal sequencing 
primer (20 nucleotides 
from the polylinker site). 
M13-40 GTF TFC CCA GTC ACG Bacteriophage M13 
AC universal sequencing 
primer (40 nucleotides 
from the polylinker site). 
991H CCT GCA GAA CCT HBV sense strand, 
GCA CG nucleotide positions 1795- 
1811. 
405J CCT GGG TGG GTA HBV sense strand, 
CFA ATT nucleotide positions 209- 
226. 
705C TCA GGA GAC TCT HBV anti-sense strand, 
AAG GC nucleotide positions 137- 
121. 
212S GGA AlT CAT CCA HBV anti-sense strand, 
ACT GGT GGT CGG G nucleotide positions 1007- 
990 with 7 additional 
nucleotides at the 5' end 
including a cleavage site 
for EcoRI. 
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O1OH GGA ATF CCC AGO HBV sense strand, 
AAC ATC AAC CAC nucleotide positions 1767- 
1783 with 7 additional 
nucleotides at the 5' end 
including a cleavage site 
for EcoRI. 
01 1H GGA A11 CCC AGG HBV anti-sense strand, 
ATG ATG GGA TG nucleotide positions 1905- 
• 1889 with 6 additional 
nucleotides at the 5' end 
including a cleavage site 
for EcoRI. 
412G ACC TFC GGA TAG HBV sense strand, 
AAA CTG CAC Cr nucleotide positions 1859- 
1881 with 1869 G–A. 
411G ACC TI'C GGA TGA HBV sense strand, 
AAA CFG CAC Cr nucleotide positions 1859- 
1881 with 1870 G—A. 
359G AAA CCT TCG GAT HBV sense strand, 
AAA AAC TGC ACC TG nucleotide positions 1857- 
1882 with 1869 G–A and 
1870 G–A. 
Oligonucleotides were synthesized by the OSWEL DNA Service, Department of 
Chemistry, University of Edinburgh. 
2A.7 Antibodies 
Antibody Description Source 
R82 anti-HBs Rabbit antiserum raised against K. Murray 
antiserum HBsAg produced in yeast. 
R87 anti-HBc Rabbit antiserum raised against K. Murray 
antiserum HBcAg produced in E. coli. 
NRAJB7-4B Rabbit antiserum raised against P. Wingfield 
SDS- and D'fl-denatured 
HBsAg. 
Monoclonal Raised against HBsAg from W. H. Gerlich 
antibody MA 18/7 serum. Reacts with the preS 1 Heermann et al. (1984) 
region of P39 and GP42, native 
or denatured form, of all 
HBsAg subtypes. 
Monoclonal Raised against HBsAg from W. H. Gerlich 
antibody Q19/10 serum. Reacts with the preS 2 Heermann et al. (1987) 
region of GP33 and GP36 of all 
HBsAg subtypes, but does not 
react with unglycosylated P31. 
Monoclonal Raised against HBsAg from H. C. Thomas and J.A. 
antibody RF-HBs-1 serum. Reacts with cyclic Waters 
peptide (124-137) of HBsAg. 
Monoclonal Raised against HB5Ag from H. C. Thomas and J.A. 
antibody RF-HBs-2 serum. Reacts with cyclic Waters 
peptide (124-137) of HBsAg. 
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Monoclonal 	Raised against HBsAg from 	H. C. Thomas and J.A. 
antibody RF-HBs-7 serum. Reacts with cyclic 	Waters 
peptide (139-147) of HBsAg. 
2A.8 Synthetic peptides 
preS 1(1 .23) (adyw subtype) 
MGQNL STSNP LGFFP NHQLD PAF 
preSl(1 . 2 (adyw subtype) 
MQWNS =HQ TLQDP RVRGL YFPAG G 
HBs (111 . 15 (adyw subtype) 
PGSST TSTGP CRTCT TPAQG ISMYP SCCCT KPSDG NCTCI 
PIPSS W 
Synthetic peptides were synthesized by R. Ramage of the Department of 
Chemistry, University of Edinburgh. 
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2B METHODS 
2B.1 Bacterial cultures 
2B.1.1 Growth of bacterial cultures 
Bacterial culture broth, either LB or Terrific broth, was inoculated with E. coli from 
a single colony or 1/100 volume of an overnight culture in a test tube or a conical 
flask with a total capacity of 5 fold to that of the culture volume to ensure good 
aeration. Cultures were incubated at 37°C with shaking for 5-6 hr or overnight. 
2B.1.2 Storage of bacterial cultures 
For long-term storage, 900#1 of fresh overnight or 6-hr culture of bacteria grown in 
LB supplemented with antibiotics if necessary, was mixed with 100 ul of sterile 
glycerol, and stored in a sterile, plastic cryo tube (Nunc, Roskilde, Denmark) at -70°C. 
To recover the bacteria, the surface of the frozen culture was scraped with a sterile 
inoculating loop and directly streaked out onto a LB agar plate, with antibiotics if 
required. E. coli strain TG1 was streaked onto a minimal agar plate to maintain the 
F' plasmid. After overnight incubation at 37°C, a single colony was picked to 
propagate a fresh bacterial culture. For short-term storage, an isolated colony was 
picked and stabbed into a vial containing LB agar. After tightening the caps, the vials 
were stored at room temperature in the dark. 
2B.1.3 Transformation of E. coli with DNA 
2B.1.3.1 Calcium chloride method 
The method was based on the report from Mandel and Higa (1970) with the 
modifications of Dagert and Ehrlich (1979). To 50 ml of LB (supplemented with 
MgCl2, 20 mM) was added 0.5-1 ml of an overnight culture of the E. coli strain to be 
transformed. Growth was allowed at 37°C with vigourous shaking to 0.2 OD 5 ,, the 
cells chilled on ice for 5 mm, and pelleted by centrifugation at 3,000 rpm (1,250 x g; 
Denley BR401, Sussex, U.K.) at 4°C for 15 mm. The cell pellet was resuspended in 
ice-cold transformation buffer (CaCl2, 50 mM; Tris-HC1, 10 mm; pH 7.5; 20 ml), and 
kept in this buffer for 30 min on ice. The cells were repelleted by centrifugation for 
15 min at 1,500 x g at 4° C, and resuspended in ice-cold transformation buffer (2 ml). 
Typically the cells were left overnight (12-16 hr) on ice (or at minimum for 2 hr) 
before use. Cells were transformed by adding 10 ng of DNA (typically a ligation 
mix), in a volume of 5-10 4ul, to 100 11 of competent cells, mixing and holding on ice 
for 30 mm. Cells were heat-shocked for 5 min at 37°C, warm LB (2 ml) added, and 
incubated for 1 hr to allow for expression of genes coded by the transformed plasmid 
DNA (i.e. antibiotic resistance). Cells were pelleted by centrifugation at 4°C and 
resuspended in LB (250 1u1). Fifty p1 aliquots were then plated to dryness on LB agar, 
with appropriate antibiotic selection and 5-bromo-4-chloro-3-indo1yl--D-
galactopyranoside (X-gal)/isopropyl--D-thiogaIactopyranoside (IPTG) if needed. The 
X-gal/IPTG allows recombinants to be identified; recombinant colonies appear 
colourless, while non-recombinant colonies appear blue. Cells were incubated 
overnight at 37°C for growth. 
2B.13.2 DMSO method 
This method for transformation of E. coli was initially described by Chung and Miller 
(1988) with minor modification. Cells were grown to 0.3 OD 60O.. in LB supplemented 
with 20 mM of MgCl2 (50 ml), kept for 10 min on ice, and pelleted from 10 ml of 
culture by centrifugation at 1,250 x g for 5 min at 4°C. The cell pellet was 
resuspended in transformation buffer [polyethylene glycol (PEG), molecular weight 
3000, 10% (w/v); dimethylsulphoxide (DMSO), 5% (v/v); MgCl 2, 10 MM;  MgS041  10 
mM; in LB; 1 ml], and incubated for 30 min on ice. DNA was added to cell 
suspension (100 p1), and the mixture was left for 30 min on ice. Transformation 
buffer containing 20 mM of glucose (900 p1) was added to the transformed cells, cells 
were shaken for 1 hr at 37°C to allow for expression of antibiotic resistant gene and 
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plated onto LB agar plates supplemented with suitable antibiotics immediately after 
incubation. 
2B.2 Preparation of nucleic acids 
211.2.1 Phenol extraction of nucleic acid solution 
Proteins present in DNA solution were removed by extraction with phenol or with 
phenol: chloroform: iso-amylalcohol (PCA). Distilled phenol was equilibrated with 
Tris-HC1 (1 M; pH 8.0) prior to use. An equal volume of phenol or PCA was added 
to aqueous nucleic acid solution, and the two liquid phases were mixed by vigourous 
vortexing. The phases were separated by centrifugation at 17,000 x g for 5 min at 
room temperature. The upper, aqueous phase containing nucleic acid was recovered. 
2B.2.2 Ethanol precipitation of DNA 
Nucleic acids were precipitated from aqueous solutions by addition of 1/10 volume 
of sodium acetate (3 M; pH 5.2), and 2.5 volumes of cold absolute ethanol (-20°C). 
The mixture was inverted gently several times and left at -20°C or lower for 20 mm. 
Precipitated DNA was recovered by centrifugation at 4°C at 17,000 x g for 15 mm. 
The pellet was then washed twice with cold 70% ethanol (-20°C), dried under vacuum, 
and redissolved in distilled water or TE. 
2B.2.3 Small-scale preparation of plasmid DNA (Minipreps) 
Buffer P1: (kept at 4°C) 
Tris-HC1, 50 mM; pH 8.0 
EDTA, 10 mM 
RNase A, 100 ug/ml 
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Buffer P2: (Kept in air-tight bottle) 
NaOH, 0.2 M 
SDS, 1% (w/v) 
Buffer P3: 
potassium acetate, 2.55 M; pH 4.8 
The method used for small-scale preparation of plasmid DNA was a modification of 
that described by Ish-Horowicz and Burke (1981). Bacteria from a single colony were 
inoculated to LB or Terrific broth supplemented with antibiotics (5 ml) and incubated 
at 37°C overnight with shaking. Cells (1.5 ml) were pelleted by centrifugation and 
resuspended in buffer P1 (300 dul). Cells were lysed by adding lysis buffer P2 (300 
1u1) and incubated at room temperature for 5 min. After the cell lysis, buffer P3 (300 
1ul) was added and mixed by gentle inversion. Precipitated complex consisting of 
chromosomal DNA, SDS and proteins was sedimented by centrifugation (17,000 x g) 
for 12 mm. Contaminating proteins in the clarified supernatant were extracted with 
phenol. The upper, aqueous phase was recovered and nucleic acids were precipitated 
with isopropanol (600 4ul). The DNA was washed twice with 70% ethanol, dried 
under vacuum, and resuspended in distilled water (50 jul). Plasmid "miniprep" DNA 
was then stored at -20°C. 
213.2.4 Large-scale plasmid preparation 
2B2.4.1 CsCI method 
A 100-ml culture of bacteria carrying the desired plasmid was incubated overnight at 
37°C with vigourous shaking in Terrific broth supplemented with suitable antibiotics. 
The cells were pelleted by centrifugation at 5,000 rpm (4080 x g; GSA rotor, Sorvall 
RC5B; Wilmington, U.S.A.) and resuspended in solution 1 (Tris-HCI, 25 mM, pH 8.0; 
EDTA, 10 mM; glucose, 50 mM; 10 ml). Cells were lysed on ice by adding lysis 
buffer [NaOH, 0.2 M; SDS, 1% (w/v); 10 ml], and left on ice for 20 min. Addition 
of potassium acetate (5 M, pH 5.0; 10 ml) precipitated complex of chromosomal 
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DNA, SDS and proteins, which was sedimented at 15,000 rpm (27,000 x g; SS34 
rotor, Sorvall) for 30 min at 4°C. To the supernatant, isopropanol (11 ml) was added 
and left at room temperature for 30 min to precipitate plasmid DNA The DNA was 
pelleted by centrifugation at 10,000 rpm (12,000 x g; SS34 rotor) for 20 min at 4°C. 
The pellet was washed with 70% ethanol, dried under vacuum, resuspended in TE 
containing 10 1ugfml of RNase (10 ml) and incubated at 37°C for 30 mm. Plasmid 
DNA solution (9.4 ml) was transferred to a fresh tube to which ethidium bromide 
solution (10 ,ugful; 100 1u1) and CsC1 (9.02 g) were added, giving a density of 1.55 
g/ml. The DNA was banded by centrifugation at 38,000 rpm (95,000 x g; 50Ti rotor, 
Sorvall OTD50B) for 40-48 hr at 20°C. DNA was visualised by side illumination with 
UV light. The lower band containing supercoiled plasmid DNA was removed by 
puncturing the tube with a 21-gauge needle and syringe. A second 21-gauge needle 
was inserted at the top of the tube to allow pressure release. The ethidium bromide 
was removed by extraction several times with butanol, and the CsC1 was removed by 
dialysis against 3 to 4 changes of TE (2 1) for 8 to 15 hr at 4°C. The plasmid solution 
was then phenol extracted, and residual phenol removed by extraction with an equal 
volume of chloroform: iso-amylalcohol (CA) solution. Plasmid DNA was precipitated, 
washed and resuspended in distilled water and stored at -20°C. 
2B.2.4.2 Column method (modified silica gel; Qiagen) 
Buffer QBT: 
NaCl, 750 mM; pH 7.0 
3-(N-morpholino)propane-sulphonic acid (MOPS), 50 mM 
ethanol, 15% 
Triton X-100, 0.15% 
Buffer QC: 
NaCl, 1.0 M; pH 7.0 




NaCl, 1.25 M; pH 8.2 
MOPS, 50 mM 
ethanol, 15% 
The large-scale preparation of plasmid by this method followed the culture conditions 
of the CsC1 method and the procedures of the small-scale plasmid preparation except 
using 10 ml of each solution (buffers P1, P2, and P3) instead of 300 l. The complex 
containing chromosomal DNA, SDS and proteins was sedimented by centrifugation 
at 15,000 rpm (27,000 x g; SS34 rotor) for 30 min at 25°C. The supernatant was 
applied onto the Qiagen-tip 500 column (Diagen; Dusseldorf, Germany) which had 
been equilibrated by buffer QBT (10 ml). After washing three times with buffer QC 
(10 ml), the DNA was eluted with buffer OF (10 ml). DNA was then precipitated 
with 0.5 volume of isopropanol and washed twice with 70% ethanol. Dried DNA was 
resuspended for PCA and CA extraction, followed by ethanol precipitation and 
washing. DNA samples were redissolved in sterile distilled water and stored at -20°C. 
2B.2.5 Preparation of M13 replicative form (RE), double-stranded DNA 
A fresh, single plaque of M13mp18 or M13mp19 with or without inserts of 
heterologous DNA was picked with a sterile wooden toothpick and transferred into 2 
x YT medium (3 ml) containing overnight culture of TG1 (50 4u1), and the culture was 
grown for 4-5 hr with vigourous shaking at 37°C. For small-scale preparation of RF 
DNA, the cells were pelleted by centrifugation in a microcentrifuge and the procedure 
used was that for small-scale preparation of plasmid DNA. 
2B.2.6 Preparation of M13 single-stranded template DNA 
A fresh, single plaque of M13mp18 or M13mp19 with inserts of heterologous DNA 
was picked with a sterile wooden toothpick and transferred into 2 x YT medium (3 
ml) containing overnight culture. of TG1 (50 al), and the infected culture was 
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incubated for 4-5 hr with vigourous shaking. The suspension was then transferred to 
an Eppendorf tube and the bacteria pelleted. The supernatant, containing phages, was 
transferred to a fresh tube, the centrifugation repeated, and the supernatant transferred 
to a new tube. PEG/NaCl solution [PEG 6000, 20% (w/v); NaCl, 2.5 M; 200 4u1] was 
added, mixed, and the tube left at room temperature for 15 mm. The .PEG/phage 
precipitate was pelleted by centrifugation in a microcentrifuge (17,000 x g) for 5 mm, 
and the supernatant discarded. The centrifugation was repeated for a further 2 mm 
and any residual supernatant removed by aspiration. At this stage a white pellet was 
visible. This pellet was suspended in TE (100 4) and phenol extracted twice. The 
DNA was precipitated from aqueous solution, washed twice with 70% ethanol, dried, 
resuspended in sequencing TE (50 1ul) and stored at -20°C. 
2B.2.7 Quantification of DNA 
The DNA sample was diluted in 1 ml of distilled water and the CD of absorbance at 
wavelengths 260nm and 280nm was measured by a spectrophotometer (Perkin-Elmer, 
Lambda 15, UV/VIS Spectrophotometer). An OD, value of 1.0 represents a 
concentration of 50 1ug/ml for double-stranded DNA, 40 ,ug/ml for single-stranded 
DNA, and 20 1ug/ml for oligonucleotide. The ratio OD 2,.'01)2,. provides an 
estimate for the purity of the nucleic acid. A value around 1.8 indicates pure 
preparations of DNA. 
2B.3 DNA manipulation 
2B.3.1 Digestion of DNA with restriction endonucleases 
Most digestions of DNA with restriction enzymes were performed using Boehringer 
Mannheim enzymes and buffers. DNA was digested with approximately 5 U of 
restriction endonuclease per 4ug of DNA using buffer and temperature conditions 
recommended by the manufacturer. For double digests involving enzymes with 
different recommended buffers, the buffers were checked individually in double 
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digests to determine which gave most efficient digestion. If the optimal digestion 
conditions varied for buffers, the DNA was digested with enzyme at lower salt 
concentration, the enzyme reaction stopped by heat denaturation or phenol extraction, 
and the buffer concentration altered by addition of sufficient salt solution so that the 
final concentration was appropriate for digestion by the next enzyme.. Digestion 
reactions were terminated by heating for 10 min at 65°C, by phenol extraction, or by 
addition of DNA sample buffer for agarose gel electrophoresis. 
2B.3.2 Dephosphorylation 
Calf intestinal alkaline phosphatase (CIP) catalyses the removal of 5'-phosphate 
residues from DNA, RNA, dNTP and rNTP. It can be used to remove 5-phosphates 
from fragments of DNA to prevent self-ligation and from DNA or RNA prior to end-
labelling with 32P. The typical reaction consisted of 40 #1 of DNA (-5 pg), 5 uI of 
10 x CIP buffer (Tris-HCI, 0.5 M, pH 8.5; EDTA, 1 mM) and 5 dUl of CIP (1 U/gui; 
Boehringer). The reaction mix was incubated at 37°C for 1 hr and the reaction 
stopped by addition of EDTA to a final concentration of 20 mM and heated at 65°C 
for 10 min followed by phenol extraction. 
2B.3.3 Filling-in 3' recessed termini of DNA 
Recessed 3' termini can be filled by the polymerase activity of the Kienow large 
fragment of E. coli DNA polymerase I in the presence of appropriate dNTP. The 
typical reaction consisted of 39 1u1 of DNA (- 1 1ug), 5 4 41 of 10 x Fill-in buffer (Tris-
HC1, 0.5 M, pH 7.5; MgCl, 0.1 M; Dli.', 10 mM; BSA, 0.5 mg/ml), 5 l of 5 mM 
dNTP and 1 4ul of Klenow enzyme (1 U/1 41; Boehringer). The reaction mix was 
incubated for 1 hr at room temperature and the reaction stopped by addition of 2.5 ul 
of 0.5 M EDTA and 150141 of TE followed by phenol extraction. 
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2B.3.4 Removing protruding 3 termini of DNA by T4 DNA polymerase 
T4 DNA polymerase carries a 3'-5' exonuclease activity that can be used to remove 
protruding nucleotides from the 3' termini of DNA. Its 3' exonuclease activity is 
more than 200-fold more active than that of Kienow large fragment of E. coli DNA 
polymerase I. The typical reaction consisted of 38 1d of DNA (- 5 4ug), 5 ul of 10 x 
T4 DNA polymerase buffer (Tris-HC1, 0.5 M, pH 8.8; MgCl2, 50 mM; DTI, 50 mM; 
BSA, 0.5 mglml), 2 1u1 of 5 mM dNTP and 5 4u1 of T4 DNA polymerase (1 U/1u1; 
Boehringer). The reaction mix was incubated for 1 hr at room temperature and the 
reaction stopped by phenol extraction. 
2B.3.5 Removing protruding 5 termini of DNA by Mung bean exonuclease 
Mung bean exonuclease degrades single-stranded DNA to mononucleotides or 
oligonucleotides with phosphate groups at their 5' termini. Double-stranded DNA is 
relatively resistant to the enzyme. However, it digests double-stranded DNA 
completely if large amounts are used. The activity is less severe than nuclease Si. 
Mung bean exonuclease was used for converting protruding 5' termini of DNA to 
blunt ends. The typical reaction consisted of 34.5 ul of DNA (- 5 jig), 4#1 of 10 x 
buffer (sodium acetate, 0.3 M, pH 4.5; NaCl, 0.5 M; ZnCl2 10 MM;  glycerol, 50%) 
and 1.5 ul of Mung bean exonuclease (13 U/4u1; Pharmacia). The reaction mix was 
incubated for 30 min at room temperature and the reaction stopped by addition of 
NaCl to a final concentration of 0.2 M and kept on ice followed by PCA extraction. 
2B.3.6 Ligation 
The vector and insert DNA were cut to completion with appropriate restriction 
endonucleases. After restriction and removing the restriction endonucleases, DNA was 
ethanol precipitated. If needed, the digested DNA was separated in agarose gels and 
the desired fragments recovered. Typically, between 100-200 ng insert DNA were 
ligated in a reaction with vector to insert DNA concentration at a 1:3 molar ratio. 
77. 
Ligations were carried out in 10 4u1 or 20 t1 of reaction buffer (Tris-HC1, 50 mM, pH 
7.6; MgC12, 10 mM; DTF, 1 mM; ATP, 1 mM; PEG 8000, 5%) and incubated 
overnight at 15°C (for cohesive ends), or room temperature (for blunt ends). One or 
2 units of T4 DNA ligase (1U/ul; Boehringer) was used for blunt-end ligations, and 
0.5-1 units for cohesive end-ligations. E. coli was then transformed with the ligation 
products. 
2B.4 Electrophoresis of nucleic acids 
2B.4.1 Electrophoresis of DNA in agarose gels 
DNA fragments were separated in 0.8-1.5% (w/v) agarose (electrophoresis grade; 
Sigma) with ethidium bromide (0.5 #g/ml) in 1 x TBE buffer (for routine diagnosis 
gels) or 1 x TAE buffer (for band-recovery gels). Prior to loading, DNA samples 
were mixed with 1/10 volume of sample buffer (glycerol, 20%; EDTA, 100 mM; 
bromophenol blue, 0.1%). Electrophoresis was carried out horizontally across a 
potential difference of 1-10 v/cm. Bacteriophage XDNA cut with Hindill and 4174 
RF DNA cut with HaeIII were used as size markers. DNA was visualised by UV 
illumination and photographed if necessary. 
2B.4.2 Recovery of DNA from agarose gels 
DNA was electrophoresed through 0.8% regular melting point agarose in 1 x TAE 
containing ethidium bromide (0.5 #g/ml). The desired fragment was visualised by UV 
illumination, cut out and extracted from the agarose using Geneclean kit (Bio101; 
La Jolla, U.S.A.). The agarose was weighed and 2-3 x volumes of 6 M Nal added. 
The agarose was dissolved by heating to 55°C for 5 min with occasional mixing and 
then cooled on ice for 5 mm. The "glassmilk" (a silica matrix suspended in water; 5 
jul) was added, and left on ice for 5 min with occasional mixing to allow DNA to bind 
to the silica matrix. The "glassmilk" was pelleted by centrifugation in a 
microcentrifuge, the supernatant discarded and the pellet washed three times with ice 
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cold NEW wash (NaCl/ethanol/water mix; 500 jul). After a final spin, all the NEW 
wash was discarded completely and the DNA eluted from the "glassmilk" in TE (5-10 
1u1) at 55°C. The mixture was centrifuged and the supernatant, containing the DNA, 
transferred to a new Eppendorf tube. The elution step was repeated once, the 
supernatant combined and stored at -20°C. 
DNA fragments less than 300 bp long were recovered from the agarose using 
MERmaid kit (Bio101; La Jolla, U.S.A.). DNA was electrophoresed through 2% 
ultrapure agarose (MERmaid Biogel; Bio101) in 1 x TAE containing ethidium 
bromide (0.5ug/ml). Agarose containing the DNA fragment was cut out, weighed and 
mixed with 3 x volumes of high salt binding solution (concentrated sodium 
perchiorate) in an Eppendorf tube. The "glassfog" (a silica based matrix in water; 8 
4u1) was added, the agarose melted and DNA bound to the "glassfog" by incubation at 
55°C for 5 mm. Adsorption was allowed to continue at room temperature for 5 mm 
with occasional mixing to keep the "glassfog" in suspension. The "glassfog" was 
:centrifuged, the supernatant discarded and the pellet washed three times with ethanol 
wash (300 p1). After the final wash, the tube was centrifuged again to ensure removal 
of all residual ethanol. The pellet of "glassfog" was resuspended in distilled water (10 
Ail) and the DNA eluted by incubation at room temperature for 5 mm. The "glassfog" 
was centrifuged and the supernatant containing the DNA transferred to a fresh 
Eppendorf tube. The elution step was repeated once, the supernatant combined and 
stored at -20°C. Recovery of DNA using Geneclean or MERmaid kits was usually 
around 80%. 
2B.5 Radiolabelling DNA 
213.5.1 Labelling DNA by random priming with hexadeoxyribonucleotide primers 
DNA labelled to high specific radloactivities was obtained using the randomly primed 
DNA labelling method (Feinberg & Vogelstein, 1983). It is based on the hybridisation 
of a mixture of hexanucleotides to the DNA to be labelled. Many sequence 
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combinations are represented in the hexanucleotide primer mixture, which leads to 
binding of primer to template in a statistically random manner. The complementary 
strand is synthesized from the 3'OH termini of the random hexanucleotide primer 
using Klenow fragment of the E. coli DNA polymerase during which radiolabelled 
dNTP is incorporated into the newly synthesized DNA strand. 
Oligo-labelling buffer (OLB) is made by mixing solution A (Tris-110, 1.25 M, pH 
8.0; MgC6 125 mM; 2-ME, 25 mM; dGTP, dTFP and dATP, 0.5 mM; 50 Ad), 
solution B (HEPES, 2 M adjusted to pH 6.6 with NaOH; 125 4ul) and solution C 
(random hexanucleotides, 1.8 1ug/1u1 in TE; 75 ul). 
The DNA fragment to be labelled was excised from the agarose gel and placed into 
an Eppendorf tube. Distilled water was added to the tube at a ratio of 3 ml H 20 per 
gram of gel and the tube incubated at 100°C for 10 min to melt the gel and denature 
the DNA followed by incubation at 37°C for 10 mm. The labelling reaction was 
carried out at 37°C for 2 hr or at room temperature overnight. 
DNA fragment in melted agarose (approx. 10-100 ng), 35 ul 
OLB, 1Oul 
BSA (10 mg/ml), 2 #1 
[a-32P]-dCTP (10 4uCi/1u1, Amersham), 5#1 
Kienow fragment of E. coli DNA polymerase I (5 U/ul), 1 dUl 
2B.5.2 Separation of unincorporated nucleotides from labelled DNA 
A Sephadex G-50 (Pharmacia) column was used to remove unincorporated [a- 32P]-
dCTP from labelled DNA fragment. Dry Sephadex G-50 beads were swollen in an 
excess of TE at 4°C overnight. The column was prepared by packing a 1 ml plastic 
syringe (without the plunger), in which the hole was plugged with glass wool, with 
the treated Sephadex G-50 followed by centrifugation (300 x g) for 3 mm. The 
column was equilibrated with STE (0.5 ml) followed by centrifugation (300 x g) for 
3 mm. The equilibration step was repeated once. After completion of the labelling 
reaction, STE (50 jul) was added to the reaction mixture and loaded to the Sephadex 
G-50 column. Unincorporated [a-32P]-dCTP was trapped in the column and labelled 
DNA was collected by centrifugation (300 x g) for 5 mm. 
2B.6 Colony and plaque hybridisation 
2B.6.1 Transfer of DNA from E. coli colonies or bacteriophage M13 plaques to 
membranes 
The method used for transfer of DNA from colonies was that described by Grunstein 
and Hogness (1975). Colonies harbouring putative plasmids of interest were replica 
plated by spotting onto two LB agar plates containing the appropriate antibiotics and 
the plates were incubated at 37°C overnight. Colonies were lifted, from one plate onto 
Hybond-N nylon membrane (Amersham) by placing the filter onto the plate to 
contact colonies, and peeling off the filter as soon as it had become moistened. Cells 
were lysed and DNA denatured by placing the filters, colonies face-up, onto Whatman 
No. 1 blotting paper (Maidstone, U.K.) saturated with denaturation solution (NaOH, 
0.5 M; NaCl, 1.5 M) for 2 min at room temperature. They were neutralised by 
placing the colony side up on blotting paper saturated with neutralisation solution 
(Tris-HC1, 1 M, pH 8.0; NaCl, 1.5 M) for 5 min at room temperature. The 
neutralisation step was repeated, the filters were dried on blotting paper and baked in 
a vacuum oven at 80°C for 2 hr. 
The method used for plaque lifts was that described by Benton and Davis (1977). 
Colourless plaques harbouring the putative insert of interest were picked with a sterile 
wooden toothpick and replica plated onto two plates containing cell lawns. A lawn 
of TG1 cells was prepared by adding an overnight culture in LB (100 ul) to molten 
top-layer agar (3-3.5 ml) containing X-gal (20 mg/ml in dimethylformamide; 30 jil) 
and IPTG (200 mg/ml in H 20; 20 1u1) and plating on minimal agar plates. 
Bacteriophages were allowed to grow overnight and the plates were cooled at 4°C. 
The plaques were lifted onto nitrocellulose membrane as described previously. The 
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denaturation and neutralisation steps were similar to those of colony lifts. 
2B.6.2 Hybridisation 
By adjusting the stringency of hybridisation, it is possible to distinguish between 
closely- and distantly-related members of a sequence family. In practice, to 
distinguish between the distantly-related members of a family of sequences, 
hybridisation should take place under conditions of low stringency followed by 
washing under progressively more stringent conditions. To identify closely-related 
members, a stringent hybridisation followed by a stringent wash is better. The 
stringency of hybridisation depends on a number of factors, such as Tm (melting 
temperature) which is dependent on base composition and denaturing agents, 
temperature of reaction, and ionic strength of the solution. 
100 x Denhardt's solution: 
BSA (fraction V; BDH), 2% (wlv) 
Ficoll (type 400; Pharmacia), 2% (w/v) 
polyvinyl pyrrolidone, 2% (w/v) 
Prehybridisation solution: 
6 x SSC 
SDS, 0.2% (w/v) 
sonicated salmon sperm DNA, 200 ug/ml 
5 x Denhardt's solution 
formamide, 40% (v/v) 
Hybridisation solution: 
6 x SSC 
SDS, 0.2% (w/v) 
sonicated salmon sperm DNA, 200 ug/ml 
1 x Denhardt's solution 
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formamide, 40% (v/v) 
The filter containing DNA transferred from colonies or plaques was incubated in 
prehybridisation solution for at least 60 min with gentle shaking. The prehybridisation 
solution was removed and replaced with hybridisation solution. The radiolabelled 
probe which had been denatured by incubating at 100°C for 5 min and cooled by 
placing immediately in ice was added and left to hybridise at 37°C overnight. The 
filter was recovered and washed twice in 2 x SSC containing SDS (0.1%) at room 
temperature for 15 min followed by further wash twice in 0.5 x SSC containing SDS 
(0.1%) at room temperature for 20 mm. The filter was sealed wet in a plastic bag and 
autoradiographed. 
2B.6.3 Autoradiography 
Autoradiography was used to visualise and quantitate, on film, radioactive molecules 
hybridised to membranes. X-ray film (X-OMAT AR, Kodak, Rochester, U.S.A.) was 
hypersensitised by exposure to a flash of light provided by a photographic flash unit 
and exposed to the sealed filter in a light-proof cassette with intensifying screens 
(Cronex Lightning Plus; Du Pont). The cassette was stored at -70°C for various times 
depending on the intensity of the signal obtained. 
2B.7 DNA sequencing 
The method for DNA sequencing was the dideoxynucleotide chain termination method 
based on that described by Sanger et al. (1977 and 1980). 
2B.7.1 M13 sequencing using E. coli DNA polymerase I (Kienow fragment) 
10 x TM: 
Tris-HC1, 100 mM pH 8.5 
MgC121  50 MM 
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Chain-termination mix (T°, C°, G° and A°): 
Chain-termination mix 
(numbers are volumes in 4u1) 
Nucleotide P 	CO 	G° A° 
dTFP, 0.5 mM 12.5 	250 	250 250 
dCTP, 0.5 mM 250 	12.5 	250 250 
dGTP, 0.5 mM 250 	250 	12.5 250 
ddTTP, 10 mM 25 
ddCTP, 10 mM 4 
ddGTP, 10 mM 8 
ddATP, 10 mM 0.5 
sequencing TE 500 	500 	500 250 
dNTP chase mix: 
d'rTP, 0.25 mM 
dCTP, 0.25 mM 
dGTP, 0.25 mM 
dATP, 0.25 mM 
Kienow reaction mix (per template, 4 reactions): 
[a-35S]-dATP (8 4uCi/,ul, Amersham), 4 1uCi 
E. coli DNA polymerase I (Klenow fragment) (5 U/4u1), 1.5 U 
DIT, 10 mM, 8 1u1 
Tris-HC1, 10 mM (pH 8.5), 6.5 1u1 
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Formamide dye: 
xylene cyanol, 0.1% (w/v) 
bromophenol blue, 0.1% (w/v) 
EDTA, 10 mM 
in formamide 
The sequencing primer (1 pmole/ul; 1 jul) was annealed to the template (100 ng/ul; 8 
4u1) in the presence of 10 x TM (1 uI) at 80°C for 5 min and slowly cooled to room 
temperature over 30 mm. The reactions were carried out in 96-well U-shaped 
microtitre plates or HLA plates. The annealed template/primer mix (2 jul) was 
dispensed into each of 4 wells followed by addition of one of the chain-termination 
mixes (G°, A°, P or C°; 2 4u1) and the Kienow reaction mix. The solutions were 
mixed thoroughly by tapping the plate and incubated at room temperature for 25 mm. 
dNTP chase mix (2 1ul) was then added to each well, mixed thoroughly and the plate 
incubated for a further 20 min at room temperature. Sequencing reactions were 
stopped by addition of formamide dye (2 uI) to each well and the double-stranded 
reaction products were denatured by incubating the solutions at 80°C for 15 min and 
leaving on ice before separation by electrophoresis through urea-polyacrylamide gels. 
2B.7.2 Plasmid sequencing using T7 DNA polymerase 
The plasmid sequencing was performed as outlined for Sequenase' version 2.0 
(United Stated Biochemical Co.) using T7 DNA polymerase or Sequenase version 
2.0 DNA polymerase (a modified T7 DNA polymerase). Purified, RNA-free plasmid 
DNA (3-5 aug) in TE (18 1ul) was denatured by adding NaOH (2 M; 2 jul) at room 
temperature for 5 mm, the mixture was neutralised by adding ammonium acetate (5 
M, pH 5.4; 8 duI), and the DNA precipitated with ethanol. The DNA pellet was 
redissolved in distilled water (7 4u1) and ready for use as template for sequencing. 
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Sequencing reagents: 
5 x sequencing buffer Tris-HC1, 200 mM, pH 7.5; MgCl2, 100 
mM; NaCl, 250 mM 
Enzyme dilution buffer Tris-HC1, 10 mM, pH 7.5; DTT, 5 mM; 
BSA, 0.5 mg/ml 
Labelling mix (5 x) dGTP, 7.5 suM; dCTP, 7.5 suM; dTTP, 7.5 
Termination mixes Each mixture contains dGTP, 80 1uM; 
dATP, 80 suM; dCTP, 80 1uM; dTfP, 80 
uM and NaCl, 50 mM. 
In addition, the G° mix contains ddGTP, 
8 1uM; the A° mix ddATP, 8uM; the P 
mix ddTTP, 8 uM and the C° mix 
ddCTP, 8 4uM 
Stop solution formamide, 95%; EDTA, 20 mM; 
bromophenol blue, 0.05% (w/v); xylene 
cyanol FF, 0.05% (w/v) 
Labelled ATP [a-35S]-dATP, 1000 Ci/mmole 
Sequenase 	(USB) 13 U/1u1 
The sequencing primer (1 pmole/4u1; 1,u1) was annealed with DNA template (3-5 g; 
7,u1) in the presence of 5 x sequencing buffer (2 4ul). The mixture was incubated at 
65°C for 2 min and cooled slowly to room temperature. The annealed primer was 
then extended with SequenaseTM  and a nucleotide mixture, in a reaction consisting of- 
template-primer 	 10,U1 
D17 (0.1M) 	 1 ul 
1 x labelling mix 	2/41 
.[a-35S]-dATP 	 0.5 jil 
Sequenase (1:8 diluted) 	2 ul 
This reaction was incubated at room temperature for 2-5 mm. When the labelling 
reaction was complete, the reaction mixture (3.5 jul) was dispensed to each of four 
Eppendorf tubes containing prewarmed ddNTP (termination mix; G°, C', A° or To; 2.5 
86 
ul) and the solution was mixed thoroughly. The termination reaction was carried out 
at 37°C for 5 min and stopped by addition of stop solution (4 4u1). The samples were 
heated to 80°C for 5 min and loaded (2-3 #l/lane) on the sequencing gel. 
2B.73 Resolution of sequencing reaction products by electrophoresis in urea-
polyacrylamide gels 
6% urea-polyacrylamide solution: 
urea 	 17g 
40% (w/v) acrylamide 	6 ml 
[38% (w/v) acrylamide, 
2% (w/v) N,N'-bis-methylene acrylamide] 
1OxTBE 	 2m1 
Add H20 made up to 40 ml 
To the solution, ammonium persuiphate (10%; 240 4u1) and N,N,N',N'-
tetramethylethylenediamine (TEMED; 35 1u1) were added. The solution was poured 
immediately between 2 glass plates with gel dimensions of 380 mm x 200 mm x 0.5 
mm with a shark-tooth comb inserted and allowed to polymerise. The nested set of 
extension products in the sequencing reactions were loaded onto the gel and were size 
fractionated by electrophoresis using 1 x TEE buffer at constant power of 25-30 watts. 
The gels were run until the required fragment separation was achieved (bromophenol 
blue migrates with DNA fragments of about 25 nucleotides in length, xylene cyanol 
migrates with DNA fragments of about 75 nucleotides in length). After 
electrophoresis, the gel was retrieved and fixed by soaking in a solution containing 
methanol [5% (v/v)] and glacial acetic acid [5% (v/v)] for 15 mm, transferred to 
blotting paper, covered with thin plastic film (Saran Wrap), dried under vacuum at 
80°C, and autoradiographed. 
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2B.8 Site-directed mutagenesis 
2B.3.1 Phosphorylation of 5 end of oligodeoxynucleotide with T4 polynucleotide 
kinase 
Phosphorylation of the 5 end of the mutant oligonucleotide, 412G, 411G or 359G, 
was carried out at 37°C for 90 min in the following reaction mixture: 
oligonucleotide (40 pmoles/ul) 6 1u1 
10 x polynucleotide kinase buffer (Tris-HCI, 0.5 M, pH 7.5; MgC121  0.1 M; 
DT1, 50 mM; ATP, 10 mM; BSA, 0.5 mg/ml) 1 u! 
T4 polynucleotide kinase (0.5 U/1u1, prepared by S. Bruce) 2,u1 
H20 1u1 
After completion of the reaction, the mixture was heat-treated (70°C for 10 mm) 
following the addition of distilled water (40 1u1) and PCA extracted. The DNA was 
precipitated with ethanol and resuspended in distilled H 20 (8 ul) which was used for 
the following annealing reaction. 
2B.8.2 Synthesis of mutant strand DNA and recovery of mutant clones 
The bacteriophage M13 single-stranded DNA template used for mutagenesis was the 
vector M13mp19 with a 594-bp EcoRI-Sall fragment carrying the HBc (31) and 
HBs(lll  sequences. The phosphorylated, mutant primer (30 pmoles/ul; 8,u1) and the 
M13 -20 universal primer (1 pmole/1u1; 3 jul) were annealed to the template DNA (1 
1ugI4ul; 7 jul) in the presence of 10 x TM (2 Aul) at 80°C for 5 min and cooled slowly 
to room temperature. 
Synthesis of the mutant strand DNA was carried out at room temperature for 90 mm 
in the following reaction mixture: 
Annealed mixture from the above reaction 20 zl 
dNTP chase mix 20 jil 
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ATP (50 mM) 1ul 
E. coli DNA polymerase I (Klenow fragment) (5 U/ul) 1.5 jul 
T4 DNA ligase (1 U/1u1) 5 ul 
sequencing TE 2.5 ul 
After completion of the reaction, the mixture was PCA extracted and the DNA was 
precipitated with ethanol and suspended in TE (10 jul). The double-stranded DNA 
insert was excised from the bacteriophage M13 by digestion with EcoRI and SalT and 
the resulting 594-bp fragment was ligated to M13 mp19 RF DNA that had been 
linearised by digestion with EcoRI and Sail. E. coli strain BMH71-18 mutL was 
transformed with the ligation mixture and plated onto minimal agar plates containing 
X-gal and IPTG in the presence of TG1 as target cells. The colourless plaques were 
isolated and single-stranded DNA prepared. M13 clones containing a mutated HBV 
DNA insert were identified by T-track sequencing. The candidate mutants were then 
fully sequenced for the entire insert. The mutated insert was excised from the M13 
vector by digestion with EcoRI and Sail, and the resulting 594-bp fragment was 
ligated to pHBcX linearised by digestion with EcoRI and Sall (see Section 3.4.2), thus 
pHBcS 14 , pHBcS 145E  and pHBcS145K were constructed. 
2B.9 Amplification of DNA using the polymerase chain reaction (PCR) 
HBs(11156) fragment carrying wild type, 91y 145—'arg or gly 145—'9lu mutation at amino 
acid residue 145 of HB5Ag was amplified by using 010H and 011H primers which 
share 17-nucleotide homology to the 5 and 3 ends of HBs(11IS6) sequence, 
respectively, but contain additional nucleotides for an EcoRI cleavage site at the 5' 
end in each primer. pHinG2, pHinG2 145R  and pHBcS 14 were the templates for 
amplification of HBs (Illl5 carrying wild type, g1y 145—'arg and gly 145—glu mutation at 
amino acid residue 145 of HBsAg, respectively. All reactions were carried out using 
Tri-thermoblock TB1 (Biometra, Gottingen, Germany) in the following reaction 
mixture (50ul): 
10 x PCR buffer (Tris-HC1, 0.1 M; KC1, 0.5 M; MgCl2, 15 MM; 
gelatine, 1 mg/ml; pH 8.3) 5 ul 
dNTP (10 mM) 0.5 ul 
010H (52.5 pmoles/4u1) 0.5 4u1 
011H (26 pmoles/1u1) 0.8 ,td 
Taq polymerase (5 U/jul; Boehringer) 0.5 141 
DNA template (30 ng in Tris-HC1, 10 mM, pH 8.0; EDTA, 0.1 mM) 0.5 1u1 
H20 42 u1 
Submersion under 1 drop of mineral oil (Sigma) 
The reactions also include mixtures in the absence of DNA template, one or two 
primers to serve as negative controls. Cycle conditions were 3 min at 93°C, 1 min at 
50°C and 0.5 min at 70°C for 3 cycles followed by 1 min at 93°C, 1 min at 65°C and 
0.5 min at 70°C for 27 cycles. After completion of the reactions, DNA (1 l) from 
each reaction mixture was run in an agarose gel to assess the DNA concentration. 
The reaction mixtures were then PCA extracted twice, ethanol precipitated, and 
suspended in distilled water for further manipulation. 
2B.10 Protein methods 
2B.10.1 Protein assay (Lowry method) 
Lowry reagent: 
A 	2% Na2CO3 (anhydrous) in 0.1 N NaOH 
B 	0.5% CuSO4.5H20 in 1% sodium citrate 
C 	50 ml A + 1 ml B (freshly prepared) 
D 	Folin-Ciocalteau reagent (Sigma) diluted 1:1 with water 
Protein sample (0.4 ml) was added to reagent C (2 ml) and the solution was mixed 
and left at room temperature for 10 mm. Reagent D (200 u1) was added, mixed well, 
and the mixture was stood for 30 min at room temperature. OD 5 . was recorded for 
each sample. The assay was calibrated using BSA at a concentration of 10 to 200 
1ug/ml. 
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2B.10.2 Electrophoresis of proteins in SDS-polyacrylamide gels (SDS-PAGE) 
Acrylamide stock solution (30%): 
acrylamide 	 29.2% (wlv) 
N,N'-bis-methylene acrylamide 	0.8% (w/v) 	V 
in H20, filter and store in the dark at 4°C (1 month maximum). 
Separation gel solution: (numbers are volumes in ml) 
Gel 	30% Acrylamide 	1.5 M Tris-HC1 pH 8.8 	HO 
5% 	 1.66 	 4.18 	 4 
7.5% 2.5 	 3.34 	 4 
10% 	3.34 	 2.5 	 4 
12.5% 	4.16 	 1.68 	 4 
15% 	5 	 0.84 	 4 
Add SDS (10% w/v; 100 4u1), ammonium persuiphate (10% w/v; 50 jul) and 
TEMED (5 1u1). 
Stacking gel solution: 
Tris-HC1 (0.5 M, pH 6.8) 	2.5 ml 
acrylamide stock 30% 	 1.3 ml 
distilled H20 	 6.1 ml 
SDS [10% (w/v)] 	 100 Aul 
ammonium persulphate [10% (w/v)] 50 4u1 
TEMED 	 10 4u1 
10 x runner buffer (pH 8.3): 
Tris-HCI 	 0.25 M 
glycine 	 1.92 M 
SDS 	 1% (w/v) 
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2 x sample buffer: 
Tris-HC1, pH 6.8 125 mM 
SDS 4% (w/v) 
glycerol 20% (v/v) 
2-ME 10% (v/v) 
(or Dli 100 MM) 
bromophenol blue 0.02% (w/v) 
Proteins were separated by SDS-PAGE as described by Laemmli (1970). Separation 
gel solution (12.5% or 15%) was prepared and poured into the Mini-protein II dual 
slab cell (Bio-Rad, Richmond, U.S.A.) or between two sealed 16 cm x 16 cm glass 
plates separated at their edges by 1.5 mm spacers leaving 3 cm from the top for a 
stacking gel. The poured separation solution was overlaid with butanol (water 
saturated) to a depth of about 1 cm and the assembly left in an upright position at 
room temperature to allow polymerisation. The butanol was poured off the surface 
and the top rinsed with water. The stacking gel solution was prepared and poured 
onto the separating gel, and a Teflon slot-forming comb (10 or 15 wells x 0.75 mm 
for mini-gels; 10 or 15 wells x 1.5 mm for big gels) was inserted. The gel was 
allowed to polymerise and the comb was then removed. The gel assembly was 
transferred to an electrophoresis tank which was filled with 1 x runner buffer and the 
wells of the gel flushed out with running buffer. Samples were prepared by mixing 
with an equal volume of 2 x sample buffer and boiling at 100°C for 5 mm. The 
samples were then short spun in a microcentrifuge to collect condensation and pellet 
any cell debris before being loaded on the gel. Low molecular weight markers 
(Pharmacia), including phosphorylase b (94 kD), albumin (67 kD), ovalbumin (43 kD), 
carbonic anhydrase (30 kD), trypsin inhibitor (20 kD), and a-lactalbumin (14.4 kD), 
were also loaded into one well, for molecule weight determination. Rainbow 
coloured protein molecular weight markers (2.35, 3.4, 6.5, 14.3, 21.5, 30 and 46 kD; 
Pharmacia) were included in the gels for immunoblot analysis. Electrophoresis was 
performed at 25-30 mA. 
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2B.103 Staining of proteins with Coomassie blue in gels following electrophoresis 
After electrophoresis, polyacrylamide gels were removed and stained in staining 
solution consisting of methanol [40% (v/v)], acetic acid [10% (v/v] and Coomassie 
brilliant blue R-250 [0.2% (w/v); Sigma] with gentle shaking at room temperature. 
The time required for staining depends on the thickness of the gel and its 
polyacrylamide concentration. For mini-gel, 20 min of staining was sufficient. Gels 
were destained in destaining solution containing methanol [40% (vlv)] and acetic acid 
[10% (v/v)] with shaking at room temperature. 
2B.10.4 Immunoblotting (Western blot) 
Immunoblotting consists of separation of the proteins by electrophoresis, transfer and 
immobilisation of the proteins onto nitrocellulose membranes, and detection of specific 
proteins or antigens using antibodies as the probe. The method is a modification of 
the procedures described by Towbin et al. (1979). 
Transfer buffer (pH 8.3): 
Tris-HC1 25 mM 
glycine 192 mM 
methanol 20% (v/v) 
10 x Tris-saline (TS) (pH 8.1): 
Tris-HC1 	 10 mm 
NaCL 	 150 mM 
Blocking solution: 
nonfat dry milk (Marvel) 	 5% (w/v) 
[or BSA (IgG free, fraction V; BDH) 	3% (w/v)] 
sodium azide 	 0.02% (w/v) 
in 1 x IS 
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Alkaline phosphatase buffer: 
Tris-HC1 (pH 9.5) 	 100 mm 
NaCl 	 100 mm 
MgCl2 	 50 mM 
2B.10.4.1 Transfer of proteins from gels to nitrocellulose membranes 
After separation of the proteins by SDS-PAGE, the stacking gel was removed and the 
separation gel equilibrated in transfer buffer prior to blotting. The proteins were 
electroblotted using the Trans-Blot cell (Bio-Rad). The gel was overlaid with a 
nitrocellulose membrane (BioBlot-NC; Costar, Cambridge, Mass., U.S.A.) and this 
was sandwiched between 3MM filter paper and foam sponge. All the components 
were soaked in transfer buffer before assembly. The electroblot apparatus was 
assembled and filled with transfer buffer, with the nitrocellulose membrane facing the 
anode, and the proteins transferred to the nitrocellulose at 60V (350 mA) for 3-4 hr 
or 30V (120 mA) overnight. 
After transfer and prior to probing blots for the presence of a specific antigen, the total 
composition of the proteins transferred to the membrane can be stained reversibly with 
Ponceau S [0.5% (w/v) Ponceau S (Sigma) in 3% TCA (trichioroacetic acid)] for 30-
60 seconds at room temperature with agitation and destained with distilled water. In 
some experiments, Rainbow coloured protein molecular weight markers (Pharmacia) 
were run in parallel on the gels to serve as internal markers for transfer and molecular 
weight calibration. 
2B.10.4.2 Immunostaining of specific proteins using antibodies 
Before the blot could be processed for antigen detection, it was incubated in blocking 
solution at room temperature for at least 1 hr with agitation to prevent nonspecific 
adsorption of the immunological reagents. The blocking solution was poured off, and 
the blot incubated with the appropriate dilution of primary antibody in blocking 
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solution at room temperature for 2 hr or longer with agitation. The primary antibody 
was removed, and the blot was washed with 5 changes of 1 x IS for 5 min each. 
Depending on the animal source of the primary antibody, the secondary antibody was 
either goat anti-rabbit IgG (whole molecule) alkaline phosphatase conjugate (Sigma) 
or sheep anti-mouse IgG (whole molecule) alkaline phosphatase conjugate (Sigma). 
The blot was incubated with a 1:7500 dilution of secondary antibody in blocking 
solution for 2 hr at room temperature with agitation. The blot was washed with 5 
changes of 1 x TS for 5 min each. 
Just prior to developing the blot, a fresh substrate solution was prepared by adding 
nitroblue tetrazolium (NBT, 5% in 70% dimethylformamide; 66 4u1) and 5-bromo-4-
chloro-3-indolyl-phosphate (BCIP, 5% in 100% dimethylformamide; 33 4u1) to alkaline 
phosphatase buffer (10 ml). Substrate solution was added to the blot with agitation 
to develop a colour reaction usually within 10 mm. When the bands were suitably 
dark, the reaction was stopped by washing the blot in several changes of distilled 
water. 
2B.10.5 Purification of HBcAg fusion proteins produced in E. coli 
Cultures of E. coli strain RB791 harbouring recombinant plasmids directing the 
expression of various HBcAg fusion proteins were grown overnight at 37°C with 
shaking in LB supplemented with ampicillin (100 ug/ml) (L-amp medium) to high cell 
density and diluted with fresh L-amp medium (1:50) the following day. When the 
culture reached OD =1.0, expression was induced by the addition of IPTG to 0.5 
mM. After 16-18 hr of shaking at 37°C, the bacteria were harvested by centrifugation 
(12,000 x g) for 10 min at 4°C. The cell pellet was suspended in 1/200 volume of the 
culture medium of lysis buffer [Tris-HC1, 50 mM, pH 8.0; Triton-X100, 1% (v/v); 
phenylmethyl-suiphonyl fluoride (PMSF), 0.2 mM] and sonicated for 8-10 x 30 sec 
(Soniprobe, Dawe instruments type 7530A). The cellular debris in the lysate was 
sedimented by centrifugation (12,000 x g) for 10 min at 4°C and the supernatant, ie. 
crude extract, was recovered. If E. coli strain TG1 was used for the production of 
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HBcAg fusion proteins in Terrific broth, instead of E. coli strain RB791 in LB, 
approximately double the cell density was obtained. 
Proteins in the crude extract were precipitated by adding ammonium sulphate to 30% 
saturation. The precipitate was centrifuged (27,000 x g) for 15 min at 4°C and the 
pellet resuspended in 50 mM of Tris-HC1 (pH 8.0) in the same volume as the lysis 
buffer. The ammonium sulphate fraction was dialysed against three changes of 50 
mM of Tris-HC1 (pH 8.0) at 4°C overnight. The fusion protein particles were 
collected by ultracentrifugation at 100,000 x g (TH640 rotor; Combi, Sorvall) for 1-1.5 
hr at 4°C, resuspended in 50 mM of Tris-HC1 (pH 8.0; 1 ml), and centrifuged at 
12,000 x g for 3-5 min to remove few precipitated pellets. The supernatant containing 
HBcAg fusion proteins was chromatographed on Sepharose 4B-C1 in the same solvent 
containing PMSF (0.2 mM) and NaN3 (5 AuM). Fractions containing the fusion 
proteins identified by SDS-PAGE were pooled, and the product was collected by 
ultracentrifugation (100,000 x g) for 1 hr. The final products were suspended in PBS 
and dialysed against the same buffer to remove trace amount of NaN 3 . 
2B.11 Immunological methods 
2B.11.1 Preparation of immunogens for immunisation 
The antigens, eg. HBcAg, HBsAg and HBcAg fusion proteins, diluted in PBS were 
added to an equal volume of complete Freund's adjuvant (CFA) for immunisation or 
incomplete Freund's adjuvant (IFA) for boost, and two phases were mixed by using 
a tissue homogeniser (Omni-mixer; Sorvall, Newtown, Conn., U.S.A.) or by passing 
the mixtures from a syringe into a glass universal bottle and back vigourously, and 
repeatedly until a thick emulsion developed. 
2B.11.2 Immunisation and bleeding of animals 
Outbred Dutch male rabbits (-6 months of age; —1.5 kg) were immunised 
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intramuscularly (LM.) with 2 ml of immunogens containing various concentration of 
HBcAg fusion proteins (ranging from 0.2 mg to 1 mg) or other antigens (see Table 
5.1) emulsified in CFA and were subsequently boosted for a number of times (see 
Table 5.1) with the same antigen emulsified in IFA (2 ml). 
Inbred BALB/c mice were obtained from the Department of Medical Microbiology, 
University of Edinburgh, while inbred B10.S/OlafHsd (H-2 5) mice were purchased 
from Harlan Olac Ltd., Oxon, U.K. Mice were immunised intraperitoneally (I.P.) with 
various concentrations of immunogens emulsified in CFA (0.2 ml) and were 
subsequently boosted for a number of times with the same immunogen emulsified in 
IFA (0.2 ml). 
The injection and bleeding of the animals were carried out by the staff of the Medical 
Microbiology Transgenic Unit, University of Edinburgh. Rabbits were bled from the 
rear marginal ear vein. A very small amount of xylene was applied to the tip of the 
ear to encourage vein dilation and the vein was cut across by the tip of a pointed 
scalpel blade. The blood was collected into a glass universal tube containing heparin 
(15 U for 1 ml of blood) for isolation of PBLS or without heparin for separation of 
serum. Mice were bled from retroorbital plexus after anaesthesia. For terminal 
bleeding, cardiac puncture was carried out. 
2B.11.3 Separation of sera from blood 
Rabbit blood collected in a glass universal tube was allowed to clot for 30-60 min at 
37°C. The clot was then separated from the walls of the container using a Pasteur 
pipette and left at 4°C overnight for the clot to contract. The serum was withdrawn 
from the clot and was centrifuged at 10,000 x g for 10 min at 4°C to remove red 
blood cells. The rabbit sera were heat-inactivated at 56°C for 30 min,aliquoted and 
stored at -20°C. 
Mouse blood pooled from each group and collected in an Eppendorf tube was allowed 
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to clot for 30-60 min at 37°C and centrifuged for 5 min to remove red blood cells. 
The sera, aliquoted or not, were stored at -20°C. 
2B.11.4 Serum preparation from plasma 
Plasma obtained from blood collected in vessels containing heparin was centrifuged 
at 500 x g for 20 min to remove the cell fraction which was used for isolation of 
PBL.s. To prepare serum from plasma, 1/100 volume of thrombin solution (100 iu/ml 
in 1M CaCl) was added to the plasma which had been warmed to 37°C and mixed 
vigourously to promote clot formation. The treated plasma was left at room 
temperature for 60 min and the formed clot was compressed to withdraw the 
maximum serum. If clot did not form, protamine sulphate was added to enhance its 
formation. The supernatant was withdrawn, centrifuged at 17,000 x  at 4°C for 20 
mm, and the serum collected. 
2B.11.5 Solid-phase RIAs 
2B.11.5.1 Preparation of a protein- or synthetic peptide-coated solid phase 
Polystyrene beads (polystyrene balls, 6.4 mm diameter, specular finish, NBL) were 
placed in a 50-ml centrifuge tube (Falcon) and coated with HBcAg (0.54 or 0.72 
4ug/ml) or HBsAg (0.15 or 0.5 4uglml) in coating buffer (carbonate-bicarbonate buffer, 
0.05 M, pH 9.6) for 6-7 hr or overnight at room temperature. For preparation of solid 
phase coated with synthetic peptides, polystyrene beads were coated with synthetic 
peptide (20 or 50 #g/ml in coating buffer), ie. preS l(l), preS 1 or HBs(111 . l , 
overnight at room temperature. For preparation of solid phase coated with monoclonal 
anti-HBs or polyclonal anti-HBc or anti-HBs antibodies, polystyrene beads were 
coated with mouse ascites fluids (1:150 or 1:200 in coating buffer) containing 
monoclonal anti-HBs antibodies (approx. 2.5-10 1ug/ml of IgG), RFHBs-1, -2 or -7, or 
with polyclonal anti-HBc IgG or anti-HBs IgG (60 ug/ml in coating buffer) overnight 
at room temperature. 
The protein- or peptide-coated beads were washed three times with PBS and the 
remaining sites for protein binding were blocked with PBS containing 10% FCS, 
donkey or sheep serum, depending on the animal source of the second antibody used 
in the RIA, for at least 2 hr or overnight at room temperature. The beads were 
washed three times with PBS and blotted dry on tissue paper. The beads were then 
ready for use and were stored at 4°C. 
2B.11.5.2 Assay of HBc antigenicity by the sandwich RIA 
The HBcAg reactivity was determined by the sandwich RIA as illustrated in Figure 
2.1 (Stahl et al., 1982). The protein samples were diluted in RIP buffer (0.5% BSA 
in PBS) to adjust the concentration and 200 4u1 of each was added in duplicate to 
appropriate wells containing anti-HBc-coated beads. The reaction was carried out 
overnight at room temperature. On the following day, the samples were removed by 
aspiration and the beads were washed 10 times by filling the well each time with 
distilled water and removing it by aspiration. 1 I-labelled human anti-HBc IgG 
(300,000 cpm/ml in RIP buffer; 200.l), which was kindly provided by P. McCulloch 
and G. Leadbetter of the Department of Medical Microbiology, University of 
Edinburgh, was added to each well. The plate was then sealed and incubated at 45°C 
for 2 hr. After extensive washings with distilled water, the beads were transferred to 
counting tubes and counted in a y counter (1275 Minigamma; LKB, Turku, Finland). 
2B.11.5.3 Assay of HBs antigenicity by the sandwich RIA 
A commercial solid-phase sandwich RIA (AUSRIA 11-125, Abbott Laboratories) as 
illustrated in Figure 2.1 was used for detection of HBsAg and the protocol was 
according to the procedure B recommended by the manufacturer. The protein samples 
were diluted in PBS and 200 1ug of each was added to appropriate wells containing 
beads coated with guinea pig antibody to HBsAg. The reaction was carried out 
overnight at room temperature. The samples were removed by aspiration and the 
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Figure 2.1 Antigen-capture (sandwich) RIA. 
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(0.74 ,uCi/ml; 200 1) was added to each well and incubated with the beads for 1 hr 
at 45°C. After extensive washings with distilled water, the beads were transferred to 
counting tubes and counted in a y counter (1275 Minigamma, LKB). The titre is 
expressed as the P/N ratio which represents cpm ratio of samples measured (P) and 
negative control (N). The P/N ratio equal to or greater than 2.1 is to be considered 
positive for HBsAg. 
2B.11.5.4 Assay of HBc/HBs antigenicity in the HBcAg fusion protein by the 
sandwich RIA 
The HBcIHBs antigenicity was determined using a modification of the sandwich RIA 
(Figure 2.1) in which the HBcAg fusion proteins were captured on the solid phase 
coated with human anti-HBc antibody and were then detected by rabbit anti-HBs 
antibody directed against an HBsAg epitope on the tested proteins. The HBcAg 
fusion proteins were diluted in blocking buffer (PBS containing 10% donkey serum) 
and 200 Itl was added in duplicate to appropriate wells containing anti-HBc-coated 
beads. After incubation for 2 hr at 37°C, the samples were removed by aspiration and 
the beads washed with washing buffer (PBS containing 0.05% Tween 20) for 5-6 
times and anti-HBs antibody (R82 1:1000 dilution in blocking buffer; 200 1u1) was 
added to each well. After an hour incubation at 37°C, the beads were washed and 1 1-
labelled donkey anti-rabbit immunoglobulin (250,000 cpm/ml in blocking buffer; 
—1,800 Ci/mmole, Amersham; 200 4ul) was added to each well. After a further hour 
at 37°C, the beads were washed with washing buffer extensively, transferred to 
counting tubes and counted in a y counter (1275 Minigamma, LKB). 
2B.11.5.5 Anti-HBs monoclonal antibody (RFHBs-1, -2, and -7) binding assay 
The method used to determine binding of the HBcAg fusion proteins to anti-HBs 
MAbs was the sandwich RIA (Figure 2.1) similar to that described for HBc/HBs 
antigenicity (Section 2B.11.5.4). The test samples were diluted in blocking buffer 
(PBS containing 10% donkey serum) and 200 ul of each was added in duplicate to 
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appropriate wells containing polystyrene beads coated with RFHBs-1, RFHBs-2 or 
RFHBs-7. After incubation for 2 hr at 37°C, the samples were removed by aspiration 
and the beads washed with washing buffer for 5-6 times and anti-HBs antibody (R82 
1:2000 dilution in blocking buffer, 200 4u1) was added to each well. After an hour 
incubation at 37°C, the beads were washed and ' 25I-labelled donkey. anti-rabbit 
immunoglobulin (250,000 cpm/ml in blocking buffer; —1,800 Ci/mmole, Amersham; 
200 4 41) was added to each well. After a further hour at 37°C, the beads were washed 
with washing buffer extensively, transferred to counting tubes and counted in a y 
counter (1275 Minigamma, LKB). The binding is expressed as the P/N ratio which 
represents cpm ratio of samples measured (F) and the background control (N) 
containing the blocking buffer only. 
2B.11.5.6 Assay of anti-HBc antibody by the competitive RIA 
The competitive RIA (Figure 2.2) was used to detect anti-HBc as described by Murray 
et al. (1984). Sera to be tested, including positive and negative sera, for anti-HBc 
were serially 2-fold diluted in RIP buffer and 100 4u1 of each was added in duplicate 
to appropriate wells of the reaction tray followed by the addition of 'I-labelled 
human anti-HBc IgG (480,000 cpm/ml in RIP buffer; 100 1ul), which was kindly 
provided by P. McCulloch and G. Leadbetter of the Department of Medical 
Microbiology, University of Edinburgh. After adding one HBcAg-coated bead to each 
well, the reaction tray was incubated overnight at room temperature. On the following 
day, the beads were washed with PBS or distilled water for 6-10 times and their 
radioactivity counted by a y counter (1275 Minigamma, LKB). The anti-HBc titre is 
expressed as the reciprocal of the serum dilution that gave 50% inhibition of 1I 
labelled anti-HBc binding to the solid-phase HBcAg. The titres were calibrated using 
positive anti-HBc antiserum (R87) as the standard. 
2B.11.5.7 Assay of anti-HBs antibody by the sandwich RIA 
A commercial solid-phase sandwich RIA (AUSAB, Abbott Laboratories) as illustrated 
102. 
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Figure 2.2 Competitive RIA. (A) "51-labelled antibody binds to antigen on the solid phase. (B) Unlabelled antibody inhibits the binding 
of labelled antibody. 
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in Figure 2.3 for detection of anti-HBs antibody was used according to the 
manufacturer's instructions. Test serum (200 jul), including positive and negative 
controls supplied by the kit, was added to one well containing an HBsAg-coated bead 
and the reaction tray was covered and incubated for 16-20 hr at room temperature. 
The samples were removed by aspiration and the beads were washed with distilled 
water extensively. ' 25I-labelled HBsAg (0.74 1esCi/ml; 200 4u1) was added to each well 
and incubated with the beads at room temperature for 4 hr. After extensive washings 
with distilled water, the beads were transferred to counting tubes and counted in a y 
counter (1275 Minigamma, LKB). The estimated RIA unit value is determined by 
calculating the ratio of the reactivity of the test serum to the positive control and 
selecting the estimated RIA unit value for this ratio according to the data supplied by 
the manufacturer. The RIA unit shown in the data is the mean of the value obtained 
from two or three independent experiments. 
2B.11.5.8 Assay of anti-peptide antibodies by the indirect antibody RIA 
The serum samples were assayed for anti-preS l(l), anti-preS 1 and anti-HBs (llllS 
antibodies by the indirect antibody RIA (Catty and Murphy, 1989) as illustrated in 
Figure 2.4. The tested rabbit or mouse sera were diluted 1:100 and 1:1000 with 
blocking buffer (PBS containing 10% donkey serum for rabbit serum samples or sheep 
serum for mouse serum samples) and 200 1ul of each was added in duplicate to 
appropriate wells containing synthetic peptide [preS 1(1), preS 1 or HBs(llllS ]-
coated beads. The reaction tray was incubated at 37°C for 2 to 2.5 hr. The sera were 
removed by aspiration and the beads were washed extensively with washing buffer. 
1 I-labelled donkey anti-rabbit immunoglobulin (250,000 cpm/ml; —1,800 Ci/mmole, 
Amersham; 200 jul) or 'I-1abelled sheep anti-mouse immunoglobulin (250,000 
cpm/ml; —2,400 Ci/mmole, Arnersham; 200 1u1) was added to each well and incubated 
with the beads at 37°C for 1 to 1.5 hr. After extensive washings with washing buffer, 
the beads were transferred to counting tubes and counted in a y counter (1275 
Minigamma, LKB). The titre is expressed as the P/N ratio which represents cpm ratio 
of samples measured (P) and negative control (N). The P/N ratio equal to or greater 
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Figure 2.4 Indirect antibody RIA. 
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than 2.1 is to be considered positive for anti-peptide antibody. 
2B.11.6 Liquid-phase RJAs 
2B.11.6.1 Assay of anti-HBs antibody by the double antibody radio-
immunoprecipitation (DARIP) test 
The method for the detection of anti-HBs antibody in the liquid-phase DART assay 
is based on that described by Burrell et cii. (1978) as illustrated in Figure 2.5. In the 
original method, the test human serum is incubated with 1 I-labelled HBsAg followed 
by precipitation of the human globulin (with or without complexed ' ,5I-labelled 
HBsAg) by the addition of goat anti-human IgG. 
The test rabbit sera and negative rabbit control serum were diluted 1:10 in RIP buffer, 
while positive rabbit control serum (R82) was 10-fold diluted from 10 to 10' in 
1:100 normal rabbit serum (in RIP buffer) as carrier proteins. The diluted test serum 
(50 1u1) was added in duplicate to 'MI-labelled HBsAg (adw or ayw subtype, 3,000 
cpm, corresponding to approx. 0.1-0.5 ng HBsAg; 50 l) which was kindly provided 
by P. McCulloch and G. Leadbetter of the Department of Medical Microbiology, 
University of Edinburgh. More RIP buffer (100 l) was added, mixed thoroughly, and 
the reaction mixture incubated for 24 hr at 4°C. The second antibody (100 4u1), donkey 
anti-rabbit IgG serum with appropriate dilution in RIP buffer was added to each 
reaction mixture, mixed thoroughly, and incubated overnight at 4°C to precipitate IgG. 
Each tube containing the reaction mixture was measured for radioactivity as the "total 
count". Finally, RIP buffer containing starch [0.1% (w/v); 1 ml] was added to each 
test and centrifuged at 2,500 x g for 15 min at room temperature. The supernatant 
was decanted and the amount of radioactivity in the pellet determined. The amount 
of anti-HBs antibody in the test serum is expressed as the mean of the percentage of 
'I-HBsAg co-precipitated, ie. cpm in the pellet divided by cpm added (total count), 
from duplicate tests. 
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J. 
V 
Figure 2.5 DARIP test. (A) In the absence of antibody, precipitate does not form. (B) ' 251-labelled antigen is co-precipitated with the 
complex of antibody and anti-species (depending on the origin of antibody) IgG. 
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2B.11.6.2 Assay of HBs antigenicity by the DARIP inhibition test 
The method for the detection of HBsAg in the liquid-phase DARIP inhibition test is 
also based on that described by Burrell et al. (1978). The assay uses the test samples 
to inhibit anti-HBs antibody from binding to the same antigen radiolabelled. 
Therefore, the amount of HBsAg in the sample can be expressed as percent inhibition 
of a positive DARIP test. 
The dilutions of first antibody (rabbit anti-HBs antibody), anti-rabbit IgG and carrier 
normal rabbit serum used in the DARIP inhibition test were determined by pilot 
titration experiments in this work. The test antigen (100 1u1, diluted in RIP buffer) was 
incubated with anti-HBs antibody, R82 antiserum diluted 10 in 1:200 normal rabbit 
serum (diluted in RIP buffer), at 37°C for 3 hr. 1 I-label1ed HBsAg (adw or ayw 
subtype, 3000 cpm; 50 ,ul) provided by P. McCulloch and G. Leadbetter of the 
Department of Medical Microbiology, University of Edinburgh, was added to the 
reaction, mixed thoroughly, and the mixture incubated for 24 hr at 4°C. Each tube 
containing the reaction mixture was measured for radioactivity as the "total count". 
Finally, RIP buffer containing starch [0.1% (w/v); 1 ml] was added to each test and 
centrifuged at 2,500 x g for 15 min at room temperature. The supernatant was 
decanted and the amount of radioactivity in the pellet determined. The amount of 
HBsAg in the test sample is expressed as the mean of the percent inhibition of ' 15  1 
HEsAg co-precipitated from duplicate tests. 
2B.11.7 Lymphocyte cultures 
2B.11.7.1 Isolation of rabbit PBLs 
Heparin-treated rabbit blood (10 ml) was centrifuged at 500 x g for 20 min and the 
plasma fraction was kept at 4°C for later use (see Section 2B.10.5). The cellular 
fraction (-5 ml) was diluted 1:4 with PBS and carefully layered on Ficoll-Paque 
solution (Pharmacia; 15 ml) and centrifuged at 1,490 rpm (400 x g; 43121-302 rotor, 
II 
Mistral 1000, MSE Scientific Instruments, Rawley, U.K.) for 40 min at room 
temperature. After centrifugation, erythrocytes and granulocytes were at the bottom 
layer, while the mononuclear cells, mostly lymphocytes, were found at the interface 
between the upper layer (PBS) and the Ficoll-Paque solution. The upper layer was 
then carefully drawn off by aspiration, leaving the white lymphocyte layer 
undisturbed. The lymphocyte layer was transferred to a sterile centrifuge tube by 
using a Pasteur pipette, mixed with at least 3 volumes of PBS, and centrifuged at 
1,300 rpm (304 x g) for 5-10 mm. The cell pellet was washed by resuspending in 
RPM! 1640 medium (10 ml) and centrifuging at 304 x g for 5-10 min for 3 times. 
The cells were resuspended in culture medium (RPM! 1640 medium containing L-
glutamine 2 mM, HEPES 10 mM, 2-ME 5 x 10 5M, NaHCO3 10 mM, and FCS 5%; 
5 ml), from which 50 Yl  was removed and diluted 1:5 with trypan blue (0.4%) for 
counting cell numbers on a haemocytometer (Counter chamber, Housser Scientific, 
Horsham, PA., U.S.A). The cell suspension was adjusted to an appropriate density, 
eg. 5 x 106  cells/ml with culture medium. The cell yield was 5-15 x 106/ml of blood 
with a 90-99% cellular viability. 
2B.11.7.2 Isolation of mouse splenocytes 
Mice were sacrificed by cervical dislocation and their spleens removed aseptically and 
placed in a 100-mm petri dish containing 10 ml of RPM! 1640 medium supplemented 
with penicillin (200 U/ml) and streptomycin (200 jig/ml). After trimming off any 
contaminating tissue, the spleen was transferred to another petri dish containing the 
same medium (10 ml) and macerated with the bottom of a 5m1-syringe plunger or 
with a cell dissociation sieve (Grinder kit, Sigma). To ensure a single cell suspension 
formed, the cell suspension was passed through a 23-gauge needle twice. Cells were 
then washed three times with RPM! 1640 medium and adjusted to a density to 5 x 106 
cells/mi with culture medium. 
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2B.11.8 Lymphocyte-proliferative assay 
Rabbit PBLs or mouse splenocytes were cultured at a cell concentration of 2 x 10 5 or 
5 x iø cells/well in the culture medium with a total volume of 0.2 ml in flat-
bottomed 96-well microtitre plates (Falcon) in the medium alone or in the presence 
of Concanavalin A (Con A, Pharmacia; 2 jig/ml), poly(Na-glutamate-alanine-tyrosine) 
(GAT; 6:3:1, M.W. 20,000-50,000, Sigma; 5 ,uglml), or various concentrations of 
antigens. Con A, a potent T-cell mitogen, was used to monitor the proliferative 
potential of lymphocytes, while GAT was used to monitor non-specific T-cell 
activation. The antigens used in the experiments include recombinant HBcAg 
(Biogen; Cambridge, Mass., U.S.A.), recombinant HBsAg (Biogen; or Green Cross; 
Osaka, Japan), and HBcAg fusion proteins purified in this work as well as preS l(l) 
and preS 1 ..2 synthetic peptides. Each concentration of stimulants was assayed in 
triplicate or quadruplicate. 
Following 4 days of culture with or without stimulants at 37°C (humidified 6.5% CO21  
93.5% air atmosphere), 1 Ci of 3H-thymidine (5 Ci/mmole, Amersham) was added 
to each well for an additional 18 hr of culture. The cells were harvested onto glass 
fibre filter strips (Flow Laboratories) using the Titertek7 m cell harvester (Skatron; 
Lierbyen, Norway). The filter disks obtained from the strips were placed in plastic 
vials (Ponyl vial, Packard) containing scintillation fluid (2 ml), and the amount of 3H-
thymidine incorporated into DNA was counted with a liquid scintillation spectrometer 
(Tri-CARB, 2000CA, Packard). Cell proliferation is expressed as the mean of the 
cpm of a triplicate or quadruplicate culture ± standard deviation (S.D.), while 
stimulation index (S.!.) is calculated by dividing the cpm of 3H-thymidine incorporated 
into stimulated cells by the cpm incorporated into non-stimulated cells. 
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CHAPTER 3: CONSTRUCTION OF GENE FUSIONS TO 
HBcAg AND PURIFICATION OF HBcAg FUSION PROTEINS 
3.1 Introduction 
The epitopes from the envelope proteins of HBV, HBs (llllS , preSl(l) and preS 1 , 
were selected for fusion to HBcAg. PreS l(l. ) was chosen because it carries T-cell and 
B-cell epitopes (Milich et al., 1987a) and the sequence used in this study was derived 
from the adyw subtype which lacks 11 N-terminal amino acid residues compared to 
the adw2 or adr subtype and corresponds to preS l(12.31) of adw2 subtype with 
substitution of 3 amino acid residues (Neurath, 1989). PreS 1.,, the N-terminal half 
of the preS2  region, which may elicit the production of neutralising antibody when 
conjugated to carrier proteins or not, was selected for the presence of both B- and T-
cell epitopes (Neurath et al., 1984; Thornton et al., 1987 and 1989). HBs(llllS which 
encompasses the a determinant of HBsAg was also chosen to provide B-cell epitopes 
of the S region. Several gene fusions were constructed in which coding sequences of 
inserted epitopes were linked to those for N-, C-, or both termini of truncated HBcAg. 
All plasmids expressing fusion proteins were based on ptacHpall (Stahl and Murray, 
1989), which contains the coding sequence for amino acid residues 3-144 of HBcAg 
fused to -galactosidase (amino acids 1-8) with 3 extra amino acids from a linker 
sequence, with gene expression being controlled by the tac promoter (de Boer et al., 
1983). 
The HBcAg gene fusions constructed here could be divided into 3 categories. First, 
the fusions carrying a monomer or a dimer of HBs( lll. lS as well as preS 1 and preS2 
epitopes. Secondly, the fusions carrying the mutant sequences at gly 145 of the 
immunodominant region of HBsAg, HBs(lll. lS ; these include HBcS 14 , HBcS 145E and 
HBCS 14 , which carry HB5(111156) sequence with gly145 change to arginine, glutamic 
acid and lysine, respectively. Thirdly, the fusions carrying similar insertions as the 
first category, but containing one mutant sequence at g1y 145 of HBs(lll.lS The 
principal HBcAg fusion proteins are presented schematically in Figure 3.1. The fusion 
proteins carrying wild-type and/or mutants at amino acid residue 145 of HBs (111156) are 
shown in Figures 3.2 and 3.3. 
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Figure 3.1 Schematic representation of HBcAg fusion proteins encoded by the 
corresponding plasmids. Names and total number of amino acids (aa) of the proteins 
are at the left. Numbers in the boxes indicate the positions of the amino acids in the 
native proteins. n-gal, -ga1actosidase. The first three recombinant plasmids were 
constructed by Stahl and Murray (1989). 
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HB 	 pgaI]EFH 	HBC 	JISSOF 	HBS 	GSVDRCP 
2llaa) 
HBcPreS 1  (1-38) 	 (3ga1Jm.i 	HBc 	IE4 Presil 
(198 aa) 
HBcPreS2 -ga1 EFH 	HBc 	IssGP PreS viiicP 
1__8 	3 144 	 2 
(191 aa) 
HBcPrOS 1 ProS2 	I5ga1EFHHBC 7issRELays ProS1 ILAAGPI_ProS2 vmcP 
(218aa) 
HBcProS 1 PreS2S 	 HBc 	JISSRELGYSI_ProS1 I1
_ProS2 IVDI HBs 
(266 aa) 
SHBcPreS 1 ProS2 	I3ga1EF I1I HBs 	EFHr—  HBC 	Iao 	 LM GP IL3PI_PreS2 VDRCP 
(266 aa) 
HBcSProS 1 PreS2S 	f3..ga1EFH 	HBc 	l i&swF  HBs 1561  OSVMELOYSProSl _I LAAGPI_ProS2 Vo l HBs 	IVORcP144 
(318 aa) 
SHBcPreS 1 Pr0S2 S 	13ga1F 	HBs 	J ISSRELGYS I_ProS1 LAAop ProS2 _VDI 	HBS 	Rcp 
(314 aa) 
Figure 3.2 Schematic representation of HBcAg fusion proteins, HBcS and 
HBcPreS 1PreS2S, with wild-type or mutant sequence in gly 1 of HBs(111.15 encoded 
by the corresponding plasmids. Names of the proteins are at the left. Numbers at the 
right indicate amino acid positions on the native proteins. 
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  El PreSg 1-26 
IIIllhIHhII 
• 	PreS . .. 	:. 
Figure 3.3 Schematic representation of HBcAg fusion proteins, HBcSPreS 1PreS 2S, 
SHBcPreS 1PreS2 and SHBcPreS 1PreS2S, with wild-type or mutant sequence in g1y 145 
of HBs(lll.l  encoded by the corresponding plasmids. Names of the proteins are at 
the left. Numbers at the right indicate amino acid positions on the native proteins. 
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HBcSPreS. PreS 2S 
HBcSPreS1 PreS2SlR 
HBcSPreS1 PreS2S 145E 
HBcS1 reS 1PreS2S 
HBcEPreSl PreS2S 
SHBcProS1 ProS2 
S1 -1BcPreS1 ProS2 
SHBcPreSi PreS2SlR 
S1 -I BcPreS1 ProS 2S 
3.2 Sequences fused to the C-terminal region of HBcAg 
Plasmid pHBcPreS 1PreS2  directs the expression of fusion protein HBcPreS 1PreS2 
which contains preS l(l..W) followed by preS 1 fused to the C-terminus of HBcAg. 
The strategy for plasmid construction is shown in Figure 3.4, which was to replace the 
coding sequence for HBcAg from pHBcPreS 2 (Stahl and Murray, 1989) by coding 
sequences for HBcAg and preS l(l .W) from pHBcPreS l(l (Stahl and Murray, 1989). 
Plasmid pHBcPreS 2 was digested with HindIII and the linearised molecule was 
rendered blunt-ended by digestion with Mung bean exonuclease. The large vector-
containing fragment (4.25 kb) carrying preS 1 was isolated after digestion of the 
blunt-end molecule with EcoRI. The DNA fragment carrying the coding sequence for 
HBc(3 .
1) 
 and preSl(lW) was isolated from pHBcPreS l(l by digestion with BamHI, 
filling in cohesive ends of the linearise4 molecule with DNA polymerase (Kienow 
fragment) and digestion with EcoRI. The resulting 528-bp fragment was ligated to the 
4.25-kb fragment from pHBcPreS 2 . 
Plasmid pHBcPreS 1PreS 2S directs the expression of fusion protein HBcPreS 1PreS2S 
which contains preS 1(1., preS 1. and HBs(1l1 . 156) fused to the C-terminus of HBcAg 
and was constructed as follows (Figure 3.5). pHBcPreS 1PreS 2 was linearised by 
digestion with Sail and the cohesive ends filled in with DNA polymerase (Kienow 
fragment). The coding sequence for HBs (l11156) was isolated from amplified pHinG2, 
which contains the whole coding sequence for HBsAg in a S. cerevisiaelE. coli shuttle 
vector (Murray et al., 1984), by using a PCR protocol. The synthetic oligonucleotides 
used as primers for PCR reactions were 010H (5'-GGA ArF CCC AGG AAC ATC 
AAC CAC-3') and 011H(5'-GGA ATI CCC AGG ATG ATG GGA TG-3') which 
carry an EcoRI site at their 5' end. The PCR product containing HBs (1l1l was 
digested with EcoRI and the cohesive ends rendered blunt by digestion with Mung 
bean exonuclease. The PCR fragment was then fused to linearised pHBcPreS 1PreS 2 . 
Plasmid pHBcSPreS 1PreS 2S directs the expression of fusion protein HBcSPreS 1PreS2S 
and was constructed as follows (Figure 3.6). pHBcS (111 . 15 (Stahl and Murray, 1989) 
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Figure 3.4 Construction of pHBcPreS 1PreS2 for generating HBcAg fusion protein 
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Figure 3.5 Construction of pHBcPreS 1PreS 2S for generating HBcAg fusion protein 
with the preS l(l..W), preS 1 and HBs 1111 fragments at the C-terminus. Selected 
restriction sites are shown. 
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Figure 3.6 Construction of pHBcSPreS 1PreS2S for generating HBcAg fusion 
protein with the preS l(l) and preS 1 fragments sandwiched by two HBs (111 . l  
fragments at the C-terminus. Selected restriction sites are shown. 
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was digested with Sail and Aval and the cohesive ends of the large fragment were 
filled in with DNA polymerase (Kienow fragment). The resulting 3.9-kb fragment 
carrying the coding sequences for HBc (3) and was ligated to a 1.1 kb 
fragment containing preS l(120), preS 1 and HBs(lll.l which had been generated 
from pHBcPreS 1PreS 2S by digestion with Aval and filling in the cohesive ends of the 
small fragment with DNA polymerase (Klenow fragment). The coding sequence for 
HBsAg in pHBcS(lll.l was subcloned from a variant of plasmid pHBV130 (Gough 
and Murray, 1982) which contains a missense transition (HBV nucleotide 1794, C 
changed to T) resulting in a substitution from proline to serine at amino acid residue 
120 of HBsAg. The plasmid pHinG2 used for amplification of the HBs (1l115 
sequence was, in fact, a mutant plasmid with a substitution from serine to threonine 
at amino acid residue 113 of HBsAg. Therefore, in HBcSPreS 1PreS 2S, there are two 
amino acids different between the two HBs (llllS fragments. 
The nucleotide sequence in the junction region was determined by DNA sequencing. 
In addition, the coding sequence for HBs (lll.lS from the PCR product in 
pHBcPreS 1PreS2S was confirmed by DNA sequencing. 
3.3 Sequences fused to the N-terminal region of HBcPreS 1PreS2 
Plasmid pSHBcPreS 1PreS2 directs the expression of fusion protein SHBcPreS 1PreS2 
and was constructed as follows (Figure 3.7). The coding sequence for HBs (lll.lS was 
amplified from pHinG2 by PCR as described previously (Section 3.2). The amplified 
DNA fragment carrying the coding sequence for HBs (llllS with EcoRI sites at both 
ends was digested with EcoRI and fused to pHBcPreS 1PreS 2 that had been linearlised 
and digested with EcoRI. The fusion protein SHBcPreS 1PreS 2S, therefore, carries 
foreign epitopes at both N- and C-termini of HBcAg. The coding region of 
within the vector was verified by DNA sequencing. 
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Figure 3.7 Construction of pSHBcPreS 1PreS2 for generating HBcAg fusion protein 
with the HBs(lll .l fragment at the N-terminus as well as with the preS l(l) and 
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3.4 Mutant sequences of HBs (lfl. fused to the C-terminal and/or N-terminal 
regions of HBcAg 
The impetus for creating mutant sequences of HBs (lll..lS fused to HBcAg is the 
finding of the vaccine-induced escape mutant with an amino acid substitution from 
glycine to arginineat amino acid residue 145 of HBsAg, which cannot be neutralised 
by vaccine-induced anti-HBs antibody (Carman et al., 1990). By using site-directed 
mutagenesis, three mutant HBcAg fusion proteins were constructed which carry the 
HBs(llIl sequence with g1y 145 change to arginine, mimicking the escape mutant 
described previously, or glutamic acid or lysine. A study by Ashton-Rickardt and 
Murray (1989b) indicated that site-directed mutagenesis can be used to change the 
immunological specificity of an antigen. Therefore, an attempt has been made to alter 
the immunological specificity of HBcS carrying wild-type or gly 145 mutant HBs (lll. lS . 
In addition, on the basis of these mutant sequences, fusions were also constructed 
carrying a dimer of HBs(lIllS , one from wild-type and the other from a mutant 
sequence, accompanied by preS l(1 .20) and preS l) sequences. The goal of this part 
of the study is an attempt to create multivalent immunogens based on HEcAg that 
may induce antibody with a wider specificity to confer immunity against HBV 
infection, including antigenic variants. 
3.4.1 Site-directed mutagenesis of pHBcS (111 .1 
The target for mutagenesis, a 594-bp EcoRI-SalI fragment, bearing the HBc (31) and 
HBs(llllS sequences, was excised from pHBcS (llllS), and subcloned into the 
M13mp19 vector (Norrander et al., 1983), which resulted in the construction of 
M13HBcS. The following three 23- or 26-mer oligonucleotides were used for site-
directed mutagenesis. 412G: 5'-ACC TrC GGA TG AAA CTG CAC CT-3' 
(nucleotide 1869 in HBV G—A, amino acid residue 145 in HBsAg gly—arg). 411G: 
5'-ACC TTC GGA TGA AAA CTG CAC CT-3' (nucleotide 1870 in HBV G-A, 
amino acid residue 145 in HBsAg g1y-glu). 359G: 5'-AAA CCT TCG GAT AAA 
AAC TGC ACC TG-3' (nucleotides 1869 and 1870 in HBV GG—AA, amino acid 
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residue 145 in HEsAg gly-1ys). Site-directed mutagenesis was performed to convert 
amino acid residue 145 in HBsAg from glycine to arginine, glutamic acid, or lysine. 
The M13mp19 clones containing a mutated insert were identified by T-track 
sequencing. The candidate mutants were then fully sequenced for the entire insert. 
No undesired mutations occurred during the reactions. 
3.4.2 Construction of mutant pHBcS (l11 .1 recombinants 
Three mutants to pHBcS (lll.lS at amino acid residue 145 of HBsAg were constructed 
as follows (Figure 3.8). Plasmid pHBcX (Rossner, 1991) which contains the coding 
regions for 1113c (3 . 1 , HBs(111120) and HBx(l) was digested with EcoRI and Sail and 
the large fragment from this digest was then ligated to EcoRI-Sall fragment excised 
from M13 RF DNA carrying mutant sequence (M13HBcS 14 , M13HBcS I45E and 
M13HBcS 14 J. This resulted in recombinant plasmids pHBcS 14 , pHBcS145E and 
pHBcS 14 , which directed the expression of fusion protein HBcS 14 , HBCS 14 , and 
HBcS 14 , respectively. The entire coding regions for HBc (3 .1) and HBs (l11. 15 in three 
mutant recombinant plasmids were verified by M13 sequencing after subcloning 594-
bp EcoRI-Sall fragments bearing the coding sequence of HBc (3) and HBs(llllS into 
M13mp18 (Norrander et al., 1983). The sequences of the mutated sites in the three 
mutants are presented in Figure 3.9. 
3.4.3 Mutant sequence of HBs (111 .1 with preS 1(1 . 20) and preS2(1. fused to the C-
terminal region of HBcAg 
Plasmids pHBcPreS,PreS 2S,45R and pHBcPreS,PreS2SI45Ewere constructed using the 
same strategy as that for pHBcPreS 1PreS 2S (Figure 3.5). The coding sequences for 
HBs(llll with g1y 145 changed to arg and glu were derived from pHinG2, 4sR carrying 
the mutant sequence for arg 145 in HBsAg, and pHBcS 145E carrying the mutant sequence 
for g1u145 in HBsAg, respectively. The two mutant recombinant plasmids thus directed 
the expression of fusions proteins HBcPreS 1PreS2S 14 and HBc?reS 1PreS2S 14 . 
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Figure 3.8 Construction of pHBcS, 45R for generating HBcAg fusion protein with 
HBs(l11 . 1  fragment carrying arg substitution at amino acid residue 145. Selected 
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Figure 3.9 Nucleotide (non-coding strand) sequences of HBsAg gene mutated at 
amino acid residue 145 of HBsAg. Plasmids pHBcS 1 , pHBcS,45E and pHBcS14 
were digested with EcoRI and Sail and the resulting 594-bp fragment bearing coding 
strand of HBc(3 ..1) and HBs(lll.. l sequences were subcloned into M13mp18 for 
sequencing. For comparison, the corresponding wild-type sequence obtained from 
plasmid sequencing of pHBcS (11l . 156) is also shown. 
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Four mutant recombinant plasmids, pHBcSPreS 1PreS 2S 1 , pHBcSPreS 1PreS2S 1 
pHBcS 14 PreS 1PreS2S, and pHBcS 1 PreS 1PreS2S, were constructed using the same 
strategy as that for pHBcSPreS 1PreS2S (Figure 3.6). The coding sequence for HBcAg 
and its adjacent HBs(lll..l was derived from wild-type or mutant pHBcS (Lll . j while 
the coding sequence for preS l(l , preS 1 and HBs (l111S at the C-terminus of the 
fusion protein was derived from pHBcPreS 1PreS2S with the wild-type or mutant 
sequence at amino acid residue 145 of HBsAg. The four mutant recombinant 
plasmids direct the expression of the corresponding HBcAg fusion proteins. The 
nucleotide sequences in the junction region of the recombinant plasmids were 
confirmed by DNA sequencing. 
3.4.4 Construction of plasmids pS 1 HBcPreS1PreS2, pS1 HBcPreS1PreS2S and 
pSHBcPreS1PreS2S1 
Plasmid pS 14 HBcPreS 1PreS 2 directs the expression of fusion protein 
S14 HBcPreS 1PreS 2 and was constructed similarly to pSHBcPreS 1PreS 2 except that the 
coding sequence for HBs (ll1. 15 with 91y145 changed to arg was derived from 
pHinG2145R carrying the mutant sequence for arg 145 in HBsAg. 
Plasmid pS 14 HBcPreS 1PreS 2S directs the expression of fusion protein 
S14 HBcPreS 1PreS2S and was constructed as follows (Figure 3.10). Plasmid 
pS14 HBcPreS 1PreS 2 was digested with Smal and PVUI and the small fragment (1.6 
kb) from this digest was fused to a large SmaI-PVUI fragment (3.4 kb) from 
pHBcPreS 1PreS2S. Plasmid pSHBcPreSPreS 2S 145R directs the expression of fusion 
protein SHBcPreS,PreS 2S,45R and was constructed similarly to pS 14 HBcPreS 1PreS 2S, 
but using pSHBcPreS 1PreS2 and pHBcPreS,PreS2Sl45R  instead. The nucleotide 
sequences in the junction region were also verified by DNA sequencing. 
3.5 Production and purification of HBCAg fusion proteins in E. coli 
Cultures of the laclq strains of E. coli RB791 or TG1 harbouring various recombinant 
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Figure 3.10 Construction of pS 14 HBcPreS 1PreS2S for generating HBcAg fusion 
protein with the HBs(llll fragment carrying gly 145-arg mutation at the N-terminus 
as well as with preS 1(1 . ), preS 1 and HBs(l1115 fragments at the C-terminus. 





















plasmids were grown in LB supplemented with ampicillin, and the tac promoter was 
induced with IPTG. After shaking at 37°C overnight, the bacteria were harvested and 
lysed by sonication and the cellular debris was removed by centrification (12,000 x 
g, 10 mm). The soluble fractions were initially analysed on 12.5% or 15% SDS-
PAGE. At this stage, it was usually possible to visualise expressed HBcAg fusion 
proteins by Coomassie blue staining, but the natural host proteins of similar molecular 
weight sometimes obscured the gel profile. The crude extract was then precipitated 
by ammonium sulphate at 30% saturation. The pellets from ammonium sulphate 
precipitation were dissolved in 0.1 M of Tris-HC1 (pH 7.0) buffer and dialysed against 
the same buffer. At this stage, the induced HBcAg fusion proteins were easily 
visualised by Coomassie blue staining after SDS-PAGE compared to a counterpart 
from uninduced cell extract. Figure 3.11 shows SDS-PAGE profiles of HBcS wild-
type and the three g1y 145 mutants as well as HBcS(lll (Stahl and Murray 1989) with 
7 amino acid residues more than HBcS. The mutant protein HBcS 14 , containing a 
glutamic acid substitution at g1y 145 of HBsAg, runs slower than expected, whereas no 
change is observed for HBcS, 45R and HBcS,45K containing arginine and lysine 
substitutions, respectively. It has been reported that alteration of a single amino acid. 
by mutagenesis may alter the mobility of some proteins in SDS-PAGE (Fasano et al., 
1984). However, the reason for the decrease in electrophoretic mobility in HBcS 14 
is not clear. 
The HBcAg fusion proteins were collected by ultracentrifugation at 100,000 x g for 
1 hr and resuspended in 0.1 M of Tris-HC1 (pH 7.0). The HBcAg fusion proteins 
carrying inserts only at the C-terminus were soluble and readily chromatographed on 
Sepharose 4B-Cl, whereas those carrying both N- and C-terminal inserts, e.g. 
SHBcPreS 1PreS2 and SHBcPreS 1PreS 2S, were aggregated as insoluble fractions, which 
impede them from being purified by the method used for HBcAg and its C-terminal 
fusion derivatives. In addition, the production of HBcAg fusion proteins containing 
both N- and C-terminal inserts appeared to be less than that obtained with those 
containing only C-terminal inserts when estimated in SDS-PAGE (results not shown). 
The purification of HBcAg fusion proteins containing both N- and C-terminal inserts 
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Figure 3.11 SDS-PAGE of expressed HBcAg fusion proteins. Protein samples from 
soluble fractions of crude extracts after 30% ammonium sulphate precipitation from 
IPTG-induced or uninduced cultures harbouring recombinant plasmids were 
fractionated in a (A)15% or (B)12.5% acrylamide gel and stained with Coomassie 
blue. 
(A) Lanes: 
M 	- Molecular weight size standards 
1 	- HBcS from IPTG-induced cultures 
2 	- HBcS 14 	from IPTG-induced cultures 
3 	- HBcS 14 	from IPTG-induced cultures 
4 	- HBCS 14 	from IPTG-induced cultures 
5 	-. 3 1ug purified HBcAg 
(B) 	Lanes: 
M 	- Molecular weight size standards 
1 	- 3 ug purified HBcAg 
2 	- HBCS from IPTG-induced cultures 
3 	- HBCS(1l11 	from IPTG-induced cultures 
4 	- HBCS(Ill . L 	from uninduced cultures 
5 	- HBCS14 	from IPTG-induced cultures 
6 	- HBcS 14 	from uninduced cultures 
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was not further explored. Other approaches, such as SDS, urea, or guanidinium 
chloride treatments, might be useful for solubilising the proteins; however, they should 
not cause protein denaturation, for this would complicate the immunogenicity 
experiments. 
After fractionation by chromatography, fractions containing HBcAg fusion proteins 
visualised by SDS-PAGE were pooled and collected by ultracentrifugation. Purified 
proteins were analysed by SDS-PAGE on 15% gels followed by Coomassie blue 
staining. The differences among the apparent molecular sizes of the various HBcAg 
fusion proteins lacking or carrying insertions are in good agreement with the lengths 
of the amino acid sequences encoded by the inserts. Yields of the HBcAg C-terminal 
fusion proteins range from 5 to 34 mg per litre of culture. The purified proteins 
reacted with rabbit anti-HBc antibody (R87 rabbit serum) as shown in immunoblots 
(Figure 3.12). 
Since HBcAg fusion proteins can be pelleted by ultracentrifugation as in the method 
employed for the purification of HBcAg, it is likely that they all form particles. 
Direct visualisation by using electron microscopy, which was performed by D. Notman 
of the Department of Medical Microbiology, University of Edinburgh, shows that the 
HBcAg fusion proteins carrying inserts only at the C-terminus were assembled into 
particles similar to recombinant HBcAg produced from E. coli (Figure 3.13). In 
addition, electron microscopy of the ammonium sulphate fraction containing 
SHBcPreS,PreS 2S,45R which carries both N- and C-terminal inserts, also revealed core-
like particles (result not shown). Therefore, the assembly of core-like particle was 
unimpeded by the addition of peptide sequences to both the N- and C-termini of the 
truncated HBcAg. 
3.6 Discussion 
Apart from the higher immunogenicity of HBcAg in terms of T-cell activation and 
antibody production compared to HBsAg, the wide range of hosts for its expression 
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Figure 3.12 Immunoblot analysis of HBcAg fusion proteins probed by anti-HBc 
serum. Purified protein samples were electrophoresed through a 15% SDS-PAGE and 
transferred to nitrocellulose membrane and HBcAg was detected by incubation with 
(A) Rabbit 87 anti-HBc serum diluted 1:250 or (B) mouse anti-HBc serum diluted 
1:500 followed by incubation with appropriate anti-species IgG conjugated with 
alkaline phosphatase and subsequent incubation with NBT and BCIP. 
(A) 	Lanes: 
M 	- Coloured molecular weight size standards 
1 	- HBcAg 
2 	- HBsAg 
3 	- HBCS 
4 	- HBCS 14 
S 	- HBCS 14 
6 	- HBCS 14 
(B) 	Lanes: 
M 	- Coloured molecular weight size standards 
1 	- HBcAg 
2 	- HBsAg 
3 	- HBcPreS 1PreS2S 
4 	- HBcPreS 1PreS2S 14 
5 	- HBcPreS 1PreS2S 14 
6 	- HBcSPreS 1PreS 2S 14 
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makes it very attractive as a carrier for presentation of foreign epitopes. HBcAg can 
be expressed in a wide range of hosts, including E. coli (Pasek et al., 1979), B. 
subtilis (Hardy et al., 1981), Salmonellae (Schodel et aL, 1990), yeast (Kniskern et aL, 
1986) and mammalian cells (Rossinck et aL, 1986; Clarke et aL, 1987). The HBcAg 
fusion proteins carrying foreign epitopes at the C-terminus of truncated HBcAg 
expressed in E. coli were produced in high yield and could be purified following the 
method described previously (Stahl et aL, 1982; Stahl and Murray, 1989) with some 
modifications. They assembled into core-like particles, which allow easy purification 
of the fusion proteins. 
The largest HBcAg fusion protein, HBcSPreS 1PreS 2S, has 165 amino acid residues 
attached at the C-terminus of residue 144 of HBcAg via 5 residues from the linker 
sequence and has 318 residues in all, compared with 183 of the normal, full-length 
HBcAg. A similar size of extension has been reported in the HBcX fusion protein 
carrying HBs (111120) and the complete X antigen (1-154) fused to the C-terminus of 
truncated HBcAg (Rossner, 1991). However, unlike the C-terminal fusion particles 
made in this study and those described by Stahl and Murray (1989), HBcX could not 
be dissociated by treatment with 1% Triton-X 100 and harsher treatments were needed 
to dissociate the aggregated proteins. 
The HBcAg fusion proteins carrying inserts at both N- and C-termini of truncated 
HBcAg displayed different physical and/or chemical characteristics from those 
carrying only C-terminal inserts. They were insoluble when pelleted by 
ultracentrifugation after 30% ammonium sulphate precipitation of the soluble fractions 
from crude extracts. For this reason, these HBcAg fusion proteins with inserts at both 
termini were not purified, and their immunogenicity was not studied. The aggregation 
of SHBcPreS 1PreS2 and SHBcPreS 1PreS 2S carrying the HBs (111156) fragment at both N-
and C-terminal region of truncated HBcAg may be due to a peculiarity of the HBs (111 
sequence used for the N-terminal fusion. The HBs (lll..l sequence consists of 46 
amino acid residues, among which 7 are cysteine residues. If some of the cysteine 
residues are exposed on the particle surface, they may be available to form 
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interparticle disulphide bonds. There is evidence that the synthetic HBs (1147) peptide 
carrying 5 cysteine residues spontaneously self-assembles to yield a heterogenous 
mixture of multiple forms via disulphide bonds (Manivel et al., 1992b). Recently, a 
synthetic 323-bp gene with the ORF of a multiple-epitope polypeptide consisting of 
epitopes from preS 1, preS2 and S regions separated by pairs of glycine residues has 
been assembled, cloned and expressed in E. coli (Kumar et al., 1992). The expressed 
polypeptide appeared in the cell pellets and only urea could solubilise it from the 
pellet. Nevertheless, HBcS, HBcPreS 1PreS2S and HBcSPreS 1PreS 2S carrying a 
monomer or a dimer of the HBspi-Lso  sequence fused to the C-terminal region of 
truncated FlBcAg are soluble. How the position within HBcAg of the inserted 
epitopes influences aggregation of the formation of disulphide bonding of the HBcAg 
fusion proteins is not known. 
Clarke et aL (1987) first reported the presentation of the major immunogenic sequence 
from FMDV comprising amino acids 141-160 from the viral protein VP1 on the 
surface of HBcAg fused to the N-terminal part of the HBV pre-core sequence. 
Because of toxicity problems, the fusion protein could not be produced in E. coli, but 
was produced by expression in a mammalian cell system. Later, the problem of 
expression in E. coli was overcome and a bacterial expression system developed for 
production of HBcAg fusion proteins with FMDV or rhinovirus epitopes joined 
through a short linker sequence to 6 residues of the HBV pre-core sequence followed 
by the full HBcAg sequence (Clarke et al., 1990; Francis et al., 1990). Recently, 
similar constructs containing epitopes from the preS region of HBV (Schodel et al., 
1992) or simian immunodeficiency virus (Yon et al., 1992) were made and expressed 
in E. coli without difficulty. 
The strategy for N-terminal fusion in this study differs from that used by other groups. 
The HBs(lll.l sequence was fused upstream of HBc (31) using a unique EcoRI site 
in pHBcPreS 1PreS2 and pHBcPreS 1PreS2S for insertion of the S sequence, so that the 
resulting gene fusions contained the -galactosidase (14) sequence followed by 2 amino 
acid residues from the linker sequence, the inserted epitope HBs (l11 . l5 , 3 amino acid 
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residues from another linker sequence, and HBc (3) further followed by the insertions 
at the C-terminus. Recently, it has been reported that a preS 1 epitope linked to the N-
terminus of HBcAg was not surface accessible and not immunogenic, although the 
hybrid HBcAg proteins were particulate; while that linked to the amino terminus 
through the C-terminal 4 amino acid residues of the pre-core sequence, became surface 
accessible (Schodel et al., 1992). The authors claimed that the N-terminus of native 
HBcAg might not be exposed on the particle surface, and heterologous epitopes were 
exposed at the exterior of HBcAg particles by virtue of the pre-core and/or linker 
amino acids. 
Gene fusions to the C-terminus of HBcAg have been made at amino acid residue 144 
via a short linker sequence (Stahl and Murray, 1989) or directly (Borisova et al., 
1989) and at amino acid residue 156 (Schodel et aL, 1990 and 1992) so that the 
arginine-rich region at the C-terminus of HBcAg was not present. The fusion proteins 
produced in bacteria assembled into core-like particles, indicating that the arginine-rich 
C-terminal region is dispensable for core particle assembly. 
Insertion of foreign epitopes at an internal site in HBcAg has also been explored. 
PreS epitopes and non-HBV viral epitopes have been inserted into a polylinker 
sequence positioned between amino acid residues 144 and 145 of HBcAg and the 
fusion proteins formed core-like particles (Borisova et al., 1989). Moreover, the 
introduction of foreign epitopes between amino acid residues 80 and 81 (Yon et al., 
1992) as well as between 75 and 83, thereby deleting residues 76 to 82, (Schodel et 
aL, 1992) did not prevent particle formation. 
Based on the concept that presentation of foreign epitopes on the surface of particulate 
structures enhanced immunogenicity, the use of self-assembling particles using HBsAg 
as carrier moieties has also been explored. However, the HBsAg fusion proteins were 
expressed in yeast or mammalian cells (Delpeyroux et al., 1986; Michel et al., 1988; 
Schlienger et aL, 1992) and were unstable in E. coil. In contrast, the HBcAg fusion 
proteins are produced in high yields in E. coil, which facilitates their purification. 
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Schodel et al. (1990) expressed HBcAg fusion proteins in strains of various 
Salmonella species for the development of oral vaccines. 
In conclusion, in the work described here, the preS l(l., preS 1 and HBs(llll 
wild-type or gly, 45  mutant, sequences were fused to truncated HBcAg at the N- and 
C-termini and the HBcAg fusion proteins were expressed in E. coil. Fusions of the 
epitopes at the C-terminus of HBcAg were soluble and could be purified based on 
their particulate nature. However, insertion of the epitopes at both N- and C-termini 
of HBcAg appeared to alter the physical and/or chemical properties of the proteins, 
and rendered them aggregated. Nevertheless, they still formed particles. The purified 
HBcAg fusion proteins were then evaluated for antigenicity and immunogenicity. 
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The purified HBcAg fusion proteins including HBcS, HBcPreS 1PreS2, HBcPreS 1PreS2S 
and HBcSPreS 1PreS 2S in which the inserted HBs sequence possesses either wild-type 
or mutant amino acid residue at g1y 145 were tested for HBc and HBs antigenicity. The 
reactivities of HBcAg fusion proteins with anti-HBc and anti-HBs antibodies were 
tested by immunoblot analyses and RIAs. Because suitable antibodies against preS l(l. 
20) and preS 1 epitopes were not available in this laboratory, the preS 1 and preS2 
antigenicity of the HBcAg fusion proteins was not examined. However, 
immunogenicity in terms of the production of anti-preS 1 and anti-preS 2 antibodies were 
assessed (see Chapter 5). 
4.2 HBc antigenicity 
The result of the immunoblot experiment is shown in Figure 3.12. Polyclonal anti-
HBc antiserum recognised HBcAg and all the HBcAg fusion proteins. The HBcAg 
fusion proteins with both N- and C-terminal inserts, e.g. SHBcPreS 1PreS 2 and 
SHBcPreS 1PreS2S, although not purified due to aggregation during the purification 
process, also reacted with rabbit anti-HBc serum in immunoblot analysis when the 
reduced, boiled, insoluble samples were applied to SDS-PAGE (result not shown). 
The antigenic reactivity of HBcAg was further analysed by a sandwich RIA in which 
HBcAg fusion proteins were trapped on a solid phase with human anti-HBc IgG. 
When 'I-labelled human anti-HBc is added, it binds to antigen-antibody complex on 
the solid phase, creating a radioactive antibody-antigen-antibody "sandwich". Figure 
4.1 shows that all HBcAg fusion proteins display similar HBcAg reactivity. The assay 
is specific to HBcAg reactivity because HBsAg in the same concentrations failed to 
bind to the beads coated with anti-HBc IgG and all the HBcAg fusion proteins showed 
dose-response binding to anti-HBc antibody similar to that of full-length HBcAg. In 
this antigen-capture sandwich assay, the signal generated is not high, hence the 
detection range is between 1 to 10 ng of HBcAg and the assay reaches a plateau when 
more than 10 ng of antigen is present. However, the signal in the assay could be 
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Figure 4.1 HBc antigenicity of HBcAg fusion proteins. The HBc antigenicity was 
measured by the sandwich RIA in which HBcAg fusion proteins were trapped with 
anti-HBc IgG and the bound antigens were measured using ' 25I-labelled anti-HBc 
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amplified to some extent by using an unlabelled polyclonal anti-HBc antibody from 
mice, while the coating anti-HBc antibody was from human, and 'I-labelled sheep 
anti-mouse immunoglobulin (data not shown). 
These results indicate that all HBcAg fusion proteins bearing amino acid 3 to 144 
residues of HBcAg and containing up to 318 amino acid residues compared with 183 
of the full-length HBcAg or 157 of its HBcAg counterpart used for the construction 
of these gene fusions, retain HBc antigenicity. 
4.3 HBs antigenicity 
The reactivity of HBcAg fusion proteins carrying the HBs (11l156) sequence with anti-
HBs antibody was tested in the DARIP inhibition assay and also by the AUSRIA II 
RIA detection kit (Abbott laboratories). In the DARIP inhibition test, an " -51-labelled 
HB5Ag and anti-HBs antibody reaction can be demonstrated by concentration-
dependent competitive inhibition in the presence of increasing amounts of HBsAg. 
In Table 4.1, HBsAg, serving as a positive control, demonstrated a dose-response 
• inhibition of the binding of "51-labelled HBs to anti-HBs antibody. However, no 
inhibition was observed with the HBcAg fusion proteins at the 200 ng level. The 
result -indicates that HBcS, not only wild-type but also the three 91y 145 mutant proteins, 
display little or no HBsAg antigenicity. Since HBcS showed no reactivity, whether 
the antigenic determinants in the three 91y 145 mutant proteins have changed could not 
be assessed. Besides, the anti-HBs used for the assay was a polyclonal serum against 
several B-cell epitopes within HBsAg, thus it is unlikely that the possible change in 
one single epitope would abolish the binding of anti-HBs with HBcAg fusion proteins 
carrying the HBs(111156) sequence. Nevertheless, it is tempting to suggest that the 
inserted HB5 (111156) sequence may be surface inaccessible or may - exhibit 
conformational changes that alter the accessibility of HBs epitopes on HBcAg fusion 
proteins and hinder them from reacting to anti-HBs antibody. 
The HBsAg antigenicity of HBcS carrying unmutated or mutated 91y 145 was also 
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Table 4.1 	HBs antigenicity of HBcAg fusion proteins examined in the DARIP 
inhibition assay 
Sample" 	Concentration 	%'I-HBsAg precipitated' 	% Inhibition 
(ng) 
HBsAg 200 7.2 91.6 
100 6.8 92.1 
30 6.3 92.7 
10 5.5 93.6 
3 6.2 92.8 
1 7.3 91.5 
0.3 30.4 64.6 
0.1 53.1 38.2 
0.03 74.1 13.7 
0.01 80.3 6.5 
0.003 83.9 2.3 
HBcAg 200 89.1 -3.7 
HBCS 200 83.5 2.8 
HBcS,45R 200 82.0 4.5 
HBCS 14 200 83.0 3.4 
HBcS14SK 200 86.3 -0.5 
HBcPreS l(l 200 79.5 7.5 
Buffer' - 85.9 0 
' The tested samples were used as the inhibitor in the DARIP inhibition assay. 
b  A percentage of 'I-HBsAg (ayw) bound to the precipitate compared to total ' 25  1 
added in the reaction. 
C  RIP buffer (0.5% BSA in PBS) used as the diluent in the assay. 
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examined with the Abbott AUSRIA II RIA. In this "sandwich" RIA, beads coated 
with guinea pig anti-HBs antibody are incubated with test samples. Any HBsAg 
present in the samples is bound to the solid phase antibody. Human 'MI-labelled anti-
HBs is allowed to react with antibody-antigen complex on the bead. The reactivity 
of HBsAg in these HBcAg fusion proteins, either wild-type or mutants, was poor, 
since high concentrations of the samples (100 pg), containing approximately 20 pg of 
HBs(1ll ..
15 
 fragment produced only weak binding (Table 4.2), equivalent to the binding 
of approximately 1 ng of native HBsAg. HBcPreS l(l .3 served as the negative control 
also produced weak binding (P/N ratio = 2.4 for 10 pg). In addition, when 500 pg 
of the HBcAg fusion proteins was used in the AUSRIA test, the P/N ratio remained 
low, ranging from 3.0 to 3.6 (data not shown). 
In immunoblot analysis, however, HBcS wild-type and the three mutant proteins 
reacted not only with anti-SDS-denatured HBs antibody (result not shown), but also 
with anti-native HBs antibody (Figure 4.2). These results confirm that the HBs 
sequence was presented in HBcAg fusion proteins containing HBs (1lll5 sequence. 
The immunoblotting method involves antigen presentation on a solid support, thus 
allowing antibody to bind in a multivalent manner. However, it is likely to favour 
sequence determinants, rather than conformational determinants. 
In the AUSRIA test, the antigen to be tested must present at least one target epitope 
on each side of the molecule. In other words, the two antibody components are 
required to bind spatially distinct antigen epitopes. Although the two anti-HBs 
antibodies, one as capture and the other as labelled reagents, used in the assay are 
polyclonal, the binding of HBs epitopes in HBcAg fusion proteins to the solid phase 
antibody might result in steric hindrance that prevents the HBs epitopes from reacting 
efficiently with 1 I-labelled anti-HBs antibody. Therefore, another antigen-capture 
sandwich assay was set up in which HBcAg fusion proteins were trapped on 
polystyrene beads coated with human anti-HBc IgG and then tested for the presence 
of anti-HBs reactive epitopes on the surface of the fusion proteins by using rabbit anti-
HBs serum and appropriate 'MI-labelled second antibody ('I-labelled donkey anti- 
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Table 4.2 	HBs antigenicity of HBcAg fusion proteins assessed by the AUSRIA 
II RIA 
Sample 	 Concentration 	P/N ratios 
HBsAg 10.0 ng 14.0 
3.0 ng 7.1 
1.Ong 3.4 
0.3 ng 2.4 
0.1 ng 1.7 
0.03 ng 1.7 
HBcS 100.0 pg 2.5 
10.0 1ug 2.0 
HBcS,45R 100.0 pg 2.8 
10.0 pg 2.3 
HBCS 14 100.0 pg 3.2 
10.0 pg 2.0 
HBcS 14 100.0 pg 3.1 
10.0' pg 2.7 
HBcPreS,(1 .30 100.0 pg 1.8 
10.0 pg 2.4 
The reactivity of HBsAg in the samples was assessed by the 
AUSRIA II RIA and the results are expressed as P/N ratio 
which represents cpm ratio of samples measured (P) and 
negative control (N). 
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Figure 4.2 Immunoblot analysis of HBcAg fusion proteins probed by anti-HBs 
serum. Purified protein samples were electrophoresed through a 15% SDS-PAGE and 
transferred to nitrocellulose membrane and HBsAg was detected by incubation with 
Rabbit 82 anti-HBs serum diluted 1:200 followed by incubation with appropriate anti-
species IgG conjugated with alkaline phosphatase and subsequent incubation with NBT 
and BCIP. 
(A) 	Lanes: 
M 	- Coloured molecular weight size standards 
1 	- HBcAg 
2 	- HBsAg. 
3 	- HBCS 
4 	- HBCS 14 
5 	- HBcS 14 
6 	- HBcS 14 
(B) 	Lanes: 
M 	- Coloured molecular weight size standards 
1 	- HBcAg 
2 	- HBsAg 
3 	- HBcPreS 1PreS2S 
4 	- HBcPreS 1PreS2S 14 
5 	- HBcPreS 1PreS2S 14 
6 	- HBcSPreS 1PreS2S 
7 	- HBcSPreS 1PreS 2S 14 
8 	- HBcPreS 1PreS2 
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rabbit imthunoglobulin). As shown in Figure 4.3, HBs antigenicity was detected in 
all the HBcAg fusion proteins carrying wild-type or mutant HBs (111 . 156) sequences, 
whereas HBcAg, HBcPreS l(136) and HBcPreS 2 showed no HBs antigenicity, 
demonstrating that the assay is specific for the detection of HBs antigenicity. 
Comparing the assays for HBcAg and HBsAg which share a similar strategy, i.e. 
antigen-capture sandwich assay, the amount of core fusion proteins needed to obtain 
a positive signal was much higher in the HBsAg assay than in the HBcAg assay. 
Reversely, if HBcAg fusion proteins were trapped on the solid phase coated with 
rabbit anti-HBs IgG and then tested for HBc antigenicity on the fusion proteins by 
using mouse anti-HBc serum and I-labelIed sheep anti-mouse immunoglobulin as 
the probe, non-specific binding of the HBcAg fusion proteins to the solid phase 
allowed anti-HBc serum to bind to the anti-HBc reactive epitope within the HBcAg 
fusion protein, which resulted in high background of the assay. As a result, the 
difference in binding between HBcS and HBcAg or HBcPreS, (as the negative control) 
was not high enough to differentiate the positive and negative reactions (result not 
shown). 
To investigate whether the specificity of anti-RBs antibody and HBsAg interaction 
could be inhibited by HBcAg fusion proteins carrying HBs (1111S6), an antigen-
inhibition RIA was performed in which polystyrene beads coated with HBsAg were 
incubated at 37°C for 1 hr with rabbit polyclonal anti-HBs antiserum that had been 
preincubated with HBsAg or HBcAg fusion proteins as the competitors at 37°C for 3 
hr, followed by incubation with 1 I-label1ed second antibody at 37°C for another hour. 
As shown in Figure 4.4, anti-HEs antibody was inhibited in a concentration-dependent 
manner from binding to coated HBsAg by the presence of HBsAg made in yeast. 
Approximately 60% inhibition of binding was achieved with 500 ng of HBsAg as the 
competitor. On the other hand, only about 20% inhibition was observed with 500 ug 
of HBcS or HBcPreSPreS 2S. The inhibition of binding increased slightly when 1 mg 
of HBcPreS 1PreS 2S was used (data not shown). No inhibition was found with 
HBcPreS 1PreS 2  which served as the negative control of the assay. The results 
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Figure 4.3 HBs antigenicity of HBcAg fusion proteins. The HBs antigenicity was 
measured by the sandwich RIA in which HBcAg fusion proteins were trapped with 
human anti-HBc IgG and the surface exposure of the HBs (11l on the particles was 
measured using rabbit anti-HBs serum and "I-labelled donkey anti-rabbit 
immunoglobulin. All samples were assayed concomitantly. 
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Figure 4.4 The inhibition of anti-HBs antibody binding to HBsAg by HBcAg 
fusion proteins. The inhibition of the binding of anti-HBs antibody to the solid phase 
HBsAg in the presence of the competitor was determined using "I-labelled anti-
species immunoglobulin. 
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obtained from the immunoblot analysis, the antigen-capture sandwich assays and the 
antigen-inhibition RIA indicate that HBcAg fusion proteins carrying HBs (lll display 
some cross-reactivity with polyclonal anti-HBs antiserum. Thus they appear to contain 
one or more antigenic determinants related to HBsAg. However, they do not represent 
all of the epitopes expressed by HBsAg. 
4.4 Monoclonal antibody binding studies 
Three murine MAbs, RFHBs-1, RFHBS-2 and RFHBS-7, against HBsAg used in these 
studies were kindly supplied by J.A. Waters and H.C. Thomas of the St Mary's 
Hospital Medical School, London. RFHBs-1 and RFHBS-2 bind to a cyclic peptide 
made from amino acids 124-137, and RFHBs-7 to a cyclic peptide from amino acids 
139-147 of HBsAg (Carman .et al., 1990). Thus the epitopes recognised by these 
MAbs are conformational, rather than linear peptide sequences of the antigen. In 
addition, RFHBs-1 has been shown to be capable of neutralising both ad and ay 
subtypes of HBV in chimpanzee experiments (Iwarson et al., 1985a) and the antibody 
that recognises RFHBs-1 epitope is present in the sera of patients who have recovered 
'from acute HBV infection (Waters et al., 1986a). 
The antibodies that recognise RFHBs-1 and RFHBs-7 epitopes are also present in the 
sera of vaccinees who had received the plasma-derived or recombinant HBV vaccines 
(Waters et al., 1987). Since both sequences, amino acids 124-137 and 139-147 of 
HBsAg, appear to form part of the a determinants of HBsAg, it is reasonable to use 
these MAbs to examine whether HBcAg fusion proteins carrying HBs (111 . l5 contain 
an a antigenic determinant, and whether an amino acid substitution of arg, glu or lys 
for gly at amino acid 145 of HBsAg in HBcAg fusion proteins alters the a determinant 
antigenicity. An 'antigen-capture sandwich assay was performed in which the test 
antigen, HBsAg or HBcAg fusion proteins, was captured on RFHBs-1-, RFHBs-2-, or 
RFHBS-7-coated beads followed by addition of rabbit polyclonal anti-HBs antiserum 
'and' 1 I-1abelled donkey anti-rabbit immunoglobulin which subsequently binds to the 
captured antigen. As shown in Table 4.3, HBsAg binds to all three MAbs in a 





Binding to MAb (P/N ratio) " 
RFHBs-1 	RFHBs-2 	RFHBs-7 
HBsAg 1 19.5 22.4 15.2 
0.1 6.5 12.7 12.7 
0.01 1.8 2.3 2.7 
0.001 1.2 1.2 1.0 
HBcS 1000 3.3 2.7 2.2 
100 1.8 1.6 1.4 
HBcS14 1000 2.7 2.1 2.0 
100 1.3 1.1 1.1 
HBcS,45, 1000 1.8 1.6 1.4 
100 1.4 1.1 1.1 
HBcS145K 1000 2.0 1.4 1.2 
100 1.0 1.0 1.0 
HBcS 14 PreS 1PreS2S 1000 2.8 2.0 2.0 
100 1.6 1.3 1.1 
HBcPreS l(I 1000 1.3 1.3 1.2 
100 1.3 1.1 1.0 
Buffer' - 1.0 1.0 1.0 
The tested antigens were added to polystyrene beads coated with MAb RFHBs-1, RFHBs-2 or 
RFHBs-7 and detected by rabbit anti-HBs serum and 'I-labelled donkey anti-rabbit 
immunoglobulin. 
b 	Binding results are expressed as cpm ratio of samples measured (P) and the negative control 
containing the reaction buffer (N'). 
The binding (cpm) of the reaction buffer (10% donkey serum in PBS) to RFHBs-1, RFHBs-2 and 
RFHBs-7 is 246, 252 and 380, respectively. 
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concentration-dependent manner, indicating that the epitopes that the three MAbs 
recognise are indeed presented by HBsAg. No detectable binding was observed with 
HBcPreS l(l  which bears no HBs sequence and served as a negative control for the 
assay. All the HBcAg fusion proteins reacted more weakly, if at all, with the three 
MAbs, compared to HBsAg. HBcS, HBcS, 45R and HBcS 14 PreS 1PreS 2S showed 
similar binding to RFHBs-1, RFHBs-2 and RFHBs-7, among which, HBcS showed a 
slight increase in binding to the MAbs when its P/N ratio was compared to a negative 
control. Both HBCS145Eand HBcS 145K showed similar binding to RFHBs-1, but to a 
lesser extent, as compared with HBcS, HBcS 145R and HBcS 14 PreS 1PreS2S, whereas 
they reacted poorly or negligibly with RFHBs-2 and RFHBs-7. The observation that 
HBcAg fusion proteins, either wild-type or mutant proteins, reacted poorly with MAbs 
specific to the a determinant of HBsAg, presumably due to poor surface accessibility, 
was in agreement with the results of poor reactivity of HBcAg fusion proteins with 
polyclonal anti-HBs antibody either in solid phase (AUSRIA test) or in liquid phase 
(DARIP inhibition test). These results indicate the difficulty in comparing the change 
of the a determinant of HBsAg in HBcAg fusion proteins carrying g1y 145 mutation. 
4.5 Discussion 
The plasmids expressing fusion proteins were based on ptacHpall (Stahl-and Murray, 
1989), which was constructed from elements of the plasmid pR1-11 (Stahl et al., 
1982). The plasmid pRi-11 encodes a fusion protein containing the first 8 amino 
acids of -galactosidase followed to full-length HBcAg with the first 2 amino acids 
deleted, while plasmid ptacHpall encodes a similar fusion protein with truncated 
HBcAg(31). All HBcAg fusion proteins carrying insertions at the C-terminus display 
similar HBc antigenicity as full-length HBcAg (Figures 3.12 and 4.1). Those carrying 
both N- and C-terminal insertions also show HBc antigenicity when the unpurified 
samples (ammonium sulphate fractions) were examined by immunoblotting. These 
results are in accordance with those reported previously (Clarke et al., 1987; Stahl and 
Murray, 1989; Schodel et al., 1992). Therefore, fusion of foreign sequences to the N-, 
the truncated C- or both termini of HBcAg preserves the HBc antigenicity. However, 
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insertion of a foreign sequence between HBcAg residues 75 and 83 has been 
demonstrated to abrogate recognition of HBcAg by five out of six anti-HBc MAbs and 
diminish recognition by human polyclonal anti-HBc (Schodel et al., 1992), indicating 
the importance of this region in B-cell recognition of HBcAg, which is in agreement 
with previous data from mapping of the immunodominant B-cell epitope (Salfeld et 
al., 1989). Nevertheless, the inserted epitope between HBcAg residues 75 and 83 was 
antigenic and could elicit high anti-peptide antibody response in mice. In order to 
take advantage of HBcAg-specific T-cell and anti-HBc responses that might be 
induced by HBcAg fusion proteins as suggested from the murine results reported by 
Milich and colleagues, the integrity of the HBc antigenicity might be of importance. 
Predictably, the HBcAg fusion proteins would also display HBe antigenicity. The 
HBe antigenicity of the HBcAg fusion proteins was not determined in this study. 
HBcPreSl(l)  and truncated HBcAg have been shown to display similar HBeAg 
reactivity, whereas full-length HBcAg showed very low reactivity (Stahl and Murray, 
1989). 
Although the sequence of HBeAg is contained within that of HBcAg, the two antigens 
exhibit fundamentally different biophysical and antigenic properties. Distinct epitopes 
located exclusively on HBcAg or HBeAg have been detected with polyclonal and 
monoclonal antibodies (Ferns and Tedder, 1986; Waters et al., 1986b; Colucci et al., 
1988; Salfeld et al., 1989; Sallberg et al., 1991). There is a discrepancy regarding the 
nature of the HBcAg determinant. Earlier studies have indicated that denaturation of 
core particles destroyed HBcAg specificity with a consequent release of HBeAg, 
suggesting that HBcAg determinants are sensitive to structural changes (MacKay et 
al., 1981a; Ohari et al., 1984). However, one report argued against a strict 
conformation-dependence of HBcAg. An immunodominant HBcAg determinant has 
been mapped to a linear peptide encompassing amino acids 107-118 (Colucci et al., 
1988). Nevertheless, Salfeld et al. (1989) reported that HBcAg exposes only a single 
determinant, which induces numerous anti-HBc antibodies, most of which recognise 
conformational epitopes, while HBeAg possesses 2 determinants, one linear (HBe1) 
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and the other conformational (HBe2). Furthermore, the HBcAg epitopes recognised 
by human anti-HBc antisera are predominantly conformation!. The HBcAg and HBe1 
determinants were both mapped to an overlapping hydrophilic sequence around amino 
acid 80. HBe2 was mapped to a location in the vicinity of amino acid 138, but about 
90% of the sequence, between amino acids 10 and 140, was required for its full 
antigenicity. It has been recently demonstrated that the cysteine residue, which is 
located within the ten remaining amino acids of the pre-core fragment attached to the 
HBeAg after cleavage of the leader sequence, determines the quaternary structure and 
the antigenicity of HBe protein. If this cysteine is lacking, the HBe protein is 
expressed as a disulphide-linked homodimer showing both HBe and HBc antigenicity 
(Wasenauer et al., 1992). 
The HBcAg fusion proteins containing HBs(lll , either wild-type or gly 145 mutant 
sequence, display little HBs antigenicity in the DARIP inhibition assay (Table 4.1) or 
the AUSRIA II RIA (Table 4.2). However, immunoblot analyses of HBcS and the 
three mutant counterparts confirmed that the HBs (llllS was presented on the hybrid 
HBcAg particles when anti-native HBs or anti-SDS-denatured HBs polyclonal 
antibodies were used as the probes (Figure 4.2). 
In immunoblotting, the HBcAg fusion proteins were presented on a solid support 
which allowed antibody to bind in a multivalent, affinity-independent manner. 
However, the proteins would likely not be native, since they were denatured by 
treatment with an ionic detergent and boiling under reducing conditions. Although 
electrophoretic transfer probably removes most of the detergent and the reducing 
agent, the strong non-covalent forces which result in the binding of the polypeptide 
to the nitrocellulose membrane probably prevent the polypeptide from complete 
renaturation. Therefore, immunoblotting is likely to favour linear determinants. Since 
the probes used in the immunoblotting were polyclonal antibodies raised from rabbits 
immunised with native or denatured HBsAg, it was not surprising that not only the 
wild-type HBcS but also the three 'g1y 145 mutants reacted with both polyclonal 
antibodies containing a number of antibodies against different B-cell epitopes in the 
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HBs(lllI sequence. 
In the AUSRIA test, the HBsAg is sandwich-captured by two anti-HBs antibodies, one 
immobilised on the solid phase, the other labelled with ' 25  1 as the probe. At high 
concentrations (100 1ug and 500 aug) the HBcAg fusion proteins carrying the HBs (ll1 . l  
sequence reacted poorly with anti-HBs antibody with P/N ratio ranging between 2.5 
to 3.6. 
There are two possibilities for the poor HBs antigenicity displayed in the HBcAg 
fusion proteins carrying the HBs (111.. sequence. First, the inserted HBs (llllS 
sequence may exhibit conformational changes that alter the accessibility of HBs 
epitopes on the fusion proteins and hinder them from reacting to anti-HBs antibody. 
Secondly, the binding of HBs. epitopes in HBcAg fusion proteins to the solid phase 
anti-HBs antibody might result in steric hindrance that prevents the HBs epitopes from 
reacting efficiently with ' MI-labelled anti-HBs antibody. Therefore, if human anti-HBc 
antibody, instead of anti-HBs antibody, was used as the solid phase antibody and 
rabbit anti-HBs antibody followed by 'I-labelled donkey anti-rabbit immunoglobulin 
used as the probe in the antigen-capture sandwich RIA, the possible steric hindrance 
could be overcome. Surprisingly and importantly, HBs antigenicity was displayed in 
the HBcAg fusion particles and was demonstrated in a concentration-dependent 
manner. This assay thus allows the detection of the HBc and HBs antigenicities 
within the same molecule. Furthermore, only the fusion proteins displaying both HBc 
and HBs antigenicities could be detected by this assay. However, microgram levels 
of HBcAg fusion proteins were required in the assay which were 1000-fold higher 
than those used in a similar assay for HBcAg reactivity. On a weight basis, HBcAg 
fusion proteins contained approximately three times as much of the HBc sequence as 
the HBs sequence. Thus assuming the two assays for HBs and HBc reactivities had 
a similar sensitivity, the HBs antigenicity appeared to be more than 300 fold less 
reactive than HBc antigenicity in the HBcAg fusion proteins. The poor HBs reactivity 
in the AUSRIA test appeared to result from steric hindrance. Nevertheless, 
conformational change might still occur and contribute to the lower HBs antigenicity. 
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The immunodominant determinants on HBsAg are conformation-dependent, no doubt 
because of extensive inter- and intra-molecular disulphide bonds. This is particularly 
true of the a determinant of HB5Ag. The a epitope contained within amino acid 
residues 139-147 and 122-137 of the S protein appeared to be conformational since 
cyclic forms of both the corresponding synthetic peptides were recognised with higher 
affinity than the linear analogues (Dreesman et al., 1982; Brown et aL, 1984). In 
addition, some MAbs against HBsAg bound to cyclic peptides 124-137 and 139-147 
of the S protein, but not to the linear peptides (Carman et al., 1990). 
Several reports showed that peptides derived from the a determinant of HBsAg 
displayed weaker, if any, HBs antigenicity than native, intact HBsAg. Nevertheless, 
they elicited anti-HBs antibody, although at a low level as compared with that elicited 
by native HB5Ag, when conjugated to carrier proteins. These results suggest that the 
peptides constituted do not closely mimic the tertiary structure of the native epitope 
in HBsAg. The peptide P135-155 of HBsAg showed no reactivity with anti-native 
HBs (Neurath et al., 1982). The capacity of P138-149 to bind to anti-HBs antibody 
was also limited (Prince et al., 1982). The peptide P139-147 and cyclic peptide P122-
137 have been shown to inhibit the binding of anti-HBs antibody to native HBsAg. 
However, on a weight basis, a 106-fold and 3x103-fold more P138-147 and cyclic 
P122-137 were required to achieve an equivalent degree of inhibition in comparison 
with native HBsAg, respectively (Bhatnagar et al., 1982; Ionescu-Matiu et al., 1983). 
A synthetic peptide, OS[124-147], corresponding to residues 124 to 147 of the S 
protein self-assembled into a heterogeneous mixture of multiple forms via the 
disulphide bonds formed by five possible cysteine sulphydryl groups within the 
peptide and these oligomeric peptides reconstructed a conformational, group-specific 
antigenic determinant of HBsAg (Manivel et al., 1992b). A polypeptide (MEP-1) 
comprising multiple epitopes from preS l(l., preS 11  HBs(l9), and HBs 12114 had 
been made by Kumar et al. (1992). In immunoblot analysis, MEP-1 reacted with anti-
preS1 and anti-preS2 peptide antibodies, but did not react or reacted very poorly with 
anti-HBs(124 .
147 
 and anti-HBs antisera. However, when MEP-1 was coated on the solid 
phase and detected by indirect ELISA, the S-specific epitopes became detectable and 
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rearrangement of disulphide linkages by thiocyanate treatment seemed to increase their 
antigenicity. 
In the work described here, the HBs antigenicity of the HBcAg fusion proteins is also 
weak as compared with the native HBsAg. The method employed for the assay of the 
reactivity of the protein with anti-HBs antibody may influence the result. The HBs 
antigenicity in the HBcAg fusion protein carrying either wild-type or mutant HBs (lll. 
sequences was detectable in the antigen-capture sandwich RIA, using two 
antibodies with different specificity, anti-HBc and anti-HBs, to detect the HBc and 
HBs antigenicities simultaneously, whereas little HBs antigenicity was detected in the 
equivalent assay using anti-HBs antibody for the solid phase and the probe in both 
sides of the sandwich to capture HBsAg. A 20% inhibition of binding of anti-native 
HBs antibody to HB5Ag was observed after addition of 500 jig of HBcS or 
HBcPreS 1PreS2S, while 60% inhibition of binding was achieved after addition of 500 
ng of HB5Ag. These results are in agreement with those described previously, 
indicating that mimicking of conformational determinants of HBsAg may be more 
sophisticated, either using free peptide or presentation on a particulate structure, such 
as HBcAg. Disulphide cyclisation has been shown to increase the antigenicity of 
synthetic peptides by locking their secondary structures (Dreesman et al., 1982; Brown 
et al., 1984). It was suggested that a peptide containing a conformational determinant 
may be locked into the immunodominant regions of heterologous particulate antigens. 
Thus, the antigen-capture sandwich RIA and the immunogenicity studies (see Chapter 
5) confirm the surface accessibility of the inserted HBs (lll . lS epitope. The weak 
reactivity of HBcAg fusion proteins with anti-HBs antibody might be due to different 
presentation of the HBs (1I1 . lS segment on the fusion particles from that on the native 
HBsAg. Nevertheless, the HBcAg fusion proteins carrying the HBs (1l1l5 fragment 
were able to induce antibodies cross-reactive with native HBsAg (see Chapter 5). 
Monoclonal antibodies, which by definition are directed against a single antigenic 
determinant, can provide reagents to detect the change of epitope to which they bind. 
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In the present study, since some HBcAg fusion proteins carry g1y 145 mutants of the 
HBs(ll1156)  sequence and the mutation is within the a determinant of RBsAg, it is 
reasonable to use anti-a MAbs, eg. RFHBs-1 and RFHBS-2 that bind to a cyclic 
peptide made from amino acids 124-137, and RFHBs-7 to a cyclic peptide from amino 
acids 139-147 of HBsAg, to examine the reactivity of these HBcAg fusion proteins. 
All the HBcAg fusion proteins reacted poorly with these MAbs, compared to HBsAg. 
The inserted HBs (111l5 sequence was presented in a different conformation which the 
MAbs against the a determinant could not recognise efficiently. These results are in 
accordance with those of poor reactivity of HBcAg fusion proteins with polyclonal 
anti-HBs antibody. 
Monoclonal antibody binding studies in patients carrying the 91y 145 mutant showed that 
the HBsAg in the serum at 5 years of age, when anti-HBs induced by HBV vaccine 
was no longer present, bound significantly less to RFHBs-1, RFHBs-2, and RFHBs-7 
MAbs than to the polyclonal anti-HBs (AUSRIA test) (Carman et al., 1990). The 
reduction in binding of antibodies to the a determinant suggests that the mutation has 
resulted in a conformational change affecting more that one epitope in the a 
determinant. Since arg is much larger residue than gly and is charged, the 
.hydrophilicity of this region is increased, and the HBs specificity may change. It has 
been shown that cys 147 and pro 142 are necessary for the display of full antigenicity 
(Ashton-Rickardt and Murray, 1989a). It is possible that the substitution of are , for 
gly may affect the presentation of the amino acids in the neighbourhood that 
contribute partly to the display of full antigenicity. It has also been demonstrated that 
accessibility of 1ys 141 side chain is important for the presentation of the a determinant 
(Manivel et al., 1992a). It is, therefore, possible that introduction of an amino acid 
with a bulky and positively charged side chain in the neighbourhood of l514 may 
result in steric and electrostatic repulsion between the two side chains. Consequently, 
the lys 141 side chain may remain buried or at least less accessible in the folded protein, 
leading to a reduction, or even loss of the a determinant. The buried side chains of 
the amino acids within the antigenic sites may also influence antigenicity as 
demonstrated in myohemerythrin protein (Alexander et al., 1992). 
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Recently, Waters etal. (1992) demonstrated that the recombinant HBsAg with arginine 
at amino acid 145 of HBsAg reduced the antigenicity of the HBsAg in a manner 
similar to that seen in the child infected with gly 1 —'arg variant HBV. The anti-HBs 
found in the pooled sera of convalescent patients or vaccinees which bound to the 
wild-type HBsAg did not bind to the variant antigen. In addition, the binding of 
MAbs, RFHBs-1, RFHBs-2 or RFHBs-7, to the variant antigen was also abolished. 
RFHBs-2 bound to the variant antigen, but at a 10-fold higher concentration as 
compared to the wild-type, while RFHBs-1 and RFHBs-7 did not at all. 
It is generally believed that the minimal requirement of antigenic sites in a native 
protein is the accessibility of the segment on the protein surface in order to be 
detected by antibodies binding the protein. Although accessibility is necessary, it is 
not known whether accessibility of a segment on a native protein surface is sufficient 
for antibody binding. Segmental mobility or local flexibility of the polypeptide 
backbone in portions of protein molecules may contribute to the antigenicity of these 
sites (Getzoff et al., 1987; Geysen et al., 1987). The mobility of a segment in a 
protein is the degree of atomic motion within the protein structure. Mobility data are 
only available from x-ray crystallographic or nuclear magnetic resonance studies and 
had been obtained only for segmental antigenic sites. A clear correlation between the 
mobility of a segment in a native protein and the ability of antibodies against short 
peptides corresponding to that segment to bind to the native protein has been 
demonstrated (Niman et al., 1983). Reciprocally, antibodies (anti-native protein) to 
more mobile regions of native proteins are more likely to cross-react with short 
peptides than are antibodies to less mobile regions (Moudallal et al., 1985). It is 
noteworthy that in these two approaches mobility is important in determining cross-
reactivity of either anti-peptide antibodies to native proteins or anti-native protein 
antibodies to peptides, rather than in determining the immunogenic sites on native 
proteins. 
It has been shown that epitopes fused to the C-terminus of the truncated HBcAg at 
amino acid residue 144 or at an internal site between amino acid residues 144 and 145 
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in full-length HBcAg were detected by antigen-capture sandwich EUSA or 
immunogold electron microscopy (Borisova et al., 1989), thus suggesting external 
positioning. In contrast, a hybrid HBcAg particle carrying the epitope from simian 
immunodeficiency virus fused to the C-terminus of the full-length HBcAg failed to 
induce detectable anti-peptide antibody in guinea pigs (Yon et al., 1992). Because the 
inserted epitope could not be detected by antigen-capture sandwich EUSA, it was 
suggested that the arginine-rich C-terminus of HBcAg prevented the foreign peptide 
from being presented on the surface of the hybrid HBcAg particle. Another 
explanation might be that the peptide was presented in a different conformation which 
the MAbs against the peptide could not recognise. 
A variety of viral epitopes, eg. FMDV (Clarke et al., 1987), poliovirus, rhinovirus 
(Clarke et al., 1990) and simian immunodeficiency virus (Yon et al., 1992) have been 
fused to the N-terminal region of HBcAg through part of the pre-core sequence and 
the hybrid HBcAg particles proved to be immunogenic in terms of the production of 
anti-peptide antibody. 
In the studies described here, the antigenicity of the inserted preS 1 and preS2 fragments 
in HBcAg fusion proteins carrying both sequences was not examined due to lack of 
the suitable antibodies. In immunoblotting experiments, HBcPreS l(l (Stahl and 
Murray, 1989) reacted with anti-preS 1 MAb MA18/7 (Heermann et al., 1984), while 
HBcPreS l(l. ) (Stahl and Murray, 1989) and HBcPreS 1PreS21  containing preSI(l.) and 
preS 1 fragments, did not react (results not shown). These results are in agreement 
with the epitope mapping of MA18/7 which is against a linear epitope encompassing 
the preS,(27 . 3. sequence (Dienes et al., 1990; Coursaget et al., 1991). Since the 
HBcAg fusion proteins constructed in this work contain the preS l(120) sequence, 
MA18/7 could not be used for detection of the preS 1 epitope presented on the hybrid 
HBcAg particle. The anti-preS 2 MAb Q19/10 (Heermann et al., 1984) available in 
this laboratory is against the glycosylated preS 2 region. Thus it also was not suitable 
for the detection of the preS 2 epitope derived from E. coli. Rabbits and mice 
immunised with these hybrid particles elicited anti-preS l(I) and anti-preS 1 
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antibodies (see Chapter 5), suggesting that both preS l(l) and preS2(1 -2,0 fragments were 
presented on the hybrid HBcAg particles. 
The insertion site in the carrier molecules may influence surface exposure, and hence 
the immunogenicity of the inserted epitopes. In the HBsAg fusion systems, 
Delpeyroux and colleagues (1990) have employed two sites, between amino acid 
residues 50-51 and 113-114, within hydrophilic domains of HBsAg encompassing 
residues 45 through 72 and 110 through 145, respectively, to insert poliovirus 
epitopes. The PV-1 fragment, a poliovirus neutralisation epitope, was exposed at the 
surface of the hybrid HBsAg particles when inserted at position 113 of HBsAg 
particles, as demonstrated both by reactivity with the MAbs against PV-1 fragment 
and by trypsin cleavage experiments. In contrast, when inserted at position 50 of 
HBsAg, the inserted epitope was only poorly accessible. The more intriguing result 
was that a cooperative effect was observed when the fragment was inserted at both 
sites of the same HBsAg molecule. The PV-1 antigenicity of the hybrid HBsAg 
particle carrying the double insertions seemed higher than the expected sum from two 
hybrid particles carrying a single insertion at the different sites. These results 
suggested that structural modifications might occur in the carrier part of the hybrid 
molecule which improved the accessibility and/or conformation of one or both PV-1 
fragments. 
The periplasmic maltose-binding protein (MalE) from E. coil has also been exploited 
to express foreign peptides (Martineau et al., 1992). It appeared that the antigenic 
properties of an inserted preS 13 peptide and the neutralising epitope of poliovirus 
type 1 were different at the two insertion sites within the MalE proteins. Apart from 
the position of the inserted fragment on the carrier molecules, the intrinsic structural 
features of the inserted sequences may also influence the antigenicity of the inserted 
fragment within the hybrid molecules (Delpeyroux et al., 1990; Martineau et al., 
1992). Thus, structural constraints might limit the presentation of some antigenic 
sequences. 
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FMDV was one of the earliest viruses in which a synthetic peptide approach was 
attempted for vaccine development. An antigenic fragment of the FMDV (amino 
acids 141 to 160 of protein VP1) was found to be antigenic as a synthetic peptide and 
as part of hybrid HBcAg particles (Clarke et al., 1987). Analysis of the three-
dimensional structure of the virus showed this VP1(1411) fragment to be a disordered, 
flexible, prominent loop (Acharya et aL, 1989). These characteristics might allow it 
to retain antigenicity when expressed in various systems. 
In conclusion, the HBcAg fusion proteins carrying the sequences from the preS 1, preS 2 
and S regions at the N- and C-termini of the truncated HBcAg all retained HBc 
antigenicity. In addition, the HBs antigenicity was detectable in those carrying 
HBs(llllS  sequence, albeit at a lesser extent. The antigenic determinants within the 
preS 1 and preS2 regions, which do not contain any cysteine residue, are conformation-
independent and anti-preS 1 and anti-preS2 antibodies were induced in the experimental 
animals (see Chapter 5), suggesting preS 1 and preS2 segments were surface accessible 
in the HBcAg fusion proteins, and thus the preS 1 and preS2 antigenicities were 
displayed in the hybrid particles. The presentation of conformational epitopes, such 
as the a determinant of HBsAg, to mimic the native epitope on the HBcAg particle 
appears to be more difficult than presentation of linear epitopes, such as preS 1 and 
preS2 epitopes. However, the immunogenicity studies, discussed in Chapter 5, show 
that the HBcAg fusion proteins were immunogenic in terms of production of anti-HBs, 
anti-preS 1, and anti-preS 2 antibodies. 
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Two arms of immune response, cellular immune response and humoral immune 
response, were investigated in rabbits and mice after inoculation with the HBcAg 
fusion proteins. T-cell proliferative responses to the components of the HBcAg fusion 
proteins were monitored. Immunogenicity was determined in terms of the production 
of anti-HBc, anti-HBs and anti-peptide antibodies, which include anti-preS 1(1 . 3 , anti-
preS 1 and anti-HBs(1l1 ..1S , in the immunised animals. 
5.2 Immune responses of rabbits after inoculation with the HBcAg fusion 
proteins 
Outbred Dutch rabbits were immunised intramuscularly with 0.2, 0.5, or 1 mg of 
HBcAg fusion proteins in CFA and boosted at least 2 times with the same or smaller 
doses in IFA at three-week intervals for the first boost and then 28 or 59 days later 
for the second. Some rabbits were further boosted at various time intervals. Blood 
samples were collected from each rabbit before and one to two weeks after each 
injection. Table 5.1 summarises the immunisation regimens for the rabbits. 
5.2.1 Cellular immune responses to the HBCAg fusion proteins in rabbits 
To determine whether T-cell responses to the components of the HBcAg fusion 
proteins could be detected in immunised rabbits, lymphocyte-proliferative responses 
were measured by using PBLS isolated from the rabbit before and after immunisation 
or boost at the various time intervals. The PBLs were cultured at a cell concentration 
of 2 x 105 cells/well (for R675, R676, R677, R678, R684 and R685) or 5 x 
cells/well (for the remaining rabbits) in 96-well microtitre plates in the presence of 
various antigens for 5 days and their proliferation was measured by .[ 3H-thymidine 
incorporation. 
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Table 5.1 	Immunisation regimens of rabbits [Numbers designate days of treatment and those in parentheses designate dose (mg] 
Rabbit Inimunogen Immunisation 1st boost 2nd boost 3rd boost 4th boost 5th boost 
6th boost 
R675 HBcS 0 21 80 108 287 
315 421 
(0.2) (0.2) (0.2) (0.2) (0.2) (0.2) (0.4) 
R676 HBcS145R  0 21 80 (108 287 
315 421 
(0.2) (0.2) (0.2) (0.2) (0.2) (0.2) (0.4) 
R677 HBCS1.E 0 21 80 108 287 315 
(0.2) (0.2) (0.2) (0.2) (0.2) (0.2)  
: R678 HBCSIK 0 21 80 108 287 421 
(0.2) (0.2) (0.2) (0.2) (0.2) (0.4)  
R684 HBcS 0 21 49 208 236 
(1) (1) (1) (0.2) (0.2)  
R685 HBcS 1 	 . 	 . 0 21 49 208 236 
(0.2) (0.2)  
R690 HBcPreS 1 PreS2S 0 21 49 88 137 194 
(1) (1) (0.2) (0.2) (0.2) (0.2)  
11697 HBcPreS 1 PreS2S 0 21 Sacrificed on day 48 due to long, growing teeth 
0.5) 05)  
Continued 
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Table 5.1 (continued) 
Rabbit Inimunogen Immunisation 1st boost 2nd boost 3rd boost 4th boost 5th boost 6th boost 
R691 HBcPreSPreS2S, 45R  0 21 Died on day 32 
R692 HBcPreSPreS2SIll 0 21 49 98 155 
(0.5) (0.5) (0.2) (0.2) (0.2)  
• R699 HBcPreS 1 PreS2S15 0 21 49 
(0.5) (0.5) (0.2)  
• R700 HBcPreS 1 PreS2S115 0 21 49 
(0.5) (0.5) (0.2)  
R698 FIBcSPreS 1 PTCS2SI45R  0 21 49 106 
(0.5) (0.5) (0.2) (0.2)  
• R703 • HBCSPICS lP1CS2SL4R 0 22 50 
(0.5) (0.5) (0.2)  
R702 HBcSPreS 1 PreS2S 1 0 22 50 
(0.5) (0.5) (0.2)  
R701 denatured HBSAg 0 22 50 78 
(0.01) (0.01) (0.01) (0.004)  
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Representative dose-response curves obtained 13 days after immunisation (day 13) and 
13 days after the second boost (day 93) with 0.2 mg HBcS 1 in R677 are shown in 
Figure 5.1. The PBLs from day 13 incorporated 17.4 times and 6.7 times more [3H]-
thymidine in response to stimulation with an optimal concentration of HBcS 14 (16 
1ug/ml) and HBcAg (16 1ug/ml), respectively, than did non-stimulated PBLs (Figure 
5.1a). However, the PBLs did not respond to stimulation with HBsAg at any 
concentration. In response to HBcS 14 (64 sg/ml) and HBcAg (4 1ug/ml), the PBLs 
obtained on day 93 incorporated 101 times and 26 times more [3H-thymidine than did 
non-stimulated PBL (Figure 5.1b). Moreover, the PBLs also proliferated in response 
to stimulation with HBsAg, albeit to a much lesser extent. At an optimal 
concentration of HBsAg (16 1ugfml), they incorporated 18 times more [3H]-thymidine 
than did nonstimulated PBLs. No in vitro stimulation of the PBLs from R677 was 
observed with HBcAg fusion protein, HBcAg or HBsAg before immunisation (Figure 
5.2c). 
The proliferation of PBLs in response to the antigens was monitored in each rabbit. 
Figure 5.2 summarises the kinetics of the lymphocyte proliferation in response to the 
optimal doses of the antigens in R675, R676, R677, R678, R684 and R685 immunised 
and boosted with either HBcS or its g1y 145 mutants. The magnitude of the lymphocyte 
proliferation in response to HBcAg fusion protein, HBcAg and HBsAg varied among 
different animals. The lymphocyte-proliferative response to HBcAg fusion protein and 
HBcAg appeared 7 days after immunisation and maintained but fluctuated during the 
experiments. In most rabbits, the proliferative responses to HBcAg fusion protein and 
HBcAg could be greatly augmented after the boosts in those rabbits with declined 
responses. A weak and delayed specific proliferative response to HBsAg was 
observed in some rabbits only after the boost. Comparison of proliferative response 
to the antigens showed that R684 and R685 elicited higher T-cell response than R675, 
R676, R677 and R678. However, it should be noted that the HBcAg fusion protein 
used for immunisation and boost of the former were four times the amount compared 
with that used for the latter. The data from days 49 and 61 of R684 show enormous 
increases of S.I. in response to HBcAg fusion protein, HBcAg or HBsAg. However, 
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Figure 5.1 	Lymphocyte-proliferative responses in R677 immunised with HBcS 14 
on (a) day 13 and (b) on day 93, i.e. 13 days after the second boost. The PBLs were 
cultured with HBcAg, HBsAg or HBCS 1 at different concentrations for 5 days. 
Sixteen hours before harvest, the cultures were pulsed with [3H]-thymidine and the 
CH]-thymidine incorporated into the stimulated cells was determined by liquid 
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Figure 5.2 Kinetics of lymphocyte-proliferative responses in 6 rabbits immunised 
with HBCS, HBcS 14 , HBcS 14 or HBcS 14 . (a) R675, (b) 676, (c) R677, and (d) 
R678 were injected with HBcS, HBcS 14 , HBcS 14 and HBcS 14 respectively, on 
days 0, 21 and 81 etc. (e) R684, and (f)  R685 were injected with HBcS and HBcS 14 , 
respectively, on days 0, 21 and 49 etc. The PBLs at the indicated days were cultured 
with the corresponding HBcAg fusion protein (64 1ug/ml), HBcAg (16 ug/ml), or 
HBsAg (16 1ug/m1) for 5 days. [3H]-thymidine incorporation in response to these 
antigens was monitored as described. The stimulation index was calculated by 
dividing the cpm of [3H]-thymidine incorporated into stimulated cells by the cpm 
incorporated into nonstimulated cells (mean ± S.D.). 
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the PBLs from R684 also responded to poly (Na glutamate-alanine-tyrosine), an 
unrelated polypeptide used to monitor non-specific T-cell activation, with S.I. of 15.9 
and 47.2 on days 49 and 61, respectively. Thus, R684 may have had non-specific T -
cell activation on these two occasions. 
In the following experiments, rabbits were immunised andboosted with the HBcAg 
fusion proteins containing preS 1 and preS2 epitopes as well as either a monomer or a 
dimer of the HBs(lll .. l fragment. The PBLS isolated from the animals were cultured 
at a cell concentration of 5 x 105 cells/well in the presence of various antigens. The 
optimal concentrations of HBcAg fusion protein (64 pg/mi) and HBcAg (16 1ug/ml) 
produced only a small increase in proliferation, or even lower proliferation, 
presumably due to over-proliferation of the cells resulting in nutrient deprivation and 
thus leading to cell death. Thus, in the following experiments, the maximal 
concentrations of the antigens used in vitro were 16 pg/mi of HBcAg fusion protein 
and 4 pg/mi of HBcAg. The results in Figure 5.3 expressed as S.I. show the kinetics 
of lymphocyte proliferation in response to stimulation with HBcAg fusion protein, 
HBcAg, HBsAg and preS l(L) peptide in the rabbits immunised and subsequently 
boosted with HBcPreS 1PreS 2S, either wild-type or g1y 145 mutants. The maximal 
proliferative responses of the PBLS from R690 to HBcAg, HBsAg and preS l(l ) 
peptide occurred after the first boost, except to HBcAg fusion protein in which the 
highest response developed at a later stage. The proliferative response could be 
elicited following several boosts and maintained for longer than 6 months (Figure 
5.3a). 
No in vitro stimulation of the PBL.s from these rabbits was observed with the antigens 
before immunisation. After immunisation, the response varied considerably from 
rabbit to rabbit. There were significant increases in lymphocyte proliferation in 
response to HBcAg and HBcAg fusion protein in all rabbits except R692 in which a 
weak proliferation was found on days 60 and 109, which corresponded to 11 days 
after the second and third boosts, respectively. In R692, IFA, rather than CFA, was 
used as the adjuvant for immunisation by mistake, which might contribute to the weak 
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Figure 5.3 Kinetics of lymphocyte-proliferative responses in 6 rabbits immunised 
with HBcPreS 1PreS2S, HBcPreS 1PreS2S 1 or HBcPreS 1PreS2S 1 . (a) R690 was 
injected with HBcPreS 1PreS2S on days 0, 21, 49, 88, 137 and 194. (b) R697 was 
injected with HBcPreSPreS 2S on days 0 and 21. (c) R692 was injected with 
HBcPreS 1PreS2S1 on days 0, 21, 49, 98 and 155. (d) R691 was injected with 
HBcPreS 1PreS2S14  on days 0 and 21. (e) R699 and (f) R700 were injected with 
HBcPreS 1PreS2S14  on days 0, 21 and 49. The PBLs at the indicated days were 
cultured with the corresponding HBcAg fusion protein (16 #g/ml), HBcAg (4 4ugfml), 
HBsAg (16 1ug/ml) or preS l(l) synthetic peptide (100 4ug/ml) for 5 days. [3H]-
thymidine incorporation in response to these antigens was monitored as described. 
The stimulation index was calculated by dividing the cpm of [3H]-thymidine 
incorporated into stimulated cells by the cpm incorporated into nonstimulated cells 
(mean ± S.D.). 
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lymphocyte proliferation (Figure 5.3c). Some rabbits responded to HBsAg or preS l(1. 
23) peptide, among which R691 showed the highest response (Figure 5.3d). Due to the 
unavailability of preS 1 peptide until the later stage of the experiments, only a 
limited number of PBL samples were tested in response to preS,,- 2,, peptide and no 
proliferative response was found (data not shown). 
The results of lymphocyte proliferation in response to various antigens in the rabbits 
immunised with HBcAg fusion protein carrying a dimer of HBs (lll sequence, 
HBcSPreS,PreS 2S,45R in R698 and R703 or H.BcSPreSPreS 2S,45E in R702, are given 
in Figure 5.4. Similar to the results in Figure 5.3, the PBLs of the three rabbits 
proliferated in response to stimulation with HBcAg or HBcAg fusion protein. In 
comparison with the response to HBsAg, the PBLs from R698 showed the highest 
response (Figure 5.4a) and those from R703 and R702 showed only marginal 
responses (Figures 5.4b and 5.4c). In regard to preS l(123) and preS 1 . peptides, only 
the PBLs from R703 responded to preS l(123) peptide (Figure 5.4b), but no response 
was found to preS 1 . peptide (data not shown). 
In the rabbit experiments, R701 was exclusively immunised and boosted with 10 4ug 
of SDS-denatured HBsAg, rather than HBcAg fusion protein, for the preparation of 
anti-denatured HBs antibody. The PBLs isolated 11 days after the first and second 
boosts proliferated in response to stimulation with HBsAg at concentrations of 4 pg/rn 1 
(S.I. = 5.0 and 6.0, respectively) and 16 pg/ml (S.I. = 5.6 and 8.2, respectively) 
(Figure 5.5). The HBsAg-specific T-cell response in R701 was lower than HBcAg-
specific T-cell response in those immunised with the HBcAg fusion proteins. 
Similarly, the HBsAg-specific T-cell response was also consistently lower than the 
HBcAg-specific response in the rabbits immunised with HBcAg fusion proteins 
(Figures 5.2 to 5.4). Cumulatively, the results are in agreement with previous data 
indicating that HBcAg was more immunogenic than HBsAg in terms of T-cell 
activation in mice (Milich et al., 1987b). 
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Figure 5.4 Kinetics of lymphocyte-proliferative responses in 3 rabbits immunised 
with HBcSPreS 1PreS2S14 or HBcSPreS 1PreS2S 14 . (a) R698 was injected with 
HBcSPreS 1PreS2S 14 on days 0, 21, 49 and 106. (b) R703 was injected with 
HBcSPreS 1PreS2S 14 on days 0, 22 and 50. (c) R702 was injected with 
HBcSPreS 1PreS2S1 on days 0, 22 and 50. The PBLs at the indicated days were 
cultured with the corresponding HBcAg fusion protein (16 ug/m1), HBcAg (4 #g/ml), 
HBsAg (16 #g/ml) or preS l(l) synthetic peptide (100 jig/ml) for 5 days. [3H]-
thymidine incorporation in response to these antigens was monitored as described. 
The stimulation index was calculated by dividing the cpm of [3H]-thymidine 
incorporated into stimulated cells by the cpm incorporated into nonstimulated cells 
(mean ± S.D.). 
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Figure 5.5 Kinetics of lymphocyte-proliferative responses in R701 injected with 
SDS-denatured HBsAg on days 0, 22 and 50. The PBLs at the indicated days were 
cultured with various concentrations of native HBsAg for 5 days. [3H]-thymidine 
incorporation in response to the antigen was monitored as described. The stimulation 
index was calculated by dividing the cpm of [3H]-thymidine incorporated into 
stimulated cells by the cpm incorporated into nonstimulated cells (mean ± S.D.). 
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In summary, the results of the lymphocyte proliferation measurements indicate that 
immunisation of rabbits with the HBcAg fusion proteins carrying the HBs (1ll ..l  
fragment with or without preS 1 and preS 2 fragments elicited high T-cell proliferative 
responses to HBcAg and HBcAg fusion proteins in all rabbits, while a moderate to 
low response to HBsAg was observed in most rabbits, with variable responses to 
preSl(l. ) (5 out of 9 rabbits with S.I. between 2.4 and 71.7), and no response to the 
preS 1 peptide. However, there was considerable variation in the T-cell 
proliferative responses among the rabbits. Comparison of R684 and R685 (Figures 
5.2e and 5.20 with R675, R676, R677 and R678 (Figures 5.2a to 5.2d), in which the 
former two rabbits received 4 times more antigen than the latter, indicates that the 
doses of immunisation and boost might influence the T-cell proliferative responses to 
HBcAg, HBcAg fusion protein and HBsAg, as higher responses were found in R684 
and R685. Moreover, comparison of R690 and R691 (Figures 5.3a and 5.3d) with 
R684 and R685 (Figures 5.2e and 5.20, in which the former received HBcPreS 1PreS2S 
and the latter received HBcS, but with the same dose, suggests the inclusion of preS 1 
and preS2 regions in the HBcAg fusion protein might enhance the HBsAg-specific T -
cell response. Since lymphocyte-proliferative responses to HBsAg and preS l(l. ) in 
the rabbits immunised with HBcSPreS,PreS2Sl4,5R  or HBcSPreS 1PreS2S 14 varied 
(Figure 5.4), it was not possible to determine the influence of the number of the 
HBs(lll..15 fragments, ie. a monomer or a dimer, on the HB5Ag- or preS 1-specific T- 6 
cell response. 
5.2.2 Humoral immune responses to the HBcAg fusion proteins in rabbits 
Blood samples were taken from immunised rabbits at regular intervals, 7 to 14 days 
after immunisation and each boost, and sera were assessed for the presence of anti-
HBc, anti-HBs and anti-peptide antibodies. Tables 5.2 to 5.16 summarise the humoral 
immune responses of the rabbits to the HBcAg fusion proteins and Table 5.17 shows 
anti-HBs response in R701 which was immunised with SDS- and DTT-denatured 
HBsAg. 
174 
Table 51 	Antibody responses of R675 to HBcS 
Anti-HBs 
Titmen1' 	 Days 	 Anti-HBc 
postimmunisalion titreL DARIP 
(%)C AUSABd 
adw ayw (RIA unit) 
Immunisation 0 0 5.7 27.6 
92 
14 20 8.0 MY 54 
1st boost on day 21 35 1280 41.8 ND 
92 
2n d boost on day 79 93 5120 57.8 ND 
92  
3rd boost on day 108 120 5120 57.9 46.1 92 
4th boost on day 287 297 2560 ND 42.9 
36 
5th boost 315 2560 ND 36.8 
ND 
322 5120 ND 48.1 ND 
329 5120 ND 50.4 54 
6th boost on day 421 435 2560 ND 7.5 0 
Rabbit 675 was immunised with 0.2 mg of HBcS and boosted 6 times on the indicated days with the same dose of antigen except for the 6th boost in which 0.4 mg was given. 
b 	Anti-l-lBc was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 	
'!-labelled antibody binding. 
Anti-HBs was determined by the DARIP test using either adw or ayw subtype of WI-labelled HBsAg and the titres are expressed as % of 1 I-HBsAg co-precipitated with anti-HBs 
and anti-rabbit lgG. 
d 	Anti-liBs was determined by the AUSAB RLA and the titres are expressed as RIA units per 0.2 ml of serum. 
Not determined. 
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Table 53 	Antibody responses of R676 to HBCS IdR 
Anti-FIBS 
Treatment' 	 Days 	 Anti-HBc  
postimmunisation 	 litre' 	 DARIP 
(%)C 	 AUSABd 
adw 	ayw (RIA unit) 
Immunisation 0 0 7.5 9.8 8 
14 160 8.4 NDC 16 
1st boost on day 21 35 5120 29.7 ND 54 
2nd boost on day 79 93 20480 38.2 ND 16 
3rd boost on day 108 120 20480 35.6 33.1 8 
4th boost on day 287 297 10240 ND 43.9 36 
5th boost 315 10240 ND 34.9 ND 
322 10240 ND 37.1 ND 
329 10240 ND 39.8 16 
6th boost on day 421 435 10240 ND 47.5 54 
Rabbit 676 was immunised with 0.2 mg of HBcS14  and boosted 6 times on the indicated days with the same dose of antigen except for the 6th boost in which 0.4 mg was given. 
b  Anti-1113c was determined by the competitive RIA and the litres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 114abelled antibody binding. 
C 4, Anti-HBs was determined by the DARIP test using either adw or ayw subtype of 1 f-labelled HBsAg and the titres are expressed as % of I-HBsAg co-precipitated with anti-HBs 
and anti-rabbit lgG. 
d : 	Anti-1113s was determined by the AUSAB RIA and the litres are expressed as RIA units per 0.2 ml of serum. 
Not determined. 
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Immunisation 0 0 5.3 10.8 8 
14 160 4.7 NDC 8 
1st boost on day 21 35 2560 7.4 ND 8 
2nd boost on day 79 93 20480 13.9 ND 16 
3rd boost on day 108 120 20480 14.0 24.3 36 
4th boost on day 287 297 5120 ND 16.3 54 
5th boost 315 10240 ND 9.7 ND 
322 5120 	. ND 17.9 ND 
329 10240 ND 30.0 72 
l, 	Rabbit 677 was immunised with 0.2 mg of IIBcS L4SE  and boosted 5 times on the indicated days with the same dose of antigen. 
b Anti-11113c was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 
I251labell ed antibody binding. 
Anti-Hl3s was determined by the DARIP test using either adw or ayw subtype of ' 2 I-labelted Ill3sAg and the titres are expressed as % of 51.1-[BsAg co-precipitated with anti-I-lBs 
and anti-rabbit lgG. 
Anti-11113s was determined by the AIJSAB RIA and the titres are expressed as RIA units per 0.2 ml of serum. 
Not determined. 
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Table 5.5 	Antibody responses of R678 to HBcS14 
Anti-HBs 
Treatmenta 	 Days Anti-HBc  
postimmunisation titre DARIP 
(%)C AUSABd 
adw 	ayw (RIA unit) 
Immunisation 	 0 0 3.9 	 9.3 0 
14 40 4.4 ND° ND 
1st boost on day 21 	 35 	 640 	 36 	 ND 	 ND 
2nd boost on day 79 	 93 	 5120 	 6.8 	 ND 	 ND 
3rd boost on day 108 	 120 	 10240 	 6.3 	 12.3 	 0 
4th boost on day 287 297 2560 ND 13.3 ND 
Sib boost on day 421 435 5120 ND 58.3 54 
Rabbit 678 was immunised with 0.2 mg of HBcS IbK and boosted 5 times on the indicated days with the same dose of antigen except for the 5th boost in which 
0.4 mg was given. 
b 	Anti-HBc was determined by the competitive RIA and the litres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 1251-labelled 
antibodybinding. 
Anti-1113s was determined by the DARIP test using either adw or ayw subtype of ' 251-labelled HBsAg and the litres are expressed as % of 1251-HBsAg co-precipitated 
with anti-HBs and anti-rabbit IgG. 
Anti-HBs was determined by the AUSAB RIA and the litres are expressed as RIA units per 0.2 ml of serum. 
Not determined. 
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Immunisation 0 0 4.2 8.7 0 
13 320 4.0 ND* 0 
1st boost 21 1280 6.2 ND ND 
35 2560 48.6 ND 92 
2nd boost 49 10240 ND ND ND 
61 40960 ND 42.4 54 
3rd boost on day 208 218 20480 ND 59.0 72 
4th boost 236 20480 ND 52.8 16 
243 20480 ND 48.9 8 
250 20480 ND 51.9 8 
• 	Rabbit 684 was immunised with 1 mg of HBcS and boosted 4 times on the indicated days with 1 mg of antigen in the first two boosts and 0.2 mg in the rest. 
b Anti-llBc was determined by the competitive RIA and the litres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 9-labelled antibody binding. 
o 	Anti-HBs was determined by the DARIP test using either adw or ayw subtype of l-labelled HBsAg and the litres are expressed as % of ' 231-HBsAg co-precipitated with anti-HBs 
and anti-rabbit IgG. 
'Anti-liBs was determined by the AUSAB RIA and the litres are expressed as RIA units per 0.2 ml of serum. 
' 	 Not determined. 
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Table 5.7 	Antibody responses of R685 to HBcS 1 43R 
- - -. 	 Anti-HBs 
Treatment' 	 Days 	 Anti-HBc 	__________________________________ 
postimmunisation 	 titre, DARIP 
(%)C 	 AUSABd 
adw 	 ayw (RIA unit) 
Immunisation 0 0 4.6 10.5 0 
13 320 6.4 14D0 0 
1st boost 21 1280 14.2 ND ND 
35 5120 63.0 ND 36 
2nd boost 49 20480 ND ND ND 
61 40960 ND 63.8 36 
3rd boost on day 208 218 10240 ND 68.7 72 
4th boost 236 10240 ND 64.4 36 
243 10240 ND 74.7 54 
250 10240 ND 80.9 72 
Rabbit 685 was immunised with 1 mg of HBcS 14  and boosted 4 times on the indicated days with 1 mg of antigen in the first two boosts and 0.2 mg in the rest. 
b 	Anti-HBc was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of l-labelled antibody binding. 
O Anti-HBs was determined by the DARIP test using either adw or ayw subtype of 12 I4abelled HBsAg and the titres are expressed as % of 'I-HBsAg co-precipitated with anti-HBs 
and anti-rabbit lgG. 
d 	Anti-HBs was determined by the AUSAB RIA and the litres are expressed as RIA units per 0.2 ml of serum. 
... 	determined. 
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Table 5.8 	Antibody responses of R690 to HBcPreS 1 PreS2S 
Anti-HBs 	 Anti-peptide (P/N ratio)' 
Treatment' 	 Days 	 Anti-HBc  
postimmunisation 	titre' 	DARIPC AUSABd 	 (111.156) 	 PreS 1(1 . ) 	PreS 1 
(%) 	(RIA unit) 
Immunisation 	 0 	 0 	 8.6 	0 	 0.7 	 0.4 	 0.4 
1st boost 	 21 	 1280 	23.6 	262 	 ND 	 4.2 	 1.0 
	
32 2560 75.1 352 12.8 10.8 7.6 
2nd boost 	 49 	 10240 	80.8 	ND 	 ND. 	 12.5 	 14.7 
60 10240 81.6 292 ND 12.4 13.4 
3rd boost 	 88 	 20480 	60.6 	ND 	 ND 	 12.5 	 10.5 
99 20480 52.8 112 ND 12.3 8.8 
4th boost on day 137 	 149 	 10240 	73.2 	112 	 ND 	 10.2 	 9.0 
5th boost on day 194 	 205 	 5120 	863 	72 	 13.8 	 6.6 	 10.9 
Rabbit 690 was immunised with 1 mg of HBcPreS 1PreS2S and boosted 5 times on the indicated days with 1 mg of antigen in the first boost and 0.2 mg in the rest. 
b  Anti-HBc was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 'l-label1ed antibody binding. 
Anti-HBs was determined by the DARIP test using ayw subtype of 1211-labelled HI3sAg and the titres are expressed as % of l-HBsAg co-precipitated with anti-HBs and anti-rabbit 
lgG. 
d 	Anti-liBs was determined by the AUSAB RIA and the titres are expressed as RIA units per 0.2 ml of serum. 
Anti-peptide antibodies were determined by the indirect antibody RIA in which the indicated synthetic peptides were used as the solid-phase ligand and the titres are expressed as 
P/N ratio which represents cpm ratio of samples measured (P) and negative control (N). 
Not determined. 
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Table 5.9 	Antibody responses of R697 to HBcPreS 1PreS2S 
Anti-1413s 	 Anti-peptide (P/N ratio) 
Treatment' 	 Days 	Anti-HBc 	 __ 
postimmunisation 	titre" DARIPC AUSABd 	HBs(Ill .l) 	PreS,() 	PreS 1 . ) 
(%) 	(RIA unit) 
Immunisation 	 0 	 0 	12.0 	54 
	
1.0 	 0.9 	 1.9 
1st boost 	 21 	 1280 	15.8 	72 	 ND 	 3.3 	
2.2 
	
32 2560 51.7 262 ND 9.5 7.1 
48 	 2560 	68.1 	ND 	 6.8 	 3.7 	12.3 
$ 	Rabbit 697 was immunised and boosted once with 0.5 mg of HBcPreS,PreS 2S. The rabbit was sacrificed on day 48 due to long, growing teeth. 
b 	Anti-HBc was determined by the competitive RIA and the litres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of ' 251-labelled antibody binding. 
Anti-HBs was determined by the DARIP test using ayw subtype of 1251 labelled HBsAg and the litres are expressed as % of ''I-HBsAg co-precipitated with anti-HBs and anti-rabbit 
lgG. 
d 	Anti-HBs was determined by the AUSAB RIA and the litres are expressed as RIA units per 0.2 ml of serum. 
Anti-peptide antibodies were determined by the indirect antibody RIA in which the indicated synthetic peptides were used as the solid-phase ligand and the titres are expressed as 
P/N ratio which represents cpm ratio of samples measured (P) and negative control (N). 
Not determined. 
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Table 5.10 	Antibody responses of R691 to HBcPreS 1PreS 2S14 
Anti-HBs 
Treatment' 	 Days 	 Anti-HBc  
postimmunisation 	titre'DARIPC AUSABd 
(%) 	(RIA unit) 
Anti-peptide (P/N ratio)* 
HBs(11) 	PreS l(l . ) 	PreS2(1 .26) 
Immunisation 	 0 0 14.2 0 0.8 0.7 1.0 
1st boost 	 21 1280 49.3 16 ND 2.2 15.9 
32 2560 80.6 36 10.5 3.0 11.5 
Rabbit 691 was immunised and boosted once with 1 mg of HBcPreS 1PreS2S14 . The rabbit died on day 32. 
b 	Anti-1113c was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 1251-labelled antibody binding. 
Anti-HBs was determined by the DARIP test using ayw subtype of 1251-HB5Ag and the titres are expressed as % of 121-HBsAg co-precipitated with anti-HBs and anti-rabbit IgG. 
d 	Anti-HBs was determined by the AUSAB RIA and the titres are expressed as RIA units per 0.2 ml of serum. 
Anti-peptide antibodies were determined by the indirect antibody RIA in which the indicated synthetic peptides were used as the solid-phase ligand and the titres are expressed as 
P/N ratio which represents cpm ratio of samples measured (P) and negative control (N). 
Not determined. 
4 . ; 
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Table 'S.11 	Antibody responses of R692 to HBcPreS 1PreS 2S14 
Anti-HBs Anti-peptide (P/N ratio)* 
Treatments 	 Days Anti-HBc __ 
postimmunisation litre" DARIPC AUSABd HBs(ll 	PreS I(1 . ) 	PreS 1) 
(%) 	(RIA unit) 
Immunisation 	 0 0 10.4 	8 5.5 	 0.6 	 0.7 
1st boost 	 21 640 ND 	54 ND 	 0.8 	 1.2 
32 5120 73.3 54 ND 3.4 7.8 
2nd boost 49 20480 73.1 ND ND 1.4 1.8 
60 40960 74.4 72 ND 1.3 2.1 
3rd boost on day 98 109 5120 74.9 36 ND 1.1 1.1 
4th boost on day 155 166 10240 40.4 36 7.0 1.6 1.0 
Rabbit 692 was immunised with 03 mg of HBcPreS 1PreS2S14 ,, and boosted 4 times on the indicated days with 0.2 mg of antigen except for the 1st boost in which 03 mg was 
given. 
b 	Anti-HBc was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of '"1-labelled antibody binding. 
Anti-HBs was determined by the DARIP test using ayw subtype of 'l-HBsAg and the litres are expressed as % of 121-HBsAg co-precipitated with anti-HBs and anti-rabbit IgG. 
d 	Anti-HBs was determined by the AUSAB RIA and the litres are expressed as RIA units per 0.2 ml of serum. 
Anti-peptide antibodies were determined by the indirect antibody RIA in which the indicated synthetic peptides were used as the solid-phase ligand and the litres are expressed as 
P/N ratio which represents cpm ratio of samples measured (P) and negative control (N). 
Not determined. 
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Table 5.12 	Antibody responses of R699 to HBcPreS 1 PreS2S14 
Anti-HBs Anti-peptide (P/N ratio)* 
Trea tments Days Anti-HBc  
postimmunisation titreb DARIPC AUSABd HBs(Ill .l 	PreSl(1) 	PreS:41-20  
(%) (RIA unit) 
Immunisation 0 0 7.4 0 0.9 	 0.6 	 0.7 
1st boost 21 1280 63.8 36 ND 	 2.1 	 1.2 
32 1280 67.8 16 ND 7.4 1.4 
2nd boost 49 1280 ND ND ND 	 10.6 	 2.5 
60 2560 62.3 16 10.7 14.1 2.4 
Rabbit 699 was immunised with 0.5 mg of HBcPreS 1 PreS2S14  and boosted twice on the indicated days with 0.5 mg and 0.2 mg of antigen, respectively. 
b  Anti-HBc was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of WIlabelled antibody binding. 
Anti-FIBs was determined by the DARIP test using ayw subtype of U$IlabeIIed HBsAg and the titres are expressed as % of USIHB sAg  co-precipitated with anti-HBs and anti-rabbit 
IgO. 
d 	Anti-HBs was determined by the AUSAB RIA and the titres are expressed as RIA units per 0.2 ml of serum. 
Anti-peptide antibodies were determined by the indirect antibody RIA in which the indicated synthetic peptides were used as the solid-phase ligand and the titres are expressed as 
P/N ratio which represents cpm ratio of samples measured (P) and negative control (N). 
Not determined. 
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Table 5.13 	Antibody responses of R700 to HBcPreS 1PreS2S14 
Anti-HBs 	 Anti-peptide (P/N ratio)* 
Treatment0 	 Days 	Anti-HBc 	 __ 
postimmunisation 	titreDARIPC AUSABd 	HBS(IlI) 	PreSl(1 .23) 	PreS l) 
(%) (RIA unit) 
Immunisation 	 0 	 0 	11.9 	8 	 2.7 	 0.7 	 1.0 
1st boost 	 21 1280 47.3 36 ND 1.1 1.2 
32 2560 68.2 36 ND 3.7 2.5 
2nd boost 	 49 2560 ND • ND ND 6.4 7.4 
60 2560 67.8 72 9.1 7.4 13.1 
• Rabbit 700 was immunised with 0.5 mg of HBcPreS,PreS rS,4m and boosted twice on the indicated days with 0.5 mg and 0.2 mg of antigen, respectively. 
b  Anti-HBc was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of "I-labelled antibody binding. 
Anti-HBs was determined by the DARIP test using ayw subtype of W1labelled HBsAg and the titres are expressed as % of USI.HB sAg  co-precipitated with anti-I-lBs and anti-rabbit 
IgG. 
d 	Anti-HBs was determined by the AUSAB MA and the litres are expressed as RIA units per 0.2 ml of serum. 
Anti-peptide antibodies were determined by the indirect antibody RIA in which the indicated synthetic peptides were used as the solid-phase ligand and the titres are expressed as 
P/N ratio which represents cpm ratio of samples measured (P) and negative control (N). 
Not determined. 
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Table 5.14 	Antibody responses of R698 to HBcSPreS 1PreS2S1 
Anti-HBs 	 Anti-peptide (P/N ratio)' 
Treatment' 	 Days 	 Anti-HBc 	 __ 
postimmunisation 	titreDARIPC AUSABd 	HBs(lll) 	PreS 1(1 . ) 	PrCS 26) 
(%) 	(RIA unit) 
Immunisation 	 0 	 0 	13.9 	8 	 1.0 	 1.8 	 1.7 
1st boost 21 160 7.8 54 ND' 0.5 0.8 
32 2560 15.8 54 ND 1.8 3.5 
2nd boost 49 10240 35.4 ND ND 11.3 18.3 
60 10240 36.6 8 ND 4.0 6.2 
3rd boost on day 106 	117 	 10240 	40.4 	16 	 1.0 	 0.9 	 1.0 
Rabbit 698 was immunised with 0.5 mg of HBcSPreS,PreSS 14sO  and boosted 3 times on the indicated days with 0.5 mg of antigen in the first boost and 0.2 mg in the rest. 
b  Anti-HBc was determined by the competitive RIA and the litres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 'I-labelled antibody binding. 
Anti-HBs was determined by the DARIP test using ayw subtype of 1"1labelled HBsAg and the titres are expressed as % of 'J-HBsAg co-precipitated with anti-HBs and anti-rabbit 
IgG. 
d 	Anti-HBs was determined by the AUSAB RIA and the litres are expressed as RIA units per 0.2 ml of serum. 
Anti-peptide antibodies were determined by the indirect antibody RIA in which the indicated synthetic peptides were used as the solid-phase ligand and the titres are expressed as 
P/N ratio which represents cpm ratio of samples measured (P) and negative control (N). 
Not determined. 
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Table 5.15 	Antibody responses of R703 to HBcSPreSIPMS2Sl4SR  
Anti-HBs Anti-peptide (P/N ratio)e 
Treatmenta Days Anti-HBc __ 
postimmunisation titre DARIP0 AUSABd HBs(1 . 1 	PreS1() 	PreS 1 
(%) (RIA unit) 
Immunisation 0 0 6.2 16 0.5 	 0.5 	
0.6 
1st boost 22 320 8.0 8 ND 	 0.5 	
0.6 
33 2560 12.6 8 ND 0.8 1.1 
2nd boost 50 10240 27.6 16 ND 	 0.6 	
0.8 
61 10240 27.9 183 1.9 1.0 0.8 
$ 	Rabbit 703 was immunised with 0.5 mg of HBcSPre5 1PrCS2S 145g  and boosted twice on the indicated days with 0.5 mg and 0.2 mg of antigen, respectively. 
b 	Anti-HBc was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 1251-labelled antibody binding. 
Anti-HBs was determined by the DARIP test using ayw subtype of 1"I-labelled HBsAg and the litres are expressed as % of usIHB
sAg co-precipitated with anti-HBs and anti-rabbit 
lgG. 
Anti-HBs was determined by the AUSAB RIA and the litres are expressed as RIA units per 0.2 ml of serum. 
Anti-peptide antibodies were determined by the indirect antibody RIA in which the indicated synthetic peptides were used as the solid-phase ligand and the titres are expressed as 
P/N ratio which represents cpm ratio of samples measured (P) and negative control (N). 
Not determined. 
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Table 5.16 	Antibody responses of R702 to HBcSPreS 1PreS2S 
Anti-HBs 	 Anti-peptide (PIN ratio)' 
Treatmene 	 Days 	Anti-HBc 	 __ 
postimmunisation 	titreDARIPC AUSABd 	HBS(lllI 	PreS l(l . ) 	PrS 2 
(%) (RIA unit) 
Immunisation 	 0 	 0 	7.4 	0 	 0.7 	 1.0 	
1.2 
1st boost 	 22 320 6.6 8 ND 0.4 
0.5 
33 2560 19.8 16 ND 1.1 1.5 
2nd boost 	 50 ND 53.6 16 ND 1.0 1.1 
61 10240 52.8 16 11.2 1.1 1.2 
Rabbit 702 was immunised with 0.5 mg of HBcSPreS,PreSA,w  and boosted twice on the indicated days with 0.5 mg and 0.2 mg of antigen, respectively. 
Anti-HBc was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of WI-labelled antibody binding. 
Anti-HBs was determined by the DARIP test using ayw subtype of 'I-labelled liBsAg and the titres are expressed as % of UIHB
sAg co-precipitated with anti-HBs and anti-rabbit 
lgG. 
d - Anti-HBs was determined by the AUSAB RIA and the titres are expressed as RIA units per 0.2 ml of serum. 
Anti-peptide antibodies were determined by the indirect antibody RIA in which the indicated synthetic peptides were used as the solid-phase ligand and the titres are expressed as 
P/N ratio which represents cpin ratio of samples measured (P) and negative control (N). 
• Not determined. 
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Table 5.17 	Antibody responses of R701 to denatured HBsAg 
Anti-HBs 
Treatment' 	 Days 	 Aflti-HBS(111.156) peptided 
postimmunisation 	 DARIPC 	AUSABd 	 (P/N ratio) 
(%) (RIA unit) 
Immunisation 	 0 5.4 0 0.5 
1st boost 	 22 9.2 54 ND 
33 60.1 92 14.0 
2nd boost 	 50 	 55.6 	 54 	 ND 
	
61 55.6 16 ND 
rdboost on day 78 	92 	 50.6 	 ND 	 13.0 
100 49.8 ND 16.3 
Rabbit 701 was immunised with 10 pg of SDS-denatured HBsAg and boosted 3 times on the indicated days with the same dose of antigen except for the last boost in which 4 
pg was given. 
b 	Anti-HBs was determined by the DARIP test using ayw subtype of 125E-labelled HBsAg and the litres are expressed as % of mIHB sAg  co-precipitated with anti-HBs and anti-rabbit 
lgG. 
Anti-HBs was determined by the AUSAB RIA and the titres are expressed as RIA units per 0.2 ml of serum. 
a 	Anti-llBs(111 . peptide antibody was determined by the indirect antibody RIA in which HBs (111 . 1  synthetic peptide was used as the solid-phase ligand and the litres are expressed 
as P/N ratio which represents cpm ratio of samples measured (P) and negative control (N). 
Not determined. 
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5.2.2.1 Anti-HBc response 
Serum samples were serially diluted two-fold and assayed for anti-HBc antibody by 
the competitive RIA. Figure 5.6 shows the kinetics of the production of anti-HBc 
antibody in R675, R676, R677 and R678 after immunisation and subsequent boost 
with HBcS carrying wild-type or gly, 4, mutant in HBs(111156). The titres reached 
maximal levels 12 to 22 days after the second boost, except in R678 which peaked 12 
days after the third boost, after which the levels of anti-HBc antibody persisted or 
declined to half or quarter of the maximal levels finally, although the animals were 
further boosted a few times. The levels of anti-HBc antibody in all rabbits remained 
in high titres at final bleeding on days 435, 329 or 250 (Tables 5.2 to 5.7). The 
production of anti-HBc antibody in rabbits immunised with the HBcAg fusion proteins 
carrying HBs(llJls as well as preS 1 and preS2 fragments is shown in Tables 5.8 to 
5.16. The kinetics of the anti-HBc production in these rabbits was similar to that 
shown in Figure 5.6. The titres continued to rise to a plateau level after the first or 
second boost, which persisted but did not appear to rise further by subsequent boosts 
in most rabbits. 
In conclusion, these results demonstrated that a high anti-HBc response could be 
elicited by the HBcAg fusion proteins, which was very similar to that elicited by 
HBcAg, and the anti-HBc levels maintained for a long time, up to 435 days 
postimmunisation. 
5.2.2.2 Anti-HBs antibody response 
Anti-HBs antibody in the sera from rabbits immunised with the HBcAg fusion proteins 
were analysed by both DARIP and the AUSAB RIA tests. In the DARIP assay, 10-
fold dilution of tested sera were incubated with 'I-labelled HBs (adw or ayw subtype) 
followed by addition of donkey anti-rabbit IgG to precipitate any 125  I-labelled antigen-
antibody complex. It should be noted that the HBV DNA used in the original cloning 
experiments (Burrell et al., 1979; Pasek et al., 1979), which led to the construction 
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Figure 5.6 Anti-HBc titres in 4 rabbits immunised with HBcS or its 91y 145 mutant 
proteins. R675, R676, R677 and R678 were injected with HBCS, HBCS 14 , HBCS 14 
and HBCS 14 respectively, on days 0, 21, 80 and 108 etc. Serum samples obtained 
at indicated days were serially diluted and tested for anti-HBc antibody by the 
competitive RIA. Titres are expressed as the reciprocal of the serum dilution that 
gave 50% inhibition of 1251-labelled anti-HBc binding to the solid phase HBcAg. 
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of pHinG2 expressing HBsAg in yeast, exhibited the complex serotype adyw. 
However, in a DARIP competition assay, the yeast-derived HBsAg showed a 
specificity for monospecific anti-y serum, but not for monospecific anti-d serum 
(Ashton-Rickardt and Murray, 1989b). Although the HBsAg coding region in the 
HBcAg fusion constructs was derived from the same source as in pHinG2, anti-HBs 
antibody raised against the HBcAg fusion proteins could react equally with both adw 
and ayw subtypes of 'I-HBsAg in the DARIP assay, suggesting that these antibodies 
were primarily directed toward the a group-specific determinant on HBsAg. The 
results in Figure 5.7 were obtained by using "I-HBsAg (adw) in the DARIP assay. 
In R675 immunised with HBcS, a low level of anti-HBs antibody was produced 21 
days after immunisation. After the first and second boosts, the titre continued to rise, 
reaching peak activity within 14 days after the second boost (day 93), after which the 
titre did not rise further. In R676 immunised with HBcS 14 , no anti-HBs antibody 
was detectable before day 21. After boosting, the response was similar to that 
observed in R675, although to a lesser extent. In R677 immunised with HBCS 14 
anti-HBs antibody was not detectable until 14 days after the second boost (day 93), 
after which the titre remained unchanged even when further boosted. In R678 
immunised with HBcS,45y, no anti-HBs antibody was detectable in all samples, 
although three boosts were given. In R675, R676 and R677 samples bled after day 
120, the anti-HBs antibody titres maintained or declined slightly, but could be boosted 
to the same levels as the day 120 samples, except that no anti-HBs antibody was 
found in the R675 day 435 samples (Tables 5.2 to 5.4). In R678, the anti-HBs 
antibody was still not detectable after the fourth boost (day 287); however, on day 
435, 14 days after the fifth boost, antibody was detected with a titre comparable to 
that in the R675 day 329 sample (Table 5.5). The anti-HBs antibody response in 
R684 and R685 immunised with HBCS and HBcS 14 , respectively, at a higher dose, 
are shown in Tables 5.6 and 5.7. R685 elicited a higher anti-HBs response than R684. 
However, the responses of the anti-HBs production were similar to those observed 
in R675 and R676. 
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Figure 5.7 Anti-HBs production in 4 rabbits immunised with HBcS or its g1y 145 
mutant proteins. R675, R676, R677 and R678 were injected with HBcS, HBcS 14 , 
HBcS 145E and HBcS 145K, respectively, on days 0, 21, 81 and 108 etc. Serum samples 
obtained at indicated days were tested for anti-HBs antibody by the DARIP assay 
using ' 251-labelled HBsAg (adw) as the reagent. The amounts of anti-HBs antibody 
present in the sera were expressed as a percentage of 'I-bound in the precipitate 
compared to total 'I added in the reaction. 
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The anti-HBs responses in rabbits immunised with HBcPreS 1PreS 2S or 
HBcSPreS 1PreS2S carrying wild-type or a gly, 45 mutant in HBs(lll .I are shown in 
Figure 5.8. HBcPreS 1PreS 2S carrying either wild-type or g1y 145 mutants provoked a 
more rapid and greater anti-HBs antibody response than HBcS or its mutant 
counterparts in rabbits (Figure 5.7). The anti-HBs titres in these rabbits (R690, R691, 
R692, R697, R699 and R700) began to rise following immunisation, and reached a 
plateau after the first boost, following which the titres persisted (Figure 5.8a). The 
responses and the titres of anti-HBs production in these rabbits were similar to those 
observed in R701 which had been immunised with denatured HBsAg (Figure 5.8b). 
In R698, R702 and R703, immunised with HBcSPreS,PreS2Sl45R or 
HBcSPreS,PreS2Sl45F, the induction of anti-HBs antibody was slower and to a lower 
level than in those immunised with HBcPreS 1PreS2S, carrying wild-type or 91y 145 
mutants in HBs(llllS (Figure 5.8b). Anti-HBs antibody could be detected with a 
moderate titre only after the first boost and was maintained at the same level after the 
second boost. 
The anti-HBs titres were also determined by the AUSAB RIA in some sera from 
rabbits immunised with the HBcAg fusion proteins. The serum samples were placed 
in contact with the plastic beads that had been coated with both ad and ay subtypes 
of HB5Ag, and during incubation, antibody, if present, was fixed to the solid phase 
and was detected following the addition of '25I-labelled HBsAg. RIA units were 
estimated according to the semiquantitative method recommended by the manufacturer. 
The specificity in the AUSAB test was in agreement with that obtained from the 
DARIP assay. Sera negative for anti-HBs antibody by the DARIP assay were also 
negative in the AUSAB test. Nevertheless, the degree of reactivity between these two 
tests varied (Tables 5.2 to 5.17). Comparion of the RIA units obtained from the 
AUSAB test shows that R690 and R697, which were immunised with 
HBcPreS 1PreS2S, elicited the highest anti-HBs response with 352 and 262 units/0.2 ml 
serum on day 32 (Tables 5.8 and 5.9). All preimmunisation sera were negative for 
anti-HBs antibody, except R675 and R697 (Tables 5.2 and 5.9) which reacted strongly 
in the AUSAB test. These false positive results were presumably due to non- 
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Figure 5.8 Anti-HBs production in 10 rabbits immunised with (a) HBcPreS 1PreS2S 
or (b) HBcSPreS 1PreS2S, carrying wild-type or a gly,4s mutant in HBs(lllI or 
denatured HBsAg on days 0, 21 (22) or/and 49 (50) etc. R697 and R691 died on days 
48 and day 32, respectively. Serum samples obtained at indicated days were tested 
for anti-HBs antibody by the DARIP assay using ' 25I-labelled HBsAg (ayw) as the 
reagent. The amounts of anti-HBs antibody present in the sera were expressed as a 
percentage of 'I-bound in the precipitate compared to total 1251 added in the reaction. 
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specificity of cross-reacting substances or components in the rabbit sera. However, 
in the DARIP tests, the preimmunisation sera from R675 and R697 were both anti-
HBs negative when 'I-HBsAg of adw or ayw was used as the test reagent. 
Collectively these data indicate that HBcAg fusion proteins carrying HBs (lll .l 
fragments, either wild-type or gly, 45 mutants in HBs(lll4 whether including preS l(l) 
and preS 1  fragments or not, elicited antibodies that could cross-react with native 
HBsAg. HBcS,4m and especially, HBcS j45K appeared to induce less antibodies 
recognised the native HBsAg. However, there was animal to animal variation in 
producing anti-HBs antibody, which could be expected from outbred animals. It 
should be noted here that R701, which was immunised with HBsAg that had been 
reduced and denatured with DTT, SDS and boiling, also elicited antibody cross-
reactive with native HBsAg (Table 5.8b), the levels of which were comparable to 
those induced from the HBcAg fusion proteins. 
5.2.2.3 Anti-peptide antibodies 
The sera from rabbits immunised with the HBcAg fusion proteins were assayed for 
reactivity against the corresponding peptide by the indirect antibody RIA. These 
assays were carried out using synthetic preS l(l , preS 1 or HBs(11115 peptide 
bound directly to the solid phase, and 'I-labelled second antibody to probe anti-
peptide antibody bound to peptide-coated beads. Data are expressed as P/N ratios 
which represent the cpm ratio of samples measured (P) and negative control(N) at the 
same dilution (102  or 10) All rabbits immunised with HBcPreS 1PreS 2S, either wild-
type or g1y 145 mutants in HBs(llllS , elicited anti-preS 1 and anti-preS 2 antibodies 
(Tables 5.8 to 5.13). Surprisingly, HBcSPreS 1PreS2S carrying a dimer of HBs (Ill . l  
fragment induced anti-preS 1 and anti-preS 2 antibodies in only one (R698) out of three 
rabbits (Tables 5.14 to 5.16). The highest levels of the anti-preS 1 and anti-preS 2 
responses were obtained 11 to 28 days after the first boost and persisted for 205 days, 
but either did not appear to alter significantly after further boosts (R690), or decreased 
with time (R692 and R698). Although the same concentration of preS l(l) and preS 1 
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peptides was used for preparing the peptide-coated beads, the binding efficiency of 
the two peptides to the solid phase might be different. It was not possible, therefore, 
to compare the titres between anti-preS 1 and anti-preS 2 antibodies in the rabbit sera. 
Moreover, the heterogeneity of the response did not allow meaningful comparison of 
the preS 1- and preS 2-specific immunogenicity between HBcPreS 1PreS2S and 
HBcSPreS 1PreS2S in rabbits. Anti-HBs(1ll . 1 antibody was also examined by the 
indirect antibody RIA in some rabbit sera (Tables 5.8 to 5.17). The levels of anti-
HBs(lll  antibody parallelled those of anti-HBs antibody obtained by the DARIP 
assay. 
53 	Immune responses of mice after inoculation with HBCAg fusion proteins 
In Section 5.2, the immunogenicity studies of the HBcAg fusion proteins were carried 
out in outbred rabbits. High-titred, anti-HBc antibodies were produced in all rabbits 
immunised with HBcAg fusion proteins. However, the immune responses to preS 1 , 
preS2  and HBs peptides were variable. These results from rabbits were in agreement 
with the observations in humans. Regardless of clinical disease, high-titred, anti-HBc 
antibodies are produced by virtually 100% of HBV-infected individuals. In contrast, 
the response to HBsAg varies, which may account for the spectrum of clinical 
manifestations associated with HBV infection. Although the variation of the genetic 
make-up in the outbred rabbits reflected the outbred human population, the use of 
inbred strains of mice to compare the immunogenicity of the HBcAg fusion proteins 
may provide more information about the immunological features of these HBcAg 
fusion proteins carrying different epitopes. 
53.1 Immunogenicity of HBcAg fusion proteins in terms of antibody responses 
To evaluate and compare the immunogenicities of HBcAg fusion proteins carrying 
HBs(llll with or without preS l(l) and preS 1. fragments in inbred strains of mice, 
groups of S BALB/c mice were immunised intraperitoneally (I.P.) with equal doses 
(20 4ug) of 6 different HBcAg fusion proteins and subsequently boosted with 20 ,ug, 
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50 1ug and 50 tg of the same immunogen on days 28, 57 and 104, respectively. Mice 
were bled and sera from each group were pooled at 2 or 3 weeks after each injection. 
As shown in Table 5.18, anti-HBc antibody was detected in all groups of mice after 
the first boost, which was similar to the results obtained from rabbit experiments. As 
expected, there was no significant difference in their abilities to elicit anti-HBc 
antibody in the mice immunised with HBcS, its three 91y 145 mutants, HBcPre 1PreS 2S 
or HBcSPreS 1PreS 2S. In contrast, these HBcAg fusion proteins induced negligible or 
low-titred anti-HBs antibody, except HBcPreS 1PreS2S elicited 82 RIA units (per 0.2 
ml serum) of anti-HBs antibody on day 118 following three boosts. The anti-HBs 
response was delayed since little anti-HBs antibody was detected until 118 days after 
immunisation followed by the three boosts. In rabbits, however, anti-HBs antibody 
was found earlier in some rabbits after immunisation and before boostings (day 21). 
In addition, low levels of anti-preS 1 and anti-preS 2 antibodies (P/N ratio zt1 1) were 
detected on days 71 and 118 in mice immunised with HBcPreS 1PreS 2S and only anti-
preS2, but not anti-preS 1, antibody detectedon 118 days in those immunised with 
HBcSPreS 1PreS2S; no anti-preS 1 and anti-preS 2 antibodies were induced in the earlier 
samples (Table 5.19). Although the dose of injection relative to the body weight for 
the mice was higher than that for the rabbit, the anti-HBs, anti-preS 1 and anti-preS 2 
antibody responses induced by the HBcAg fusion proteins were lower in mice than 
in rabbits, whereas high-titred anti-HBc antibody was induced in both species. The 
discrepancy in the former may be due to the differences in the immune responses 
among species or in the injection routes. 
Higher doses of the HBcAg fusion proteins were used in the following experiment in 
which 40 ug of immunogens were inoculated into groups of 5 BALB/c mice for 
immunisation and two boosts on days 28 and 64. As shown in Table 5.20, high-titred 
anti-HBc antibody was again produced in the mice immunised with HBcAg or the 
HBcAg fusion proteins. Mice immunised with HBcS 14 PreS 1PreS 2S or 
HBcS 14 PreS 1PreS2S also produced 72 and 26 RIA units (per 0.2 ml serum) of anti-
HBs antibodies, respectively. Despite the fact that the HBcAg fusion proteins induced 
only low anti-HBs response in BALB/c mice, the antibody response to native HB5Ag 
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Table 5.18 Anti-HBc and anti-HBs antibody responses of BALB/c mice to the HBcAg fusion proteins 
Day 13 	 Day 22 	 Day 42 	 Day 71 	 Day 118 
Immunogena 
Anti-1-113d' MtiHB sc 	Anti-HBc Anti-HBs 	Anti-HBc Anti-HBs 	Anti-HBc Anti-HBs 	Anti-HBc Anti-HBs 
HBCS 80 ND  640 16 2560 8 2560 <8 2560 8 
HBcS145R 160 ND 160 <8 1280 
8 5120 <8 5120 8 
HBCS145E 40 ND 320 <8 2560 8 5120 12 10240 26 
HBCS I45K 80 ND 320 0 5120 <8 10240 <8 5120 <8 
HBcPreS 1PreS 2S 40 ND 320 <8 1280 16 2560 <8 5120 82 
HBëSPreS 1PreS 2S 40 ND 320 0 5120 16 5120 8 5120 <8 
a Groups of 5 BALB/c mice were immunised with 20 pg of the indicated immunogens and boosted thrice with 20 pg, 50 tug, and 50 pg of the same 
antigens on days 28, 57 and 107, respectively. 
b Anti-HBc was determined by the competitive MA and the litres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 1251
labelled antibody binding. 
Anti-HBs was determined by the AUSAB RIA and the litres are expressed as RIA units per 0.2 ml of serum. 
d Not determined. 
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Table 5.19 Anti-préS 1(1 . )  and anti-preS 1  antibody responses of BALB/c mice to various immunogens 
Day 22 or 20 	 Day 42 
Immunogen 	 Dose (ug) 
AntipreSic 	AntipreS2c 	Anti-preS 1 	Anti-preS2 




HBcPreS 1(1 .36)6 	 40 	0.8 	0.7 	3.4 0.8 1.5 	1.6 ND 	
ND 
HBcPreS2a 	 40 	0.8 	1.4 	0.8 2.9 1.0 	5.4 ND 	ND 
HBcPreS 1PreS 2' 	 40 	1.0 	1.2 	4.9 2.3 5.6 	2.3 ND 	
ND 
HBcS 14 PreS 1 PreS2S 	40 	1.0 	1.2 	0.8 0.9 3.2 	2.5 ND 	ND  
HBcS14 PreSiPreS2Sa 40 	1.0 	1.3 	1.4 1.1 
1.7 	1.1 ND 	ND 
Pre,(,. ) peptide' 	100 	0.7 	0.8 	0.7 
0.8 0.9 	1.1 ND 	ND 
PreS 2 	peptide 	100 	0.8 	1.5 	0.7 2.0 0.9 	1.4 ND 	
ND 
HBcPreS1PreS2Sb 20 	1.1 	1.1 	0.9 1.2 2.3 	2.2 3.4 	37 
HBcSPreS1 PreS2Sb 	20 	0.7 	0.9 	0.9 1.1 1.1 	1.2 1.3 	2.8 
Groups of 5 BALB/c mice were immunised with the indicated immunogens and doses and boosted twice on days 28 and 62 (or 64) with the same amount of antigens. Mice were 
bled on days 20 (or 22), 42 and 77 (or 79). 
b 	Groups of 5 BALBIc mice were immunised with the indicated immunogens and doses and boosted thrice with 20 4ug, 30 4ug and 50 ug of the same antigens on days 28, 57 and 107, 
respectively. Mice were bled on days 13, 22, 42, 71 and 118. 
Anti-peptide antibody was determined by the indirect antibody RIA in which preSKl. 	or pres2(1 .20 synthetic peptide was used as the solid-phase ligand and the titres are expressed 
as P/N ratio, which represents cpm of samples measured?) and negative control (N). 
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Table 5.20 Anti-HBc and anti-HBs antibody responses of BALB/c mice to various immunogens 
immunogena Dose (ug) 
Day 22 or 20 
AntiHBcb 	AntiHBsc 
- 	 Day 42 
Anti-HBc 	Anti-HBs 
Day 79 or 77 
Anti-1-113c 	Anti-HBs 
HBcAg 4 80 2560 5120 
HBsAg 2 0 	144 0 	>2048 0 	
>10240 
HBcPreS, (1 -30 40 20 640 640 
HBcPreS 2 40 80 1280 5120 
HBcPreS 1PrCS2 40 320 1280 2560 
HBcS14 PreS 1PreS2S 40 160 	16 2560 	8 2560 	72 
HBcS14 PreS 1 PreS 2S 40 320 	 8 2560 	8 5120 	26 
PreS 1(1 . ) peptide 100 0 0 0 
PreS.26) peptide 100 0 0 0 
Groups of 5 BALB/c mice were immunised with the indicated immunogens and doses and boosted twice on days 28 and 64 (or 62) 
with the same amount of antigens 
except HBcAg and HBsAg, in which only 1 pg and 0.5 pg were used for the second boost, respectively. 
b Anti-1113c was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 1 I-labelled antibody 
binding. 
Anti-HB5 was determined by the AUSAB RIA and the titres are expressed as RIA units per 0.2 ml of serum. 
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was extremely high in the mice. Two 4ug of HBsAg induced more than 10240 RIA 
units of anti-HBs antibody. Anti-preS 1 or/and anti-preS 2 antibodies were detected in 
mice injected with HBcPreS 1(1. HBcPreS2, HBcPreS 1PreS2, HBcS 14 PreS 1PreS 2S, 
HBcPreS 1PreS2S, or HBcSPreS 1PreS2S on days 42, 71 (or 79), and 118 (Table 5.19). 
The HBcAg fusion proteins carrying the preS 1 or/and preS 2 fragments only appear to 
elicit higher anti-preS 1 or/and preS 2 antibodies than those carrying preS 1 and preS2 as 
well as a monomer or a dimer of HBs( lll..lS fragments. The HBs(llll fragment 
might affect the surface accessibility of the preS 1 and preS2 epitopes in the hybrid 
particles. When mice were immunised with 100 1ug of preSl(l ) or preS 1. peptide 
in the absence of carrier proteins, no anti-peptide antibodies were detected in any of 
samples (Table 5.19). The enhanced immunogenicity of peptide epitopes presented 
on the HBcAg particles is in accordance with the previous studies of Clarke et al. 
(1989). 
In further mouse experiments, HBcPreS,PreS2Sl45R or HBcSPreS,PreS2SI45R was 
inoculated at a range of concentrations from 10 jig to 500 ug into groups of BALB/c 
mice, which were subsequently boosted with the same dose on day 28. As shown in 
Table 5.21, the levels of anti-HBc antibody increased enormously 14 days after the 
first boost (day 42). Similar levels of anti-HBs antibody were found in the mice as 
those elicited by some rabbits (R691, R692, R698, R699, R700, R702 and R703) 
immunised with similar HBcAg fusion proteins. However, regarding the dose of 
immunisation relative to the body weight and the kinetics of the response, the anti-
HBs response in BALB/c mice appeared to be reduced and delayed as compared to 
that in rabbits, and no dose-response correlation was observed in either set of 
experiments which made it difficult to compare the immunogenicity of these two 
HBcAg fusion proteins. Furthermore, low levels of anti-preS 1 or/and anti-preS 2 
antibodies were detectable in some samples on days 42 and 92 (data not shown). 
As illustrated in Table 5.22, when a wide range of concentrations of HBCS (from 
0.005 1ug to 250 ,ug) were inoculated into groups of BALB/c mice, which were 
subsequently boosted with the same dose on days 28 and 56, the levels of anti-HBc 
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Table 5.21 Anti-HBc and anti-HBs antibody responses of BALB/c mice to HBcPmSIPMS2SI45R and HBCSPrCS IPreS2S145R 
Day 24 Day 42 Day 92 
Immunogen' 	Dose (pg) 
Anti-HBd' 	AntiHBsc Anti-HBc 	Anti-HBs Anti-HBc 	Anti-HBs 
HBcPreS,PreS2SI45R 	10 40 	 <8 1280 8 
ND  16 
50 80 12 2560 36 ND 54 
250 320 	 16 5120 36 ND 92 
500 320 <8 5120 16 ND 54 
HBcSPreS,PreS 2S 145R 	10 20 <8 640 12 ND 16 
50 160 12 10240 12 ND 54 
250 160 <8 10240 <8 ND <8 
500 160 8 10240 26 ND 72 
Groups of 4 BALB/c mice were immunised with the indicated immunogens and doses and boosted on day 28 with the same amount of antigens. 
b Anti-HBc was determined by the competitive RJA and the tines are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 125I-labelled antibody 
binding. 
Anti-HBs was determined by the AUSAB RIA and the titres are expressed as RIA.units per 0.2 ml of serum. 
d  Not determined. 
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Immunogen' 	Dose (ug) 	
Anti.HBc!' AntiHBsc 
	
Anti-HBc Anti-HBs 	Anti-HBc 	Anti-HBs 
HBCS 	 0.005 <5 <8 <5 8 <5 12 
0.05 <5 16 <5 12 <5 8 
0.4 <5 36 40 36 20 54 
2 40 <8 1280 12 640 12 
10 160 16 2560 12 5120 12 
50 320 36 5120 26 10240 16 
250 640 <8 10240 <8 10240 <8 
a Groups of 5 BALB/c mice were immunised with the indicated doses and boosted twice on days 28 and 56 with the same amount of antigens. 
Mice were bled on days 21, 42 and 70. 
b Anti-HBc was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 'VI-
labelled antibody binding. 
Anti-HBs was determined by the AUSAB RIA and the titres are expressed as RIA units per 0.2 ml of serum. 
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antibody elicited by the animals could be correlated with the amount of injected 
antigen. HBcS at a 0.05 4ug dose or less did not elicit the production of anti-HBc 
antibody, and 0.4 ug induced only marginal response, while 10 ug of the antigen 
elicited high anti-HBc antibody on days 42 and 70. Further 2-fold and 4-fold 
increases in anti-HBc titre were observed when 5-fold and 25-fold concentrations of 
the antigen were inoculated, respectively. However, the levels of anti-HBs response 
were still similar to those found in the previous experiments (Table 5.21). The highest 
anti-HBs response (54 RIA units) was found in mice inoculated with 0.4 ug of HBcS. 
Higher doses of HBcS did not stimulate higher anti-HBs response. There was little 
direct correlation between the anti-HBs response and the immunisation dose. 
In conclusion, HBcAg fusion proteins induced anti-HBc antibody in mice as high as 
in rabbits, and the induction was regulated in a dose-dependent manner. There was 
no significant difference in inducing anti-HBc antibody among different HBcAg fusion 
proteins. In terms of the production of anti-HBs antibody, the response appeared to 
be higher in mice immunised with HBcPreS 1PreS 2S than in those immunised with 
HBcS or HBcSPreS 1PreS 2S (Table 5.18). These results were consistent with the 
results obtained from the rabbits. Nevertheless, the anti-HBs response induced by 
HBcAg fusion proteins in mice was lower and later than in rabbits. It is noteworthy 
that the anti-HBs response induced by HBcAg fusion proteins, in either mice or 
rabbits, was much lower than that induced by native HBsAg. 
53.2 Immunogenicity of HBcAg fusion proteins in B1O.S mice which are 
genetically non-responsive to HBSAg 
The humoral immune response to HBsAg varies considerably from patient to patient 
during infection and after vaccination. In contrast, high titres of anti-HBc are 
produced by all HBV-infected patients. The non-responsiveness to HBsAg in man 
results in the chronic carrier state which is an important reservoir for persistence and 
transmission of HBV. It has been documented that the murine humoral immune 
response to HBsAg is regulated by H-2-linked immune response (Ir) genes (Milich and 
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Chisari, 1982). The availability of HBsAg non-responder strains, e.g. H-2' and H-2 
strains, has provided a model to study the methods of circumventing HBsAg non-
responsiveness. The H-2-restricted humoral immune response to HBsAg in mice has 
been demonstrated to be antigen dose-dependent (Milich and Chisari, 1982). Non-
responsive SJL (H-?) mice immunised with 40 pg, a 10-fold higher dose than that for 
the responder strain, did produce a primary anti-HBs response, although the magnitude 
was reduced as compared to that of high-responder strains received 4 pg of the 
antigen. Moreover, the immunisation route also influenced the responsiveness to 
HBsAg. Immunisation of SJL mice with HBsAg through the hind footpads, instead 
of I.P. injection, also resulted in a primary anti-HBs response, in contrast to I.P. 
immunisation, which did not. However, the magnitude and kinetics of the humoral 
responses were markedly reduced and delayed. 
To investigate the feasibility of using HBcAg fusion proteins carrying the HBs (llllS 
fragment to provide HBc-specific T-helper cell activity for anti-HBs antibody 
production in mice with HB5Ag non-responder haplotypes, hence circumventing the 
non-responsiveness to HBsAg, three groups of five B10.S (H-?) mice were immunised 
with a mixture of HBcAg and HBsAg, or with HBcAg fusion proteins (HBcS or 
HBCSj4 J alone. Two other groups were immunised with HBcAg or HBsAgalpne 
to serve as control groups. All groups of mice received a further 3 boosts on days 28, 
58 and 100. They were bled 10 and 24 days after immunisation as well as 14 or 15 
days after boostings. As shown in Table 5.23, except for the HBsAg-immunised mice, 
all groups produced anti-HBc antibody as early as 10 days after immunisation and the 
titres continued to rise, peaked on day 43, then maintained the same level or declined 
to a half or a quarter of the peak level, although two further boosts were given. The 
anti-HBc response among these groups did not differ significantly. With respect to 
the anti-HBs response, B10.S mice immunised with 4 pg of HBsAg produced no anti-
HBs until 14 days after the second boost (day 72). Surprisingly, those immunised 
with a mixture of HBcAg and HBsAg produced anti-HBs antibody as early as 10 
days; the titre peaked on day 24 and could not be augmented by the boostings. In 
contrast, no anti-HBs response was detected in B10.S mice immunised with HBCS or 
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Table 5.23 Anti-HBc and anti-HBs antibody responses of B10.S mice to various immunogens 
Day 10 	 Day 24 	 Day 43 	 - Day 72 	 Day. 114 
Immunogena 
(jig) 	AntiHBct Anti-HBs0 	Anti-HBc Anti-HBs 	Anti-HBc Anti-HBs 	Anti-HBc Anti-HBs 	Anti-HBc Anti-HBs 
HBcAg (16) 	320 	ND 	640 	ND 	5120 	0 	2560 	0 	1280 0 
HBsAg (4) 	<2 	0 	<2 	0 	<2 	0 	<2 	288 	<2 1614 
HBcAg (16) 	320 	59 	1280 	1468 	5120 	558 	5120 	638 	2560 302 
+ HBsAg (4) 
HBcS (20) 	160 	ND 	320 	ND 	2560 	0 	2560 	0 	1280 0 
FffiI45R(20) 	640 	ND 	640 	ND 	2560 	0 	2560 	0 	2560 0 
a 	Groups of 5 B10.S mice were immunised with the indicated doses of immunogens and boosted thrice on days 28, 58 and 100. 
Anti-HBc was determined by the competitive RIA and the titres are expressed as the reciprocal of the serum dilution that gave 50% inhibition of 'I- 
labelled antibody binding. 
° 	Anti-HBs was determined by the AUSAB RIA and the titres are expressed as RIA units per 0.2 ml of serum. 
d 	Not determined. 
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HBcS,45R  throughout the observation period. The lack of an anti-HBs response after 
primary immunisation of 4 1ug of HBsAg in B1O.S mice is consistent with the results 
previously described by Milich and Chisari (1982). However, repeated boostings of 
HBsAg could circumvent the non-responsiveness, since 288 and 1614 RIA units (per 
0.2 ml serum) of anti-HBs antibody were detected on days 72 and 114, respectively, 
which corresponded to 14 days after the second and third boosts. It should be noted 
that the anti-HBs responses in B10.S mice were consistently inferior to those in 
BALBIc mice. The results from B1O.S mice immunised with a mixture of HBcAg and 
HBsAg are of interest and imply that HBcAg-specific T cells can function to help 
anti-HBs production even when HBcAg and HBsAg were not present within the same 
molecule or particle. The results appear to contradict the previous results published 
by Milich et al. (1987c), who demonstrated that B10.S mice primed with HBcAg or 
HBc(11) peptide and subsequently challenged with a suboptimal dose of virions 
(HBV) 3 weeks post-priming, produced anti-HBs antibody, whereas HBcAg-primed 
mice challenged with a mixture of HBcAg and HBsAg did not. Their results indicate 
that HBcAg-primed T-cells can help anti-HBs antibody production, and the T-helper 
cell activity required that HBcAg and HBsAg be present within the same particle 
(virion), since the mixture was ineffective. The discrepancy between the two 
experiments could result from the different immunisation regimen used. In the work 
described here, instead of priming with HBcAg (4 pg), HBcAg (16 Aug) and HB5Ag 
(4 1ug) were concomitantly administered to mice for the immunisation and the first 
boost, and 1/4 and 1/8 of the original doses were used for the second and the third 
boosts, respectively. The mechanism underlying circumvention of non-responsiveness 
to HBsAg is unclear, however, it seems that HBcAg-activated T-cells non-specifically 
stimulated HBsAg-specific B-cells to produce anti-HBs, which differed from 
intermolecular-intrastructural T-helper cell-B-cell interactions (Milich et al., 1987c). 
However, two groups of B10.S mice immunised with 20 ug of HBcS or HBCS 14 
produced no anti-HBs antibody, which was different from that obtained from BALB/c 
- mice (Table 5.18). The results indicate that the immunisation of HBcS or HBCS14SR  
did not circumvent the non-responsiveness to HBsAg through HBcAg-specific Th.cell. 
function. 
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When BALB/c or B10.S mice were primed with HBcAg (4 4ug) and challenged 3 
weeks later (day 21) with a lower dose (2 1ug) of HBcPreS 1PreS2S, a considerable level 
of anti-HBc antibody was elicited on days 28 and 35, whereas little or no anti-HBs 
antibody was detected (data not shown). The lymphocyte-proliferative response by 
the splenocytes was also assessed on day 35 after sacrifice of the mice. Low levels 
of lymphocyte proliferation to HBcAg and the HBc fusion protein were detected in 
all mice injected with HBcAg (priming) alone, HBcPreS 1PreS2S (challenge) alone, or 
HBcAg (priming) followed by HBcPreS 1PreS 2S (challenge), while no lymphocyte-
proliferative response to HBsAg, preS l(l) or preS 1. peptide was observed (data not 
shown). The failure to elicit anti-HBs antibody in either the BALB/c or B10.S mice 
primed with HBcAg and challenged later with HBcPreS 1PreS2S might be due to low 
HBcAg-specific T-cell response resulting in no functional help for anti-HBs 
production, or due to no HB9 11115 -specific B cell response, as anti-HBs antibody 
response to HBcAg fusion proteins carrying the HBs (lll.. l fragment is low in BALB/c 
mice as shown in this work. Furthermore, the dose for challenge may be quite critical 
for such experiments, and this has not been fully explored in this study. 
5.4 HBcAg fusion proteins carrying HBs (111 . 1 fragment elicit antibodies cross-
reactive with native HBsAg 
The results obtained from Sections 5.2.2 and 5.3.1 show that rabbits and BALB/c mice 
immunised with HBcAg fusion proteins carrying the HBs (lll fragment elicited 
antibodies which could react with native HBsAg, albeit at lower levels than those 
immunised with intact, native HBsAg, as measured by the AUSAB test or the DARIP 
assay (Figures 5.7 and 5.8, Tables 5.18, 5.20, 5.21 and 5.22). On the other hand, anti-
HBs antiserum from rabbits or mice raised against native HBsAg reacted with HBs (lll . 
Lm)  peptide in the solid-phase indirect antibody RIA. To further compare the anti-HBs 
and anti-HBcAg fusion protein sera, a competition test was set up in which mouse 
polyclonal antibody against native HBsAg, with a certain dilution to saturate HBsAg 
in the solid phase, was incubated with HBsAg-coated beads along with various 
dilutions of rabbit polyclonal antibody against the HBcAg fusion protein as the 
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competitor and was probed with 'I-labelled sheep anti-mouse immunoglobulin 
(Figure 5.9). Figure 5.10 shows that binding of anti-HBs antiserum to the solid phase 
HBsAg was inhibited in a concentration-dependent manner by increasing 
concentrations of antiserum to HBcAg fusion protein. A 62.8% inhibition of binding 
was observed after addition of undiluted antiserum raised against HBcPreS 1PreS2S 1 
from R692 (day 92), whereas preimmunised serum from the same rabbit failed to 
inhibit the binding. On the other hand, binding of mouse polyclonal anti-HBs 
antiserum to the solid phase HBs (lll4 peptide was also inhibited by rabbit polyclonal 
antiserum against HBcPreS 1PreS2S 1 by 36.3% (Figure 5.11). In addition, antisera 
raised against HBCS, HBCS 14 , HBcS,4m and HBcS,45K all inhibited the binding of 
anti-native HBsAg antiserum to HBsAg to at least some extent in similar assays (data 
not shown). Therefore, the results indicate that polyclonal antibody against HBcAg 
fusion proteins carrying either wild-type or 91y 145 mutant HBs(llllS fragments and 
polyclonal antibody against native, intact HBsAg recognise either a common or 
overlapping determinant on HB5 (lll . 156) sequence. 
5.5 Discussion 
In the work described in this chapter, the immunogenicities of the HBcAg fusion 
proteins were determined in terms of T-cell response and antibody production. The 
experiments demonstrate that immunisation of rabbits with hybrid HBcAg carrying the 
S or/and preS 1 and preS2 fragments resulted in the generation of HBcAg-specific and 
envelope protein-specific antibodies and that the PBLs from such rabbits proliferated 
after in vitro stimulation with HBcAg, HBcAg fusion protein, HBsAg or preS 1(1) 
peptide. The T-cell responses to HBcAg or HBcAg fusion protein were much higher 
than those to HBsAg or preS l(l. ). Moreover, all immunised rabbits responded highly 
to HBcAg and HBcAg fusion protein, while most rabbits responded moderately to 
weakly to HBsAg. Responses to the preS l(l) peptide was variable and no response 
was observed to the preS 1 peptide. In regard to the humoral response, rabbits 
immunised with HBcAg fusion proteins (wild-type or 91y 1 mutants) with or without 
preS 1 and preS 2 fragments, elicited high-titred anti-HBc antibody. They also elicited 
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Figure 5.9 The diagram illustrating the competitive RIA. (A) Mouse anti-HBs 
antiserum binds to the solid phase HBsAg following the binding of 'MI-labelled sheep 
anti-mouse immunoglobulin. (B) Inhibition of mouse anti-HBs antiserum bound to 
the solid phase HBsAg in the presence of the competitor, rabbit antiserum against 
HBcPreS 1PrS2S 14 , as detected by ' 25I-labelled sheep anti-mouse immunoglobulin. 
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Competitor dilutions 
Figure 5.10 Competition between anti-HBcPreS 1PreS 2S 14 and anti-HBs antibodies 
for the HBs(1ll . 1S -re1ated epitope on HBsAg. Polystyrene beads coated with HBsAg 
were incubated with 100 1u1 of '/ dilution of mouse anti-HBs serum along with 100 
u1 of the indicated dilution of R692-60 (11 days after the second boost with 
HBcPreS 1PreS2S 14 J or R692-0 (preimmunised) serum as the competitor. The binding 
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Competitor. dilutions 
Figure 5.11 Competition between anti-HBcPreS 1PreS 2S 14 and anti-HBs antibodies 
for the HBs 11115 peptide epitope. Polystyrene beads coated with HBs (llllS peptide 
were incubated with 100 uI of '/ dilution of mouse anti-BBs serum along with 100 
4u1 of the indicated dilution of R692-60 (11 days after the second boost with 
HBcPreS 1PreS2S 14 ) or R692-0 (preimmunised) serum as the competitor. The binding 
of mouse anti-HBs serum to the HBs(llllS was monitored by addition of `51-labelled 
sheep anti-mouse immunoglobulin. 
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antibodies cross-reactive with native HBsAg at a lesser extent. Anti-preS 1(1 . ) and 
anti-preS 1.
2 
 antibodies could also be detected in those antibody. They also elicited 
antibodies cross-reactive with native HBsAg at a lesser extent. Anti-preS l(l. ) and 
anti-preS 1 .2 antibodies could also be detected in those immunised with HBcAg 
fusion proteins carrying preS 1 and preS 2 fragments. 
5.5.1 T-cell epitopes within the HBcAg fusion protein 
In mice, several synthetic peptides derived from the HBcAg sequence induced 
proliferation of HBcAg-primed T lymphocytes from several congenic strains, but 
HBcAg was more efficient in eliciting proliferation of HBcAg-specific T lymphocytes 
than were the synthetic peptides (Milich et al., 1987b). Reciprocally, Immunisation 
of mice with the synthetic peptides elicited T-cells that recognised native HBcAg.' 
However, the efficiency of the recognition varied from peptide to peptide and within 
responding strains, some peptide-primed T cells responded preferentially to the 
peptide. T-cell epitopes are localised between amino acid residues 85 and 140, 
depending on the H-2 haplotype of mouse strain. For example, H-2 8 and H-2" strains 
recognised amino acids 120-140, H-2f and strains recognised amino acids 100-
120, and 112d  strain recognised 85-100 predominantly. In humans, the dominant T -
cell epitopes of HBcAg were identified within amino acids 111-130 and 51-70 from 
patients with chronic HBV infection (Daniels etal., 1992). Significantly more patients 
with CAH than with CPH or normal controls showed T-cell proliferative response to 
amino acids 111-130. In contrast, three out of six patients with CPH and none of 
those with CAH responded to amino acids 51-70. 
The results obtained in the studies described here show that in rabbits the hybrid 
HBcAg particle consisting of amino acids 3-144 of HBcAg as well as the epitopes 
from HBV envelope proteins was an efficient immunogen in terms of T-cell activation 
as measured by the in vitro lymphocyte-proliferative response to HBcAg and HBcAg 
fusion protein. Since the HBsAg-specific T-cell response was much weaker and less 
consistent than HBcAg-specific T-cell response, the high response to the HBcAg 
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fusion protein was most likely attributable to the HBcAg sequence within the hybrid 
particle. It has been shown that HBcAg was approximately 100-fold more efficient 
than HBsAg in eliciting T-cell response in mice (Milich et al., 1987b). In high 
HBcAg-responsive strains of mice, HBcAg-primed T-cells isolated from the popliteal 
lymph nodes responded to HBcAg in vitro at a concentration as low as 0.03 ng/ml, 
which was equivalent to 0.0014 nM. In the work described here, rabbits immunised 
with the HBcAg fusion proteins responded in vitro to HBcAg at a concentration only 
as low as 0.0625 g/ml, which corresponded to 2.98 nM. Although the T-cell 
response to HBcAg seemed to be less efficient in rabbits than in mice, the different 
T-cell response might be due to the differences in species, the dose for immunisation, 
the injection route, or the source of T cells for the in vitro assay. It is also 
noteworthy that HBcAg-specific T-cell response was much higher than HBsAg- or 
preS 1-specific T-cell response in rabbits immunised with the HBcAg fusion proteins, 
which is consistent with the previous results from mice (Milich et al., 1987b) and 
humans (Ferrari et al., 1990). 
Ferrari et al. (1990) found that patients with acute hepatitis B showed high levels of 
proliferative response to HBcAg and HBeAg, while in patients with chronic HBV 
infection the levels of T-cell response to HBcAg and to HBeAg were lower than those 
observed during acute infection. However, T-cell responses to the S protein, preS 1 and 
preS2 peptides were only rarely and transiently present, and then only at low levels, 
during acute and chronic infections. Furthermore, that the time of appearance of a 
detectable T cell response to HBcAg is correlated with the time of clearance of 
HBsAg from the serum suggests that the amplification of the anti-HBs B cell response 
might occur via a direct cell-cell interaction of HBcAg-specific T cells with HBsAg-
specific B cells through the "intermolecular-intrastructural" mechanism described by 
Milich et al. (1987c). In addition to this mechanism, HBsAg-specific T and B cell 
responses might be augmented by the release of antigen-nonspecific lymphokines by 
activated HBcAg-specific T cells. This mechanism was also observed in B10.S mice, 
a HBsAg non-responder strain, immunised with HBcAg and HBsAg simultaneously 
in the work herein (Table 5.23). In mouse experiments, splenocytes from BALB/c or 
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B10.S mice primed with HBcAg followed by challenge with HBcPreS 1PreS 2S elicited 
weak lymphocyte-proliferative responses to HBcAg and the HBcAg fusion protein, as 
did the mice injected with HBcAg or HBcPreS 1PreS2S only (data not shown). 
Nevertheless, no lymphocyte-proliferative response to HBsAg, preS 1 or preS2 peptide 
was observed in any group of mice examined (data not shown). 
Unlike the conformational B-cell epitopes, T-cell epitopes on the major protein are 
sequential. Reduced, alkylated, formic acid-denatured HBsAg as well as denatured 
major protein (P25) isolated from HBsAg and tryptic fragments of P25 were all 
recognised by HBsAg-specific T cells, when used for immunisation, for they elicited 
an HBsAg-specific T-cell response (Milich et al., 1985c). In attempts to identify the 
sequences recognised by HBsAg-primed T cells from congenic strains of mice, several 
synthetic peptide analogues were screened for their ability to induce proliferation of 
these cells. The active peptides were distinct for different congenic strains of mice. 
The peptides encompassing amino acids 38-52, 95-109, 110-137 and 140-154 of the 
major protein were found to elicit T cell proliferation (Milich et al., 1985c). 
However, these peptides were much less efficient in eliciting T-cell proliferation than 
were equimolar quantities of HBsAg. The same authors also reported that peptides 
S(110-137) and S(38-52) stimulated T cells isolated from some HBV vaccinees. 
In humans, Celis et al. (1988) used CD4 cell lines isolated from HBV vaccinees to 
localise the dominant T cell èpitope near the N-terminus of the major protein. A 
single peptide S(4-33) contained a dominant T cell epitope and was highly efficient 
in eliciting T cell proliferation to the same extent as equimolar concentrations of 
formic acid-denatured HBsAg. The shortest peptide carrying a dominant epitope 
recognised by both helper and cytotoxic T cells was S(19-28) having the sequence 
with 9 amino acids common to all HBV subtypes. Recently, Greenstein et al. (1992) 
established 54 human T cell lines from individuals immunised with recombinant 
HBsAg vaccines. It was found that the peptide S(19-33) elicited significant 
proliferation in T cell lines derived from 50 donors. This universal T-cell epitope, 
which was recognised in donors of many different HLA-DR and HLA-DQ haplotypes, 
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was employed to construct a chimaeric peptide containing S(19-33) and the third V 
region loop structure (V3 loop) of HIV-1 envelope gp120. The BALB/c mice 
immunised with this chimaeric peptide were found to elicit potent S(19-33)-specific 
T-cell responses and anti-V3 loop antibodies that bound to the native gp120 
(Greenstein et aL, 1992). In the work described here, ten out of thirteen rabbits 
immunised with HBcAg fusion proteins carrying the HBs (lll.. fragment responded 
to native HBsAg (S.I..-&2.1) in vitro in some stage of the experiments. However, the 
HBsAg-specific T-cell responses were variable among rabbits. That the HBS (lll..l-
primed rabbits elicited an HBsAg-specific T-cell response suggests that the T-cell 
epitope for rabbits, whether dominant or not, existed within HBs (1Il ..1 sequence. 
Reciprocally, whether immunisation with native HBsAg in rabbits could elicit T cells 
that would recognise HBs(lll..lS peptide remains unknown. The result from R701 also 
shows that denatured HBsAg-primed T-cells could recognise native HBsAg in vitro. 
Several synthetic peptides [preS l(121), preS l(1232) , preS l(3253)1 preS l(5374) and preS l(I1,\,1 
from the preS 1 region of the adw2 subtype, which contains 11 more amino acids at the 
N-terminus compared with the adyw subtype used in the studies described here, 
elicited the proliferation of T cells from mice primed with HBsAg containing the preS 1 
sequence (Milich et al., 1986a). The highest proliferation was elicited by peptide 
preS 1(12.32). In reciprocal experiments, T cells from mice primed with preS 1(12-32)  or 
preSl(ll.l) were induced to proliferate by both the homologous peptide and HBsAg 
containing the preS 1 sequence (Milich et al., 1987a). The smallest peptide that elicited 
an efficient, preS 1-specific, T-cell proliferative response in vitro was preS l(1221). In 
human studies, 7 out of 11 individuals immunised with plasma-derived HBsAg 
vaccines containing low amounts of preS 1 and preS2 antigens showed detectable levels 
of T-cell response to preS 1 (Ferrari et al., 1992). Two peptides spanning residues 21-
48 of the preS 1 region (21-30 and 29-48) were stimulatory for 4 and 3 distinct 
subjects, respectively. Two further T-cell recognition sites within preS 1 for humans 
were defined by peptides 81-95 and 94-108. The T-cell epitope defined by preS l(1)  
in humans was also identified in the murine, study (Milich et al., 1985c). In the work 
described here, 5 out of 9 rabbits immunised with HBcAg fusion proteins carrying the 
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preS l(120) fragment, which corresponded to preS l(1231) of adw2 subtype used in the 
previous reports (Milich et al., 1986a and 1987a; Ferrari et al., 1992), elicited T-cell 
responses to the preS l(l)  peptide. These results indicate the existence of the T-cell 
epitope for rabbits within preS 1(1 , which was identified in the murine system (Milich 
et al., 1987a). The T-cell epitopes described above are shown in Figure 5.12. 
In regard to preS 2 region, HBsAg/p33-primed T cells from a number of murine strains 
were induced to proliferate by peptides from the C-terminal half of the preS 2 region 
encompassing residues 29-55, within which 17 distinct T-cell sites were identified 
(Milich et al., 1990a). The fine specificity of T-cell recognition of preS 2 was 
dependent on the H-2 haplotype of the responding strain and was subtype specific. 
Reciprocally, the ability of these synthetic peptides to elicit T-cells cross-reactive with 
the native HBsAgIp33 was variable and depended on the nature of the immunising 
peptide. Although preS 1 . peptide contains the neutralising B-cell epitope (Neurath 
et al., 1986) and the T-cell epitope in mice (Milich et al., 1986c), the inability of 
preS 1 -primed T cells to recognise the native preS 2 region indicates that T-cell 
recognition sites on the native preS 2 region are not identical to those on the synthetic 
preS 1..2 peptide. In the work described here, none of the rabbits immunised with the 
HBcAg fusion proteins carrying the preS 1 fragment elicited T-cell response to the 
corresponding peptide in vitro, suggesting that the T-cell epitopes recognised by 
rabbits and by mice may be different or T-cell epitopes on the preS2(1-2.  sequence 
within the HBcAg fusion proteins may not be identical to those on the synthetic 
preS 1 peptide. The immunodominant T-cell sites within preS 2 region for humans 
remain to be identified. 
5.5.2 B-cell epitopes within the HBcAg fusion proteins 
All the HBcAg fusion proteins elicited high levels of anti-HBc antibody, indicating 
the fusion of peptide epitopes at the C-terminus of the truncated HBcAg consisting of 
residues 3-144 did not change the antigenicity (see Chapter 4) and immunogenicity 
of HBcAg. Furthermore, the high anti-HBc response was correlated with high 
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Figure 5.12 T-cell epitopes of the preS 1 region. The amino acid sequences of the 
preS 1 region for adyw and adw2 subtypes are shown in the single-letter code. Lines 
below the sequences denote T-cell epitopes identified in rabbit (this study), mouse 
(Milich et al., 1985c) and humans (Ferrari et al., 1992). 
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HBcAg-specific T cell response in rabbits, which is in agreement with previous results 
in mice (Milich and McLachlan, 1986, Milich et at., 1987b). An immunodominant, 
linear HBcAg determinant was mapped to amino acids 107-118, as the corresponding 
peptide reacted with human anti-HBc sera and mouse anti-HBc MAbs. In addition, 
the peptide elicited antibodies that blocked the binding of polyclonal human anti-HBc 
to HBcAg (colucci et at., 1988). A single conformational determinant around amino 
acid 80 of HBcAg was also identified (see Section 4.5; Salfeld et at., 1989). 
Most HBsAg B-cell epitopes, either group or subtype specific, are dependent on the 
conformation of HBsAg particles, because they are destroyed by reduction and 
alkylation (Sukeno et al., 1972; Vyas et al., 1972). The major protein is rich in 
cysteine residues (in residues 48, 65, 69, 76, 90, 107, 121, 124, 137, 138, 139, 147, 
149 and 221), some of which are believed to contribute to the conformation of HBsAg 
particles and also to that of the P25 molecule by making inter- and intra-molecular 
disulphide bonds. A number of synthetic peptides derived from the major protein 
have been evaluated for the ability to raise antibodies that could recognise native 
HBsAg, in attempts to develop synthetic vaccines. Most of the studies with synthetic 
peptides have focused on the region encompassing residues 110-150 of the major 
protein as this represents one of the two relatively more hydrophilic domains on the 
protein. The HBs sequence used for fusion to HBcAg in the work described here also 
encompasses residues 111-156. The peptide containing residues 138-149 of the major 
protein, with four cysteine residues replaced by a-am inobutyric acid in order to 
prevent polymerisation and other side reactions, when conjugated onto human 
erythrocytes and injected in mice, was found to induce anti-HBs antibody (Prince et 
al., 1982). Moreover, it was shown that residues 139-147 represented the total or an 
essential part of the a determinant of HBsAg (Bhatnagar et al., 1982). However, the 
antigenicity and immunogenicity (after coupling to KLH) of the peptide were very low 
in comparison with native HBsAg. The level of anti-HBs antibody elicited by peptide 
135-155 conjugated to a carrier protein was also low as compared with anti-HBs level 
elicited by native HBsAg (Neurath et al., 1982). In the studies described here, the 
levels of anti-HBs antibody response elicited by HBcAg fusion proteins carrying the 
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HBs(1ll ..l  fragment in rabbits and in BALB/c mice were also lower than those elicited 
by native HBsAg. It proved difficult to mimic these conformational epitopes by linear 
synthetic peptides. This problem was partially overcome by using cyclic peptides 
generated by intra-molecular disulphide bond formation between cysteine residues 
present in the peptides (Dreesman et al., 1982; Brown et al., 1984). 
Two cyclic peptides containing disulphide bonds in the region between residues 117-
137 and 122-137 were shown to elicit an anti-HBs response in mice after a single 
injection without linkage to a protein carrier (Dreesman et al., 1982). The cyclic 
peptide 122-137 was also demonstrated to contain an a antigenic determinant that was 
dependent on conformation and a sequential y subtype epitope (lonescu-Matlu et al., 
1983). The a epitope contained within residues 139-147 appears to be a 
conformational one since a cyclic form of the corresponding synthetic peptide was 
recognised with higher affinity than the linear analogue (Brown et al., 1984). 
Although cyclic peptides as putative a epitope mimetics have been reported, there is 
evidence to suggest that this may not represent the whole picture. Gerin et al. (1983) 
found that the a determinant was composed of at least three nonoverlapping 
sequences. Recently, Manivel et al. (1992a and 1992b) showed that a synthetic 
peptide containing 124-147 of the major protein spontaneously self-oligomerised to 
reconstitute three distinct a epitopes that included one between residues 124-137, 
another between residues 139-147, and the third epitope including residues met 133 and 
1ys 141 . 
Studies in the preS 1 region (adw2 subtype with 119 residues) localised residues 32-53 
and 94-117 as antibody binding sites for humans and mice, as well as 1-21 and 12-32 
for additional sites for humans, as the corresponding synthetic peptides, when used as 
solid phase antigens, bound sera from mice immunised with P39/HBsAg or from 
humans collected during or soon after acute HBV infection (Milich et al., 1986a). 
Attachment of purified HBsAg particles to cultured hepatoma cells (Neurath et al., 
1985) or isolated plasma membranes from fresh human liver (Pontisso et al., 1989a) 
has been described and attributed to amino acids 21-47 in the preS 1 domain of the 
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large protein (Neurath et al., 1986; Pontisso et al., 1989b). When conjugated to a 
carrier protein, preS l(21 elicited antibodies protective against HBV infection in 
chimpanzees (Neurath et al., 1989; Thornton et al., 1989). 
The unconjugated peptide containing the complete 55 amino acid residues of the preS 2 
region (adw subtype) has been shown to protect 4 out of 4 chimpanzees from HBV 
infection of either the ad or ay subtypes (Emini et al., 1989). Residues 1-26 of the 
preS2  region have been shown to represent a dominant antibody binding site (Neurath 
et al., 1984; Milich et al., 1985d), and Thornton et al. (1987), using preS 1 
conjugated to KLH for immunisation, reported that chimpanzees were protected 
against HBV infection. Itoh et al. (1986), using preS 132) also conjugated to KLH, 
demonstrated protection in two chimpanzees. T-cell studies by Mulch et al. (1986c) 
with these two peptides showed that the T-cell epitope resided within residues 1-13 
and the B-cell epitope was located in the 14-26 region, indicating that preS 1 
contained both T- and B-cell epitopes, whereas preS 1432) contained only a B-cell 
epitope and would require a carrier protein. Indeed, it has been shown that free 
preS 1. emulsified in oil was protective against HBV infection in 2 chimpanzees 
(Thornton et al., 1989). Cumulatively, these results indicate that synthetic peptides 
derived from either the preS 1 or the preS2 region can individually elicit protection 
against HBV infection. The preS 1 fragment used in the studies described here 
encompasses residues 1-20 of an adyw subtype with 108 residues, which corresponds 
to residues 12-31 of an adw2 subtype. The rabbits and BALB/c mice immunised with 
HBcAg fusion proteins carrying the preS l(l) and preS 1 fragments elicited 
antibodies against the corresponding peptides. 
5.5.3 Enhanced immunogenicity of the HBcAg fusion proteins 
HBcAg-specific T cell response may provide functional help for the production of the 
anti-envelope antibodies. The inclusion of preS 1 and preS2 epitopes to the HBcAg 
fusion proteins appeared to enhance the immunogenicity in terms of anti-HBs 
production. 
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5.53.1 T-cell help for antibody production 
In the studies described here, very efficient T-cell responses specific to HBcAg and 
HBcAg fusion protein were elicited by the rabbits immunised with the HBcAg fusion 
proteins. However, only moderate to weak HBsAg- and preS 1-specific T cell 
responses were induced, and no preS 2-specific T cell response was observed. 
Nevertheless, antibodies against preS l(l) and preS 1 . peptides were produced in 
these rabbits. These results suggest that the source of T-cell help for the anti-preS 2 
production was attributed to the HBcAg-specific T cells. Furthermore, in R699 and 
R700, anti-preS l(123)  antibody was produced despite the failure to activate preS 1-
specific T cells; the HBcAg-specific T cells might contribute Th-cell function for anti-
preS 1  antibody production. Similarly, the results from some rabbits, eg. R675, R676, 
R700, R792 and R703, also suggest that the HBcAg-specific T cells might provide Th 
function for the production of anti-HBs antibody. However, in R703, a preS 1-specific 
T cell response was induced, but no anti-preS l(l. ) antibody was produced. In R702, 
the absence of preS 1-specific T cells correlated with the absence of anti-preS 1 
antibody. The variable responses were most likely attributed to the different 
haplotypes among outbred rabbits used in the studies. Recently, it was reported that 
immunisation of mice with hybrid HBc/preS particles exclusively primed Th cells 
specific for HBcAg and not for the inserted epitopes, even if the inserted sequence 
contained a T-cell epitope for that strain of mice (Schodel et al., 1992). This result 
suggests that the mere inclusion of a T-cell epitope in the inserted sequence does not 
guarantee that it will be functional in the context of the hybrid particles. One possible 
explanation is that the T-cell epitope within the hybrid HBcAg particles may be 
processed differently from that within the native protein. The other explanation is that 
intramolecular competition between T-cell epitopes might occur (Perkins et al., 1991). 
It has been indicated that immunodominance of the T cell response is not simply a 
function of the primary amino acid sequence, but is a function of the context of the 
epitope within the protein molecule (Perkins et al., 1991). It has also been suggested 
that immunogens are probably polar, since the orientation between the T- and B-cell 
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epitopes in a synthetic immunogen could affect immunogenicity (Golvano et a4.  1990; 
Milich et al., 1990c). Therefore, the orientation between the T- and B-cell epitopes 
within the HBcAg fusion proteins might result in the difference in immunogenicity. 
Nevertheless, it appears that the ability of the HBcAg to induce a strong HBcAg-
specific Th-cell response in the context of multimeric B-cell epitopes may explain the 
carrier effects of HBcAg particles. 
The T cell-independent nature of HBcAg raises the possibility of immunisation to 
immunodeficient patients with HBcAg fusion proteins carrying peptide epitope(s). It 
was demonstrated that anti-HBc and anti-HRV2 (Human rhinovirus type 2) antibodies 
were elicited in outbred nude mice immunised with HBcAg fusion proteins carrying 
peptide epitope HRV2, although the immunogenicity was much poorer than that seen 
in euthymic mice (Francis et al., 1990). HBcAg fusion proteins carrying preS l(l2 
sequence at the N-terminus through a pre-core linker sequence also elicited low levels 
of anti-HBc and anti-preS 1 antibodies in BALE/c (nu/nu) athymic mice (Schodel et 
al., 1992). 
5.5.3.2 Inclusion of preS1 and preS2 epitopes to the HBcAg fusion proteins 
The results presented in this work indicate that HBcPreS 1PreS2S was superior to HBcS 
in terms of the titres and onset of production of anti-HBs antibody, suggesting that the 
inclusion of preS 1 and preS2 epitopes to the HBcAg fusion proteins enhanced the 
immunogenicity with regard to anti-HBs production. However, HBcAg fusion proteins 
carrying the preS 1 and preS2 as well as a dimer of HBs (11l. lS sequences, ie. 
HBcSPreS 1PreS2S did not enhance, and even decreased the immunogenicity in eliciting 
anti-HBs antibody compared with those carrying preS 1 and preS2 as well as a single 
HBs 11115 sequence, ie. HBcPreS 1PreS2S. The possible explanation for the enhanced 
immunogenicity of HBcPreS 1PreS2S might be that the HBs(lll.. l fragment in the 
context of the fusion particle might be more surface accessible than that in HBCS, as 
HBcPreS 1PreS2S appeared to be more potent than HBcS in terms of HBs antigenicity, 
which rendered HBcPreSPreS 2S more immunogenic than HBCS in inducing anti-HBs 
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antibody. The double insertion of the HBs (lll . I sequence in the HBcAg fusion 
proteins might also result in a different arrangement of the antigenic sites, such as a 
decrease of the surface exposure, which did not favour the induction of the anti-HBs 
antibody, since the surface exposure of the antigenic fragment usually correlates well 
with its capacity to induce antibody against the corresponding antigenic site. With 
regard to the anti-peptide antibodies against preS l(l. ) and preS 1 induced by the 
HBcAg fusion proteins containing preS 1 and preS2 fragments, only one out of three 
rabbits immunised with HBcAg fusion proteins carrying a dimer of the HBs (llllS as 
well as the pres 1 and preS2 fragments produced anti-preS 1 and anti-preS2 antibodies, 
while all rabbits immunised with HBcAg fusion proteins carrying a monomer of the 
HBs(lll .l as well as the preS 1 and preS 2 fragments produced anti-peptide antibodies. 
Again, the preS 1 and preS 2 sequences in the context of HBcSPreS 1PreS2S might cause 
structural constraints that limit surface exposure of these antigenic sites. 
It has been reported that proteins containing multiple copies of the peptide 
encompassing amino acids 137 to 162 of VP1 from FMDV fused to the N-terminus 
of -galactosidase were greatly superior to that containing a single copy of the peptide 
in eliciting anti-peptide and neutralising antibody (Broekhuijsen et al., 1987). The 
addition of a cysteine residue to the C-terminus of uncoupled synthetic FMDV 
peptides resulted in the formation of dimers, and also enhanced their immunogenicity 
(Francis et aL, 1987a). Therefore, the enhanced immunogenicity of the peptide fused 
to HBcAg could also result from the increased epitope density presented on the core 
particles. However, double copies of the HBs (lll.lS sequence within HBcAg fusion 
proteins did not further improve the immunogenicity of the particles in the work 
described here. 
Clarke et al. (1987) compared the immunogenicity of the peptide encompassing amino 
acids 141-160 of the VP1 protein of FMDV in different presenting systems. On a 
weight for weight basis, the peptide on HBV core particles was about 30-40 times 
more immunogenic than, a peptide/-galactosidase fusion protein containing tandem 
copies of the FMDV epitope, 500 times more immunogenic than free synthetic 
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peptide, and almost as immunogenic as inactivated FMDV particles. It has also been 
demonstrated that rhinovirus peptide/HBcAg fusion proteins were 10 times more 
immunogenic than the peptide coupled to KLH and 100 times more immunogenic than 
uncoupled peptide with an added Th-cell epitope (Francis et al., 1990). Within the 
HBcAg particles, the position of the inserted epitope affected the immunogenicity of 
the hybrid particles. Recently, Schodel et al. (1992) showed that insertion of a preS 1 
epitope between amino acids 75 and 83 of HBcAg, which had previously been 
suggested to represent a dominant antibody-binding site, resulted in the most efficient 
anti-preS 1 antibody response compared with C- and N-terminal fusions. In addition, 
the N-terminal fusion through a pre-core linker sequence was more immunogenic than 
the C-terminal fusion to the truncated HBcAg at amino acid 156. A preS 1 epitope 
fused directly to the N-terminus of the full-length HBcAg was not surface accessible 
and not immunogenic. It has also been shown that the HBcAg fusion proteins 
carrying insertions at the N-terminus through a pre-core sequence and internal fusions 
between amino acid 80 and 81 of HBcAg both induced good anti-peptide antibody 
responses, whereas those carrying insertions at the C-terminus of the full-length 
HBcAg did not induce anti-peptide antibody (Yon et al., 1992). Since different 
epitopes were fused to the HBcAg particles as well as different species and 
immunisation regimens were used, it is difficult to compare the immunogenicity data 
presented in this work and those described earlier. 
Apart from the use of CFA and IFA as adjuvants, Francis et al. (1990) compared the 
immunogenicity of HBcAg fusion proteins in IFA, aluminum hydroxide, which is 
acceptable for use as an adjuvant in humans, and in the absence of adjuvant. 
Although IFA gave the greatest response after primary immunisation, aluminum 
hydroxide was a suitable adjuvant after single reinoculation. Furthermore, the hybrid 
HBcAg particles were also immunogenic, in the absence of adjuvant although the 
primary response was about 10-fold lower than the responses to the adjuvanted 
preparations. Therefore, adjuvantation probably does not cause problems for the 
practical application of HBcAg fusion protein as vaccines. It has been reported that. 
HBcAg fusion proteins carrying rhinovirus epitopes could elicit antibody responses 
227 
against HBcAg and the fused peptide after nasal or oral administration to BALB/c 
mice (Francis et al., 1990). Schodel et al. (1990) also showed that mice orally fed 
with the recombinant Salmonella expressing HBc(llllSWpreSl)  fusion protein 
developed high titres of serum antibodies against HBcAg and lower titres of antibodies 
to preS2. These results suggest that it may be possible to use HBcAg as a carrier for 
the development of synthetic peptide-based oral vaccines. 
5.5.4 Antibody responses to fusions carrying wild-type and mutant HBs segments 
The HBcAg fusion proteins carrying the HBs (llll fragments (derived from adyw 
subtype, but exhibiting y subtype), either wild-type or 3 g1y 145 mutants, in a monomer 
or a dimer, induced anti-peptide response that cross-reacted equally with native 
HBsAg of both ayw and adw subtypes, suggesting that the anti-HBs (lll.lS peptide 
antibodies were directed toward a group-specific epitope on HBsAg. Furthermore, 
rabbit anti-HBs antibody raised against native HBsAg reacted with 1­113s (111 _ 156) peptide 
corresponding to the inserted HBs fragment in the hybrid HBcAg particles. The 
immunological cross-reactivity between antisera raised against HBcAg fusion proteins 
carrying-the HBs (ll . lS fragment and against native HBsAg was further assessed by 
two competition RIAs. First, antiserum raised against HBcAg fusion protein carrying 
the HBs(llll fragment inhibited the binding of anti-HBs antibody to HBsAg. 
Secondly, antiserum raised against HBcAg fusion protein carrying the HBs (l1115 
fragment also inhibited the binding of anti-HBs antibody to HBs(lll .. lS peptide. 
Collectively, these results indicate that polyclonal anti-HBs antibody and polyclonal 
anti-HBs(lll.l antibody raised against HBcAg fusion protein carrying the HBs (llllS 
fragment recognise either a common or overlapping determinant on the HBs (llllS 
sequence. Since HBV cannot be propagated easily in vitro and standard virological 
techniques of detecting neutralising antibody are not available, chimpanzee-challenge 
studies are the only way to evaluate whether the anti-peptide antibodies induced by 
HBcAg fusion proteins containing the HBs (llllS or/and preS l(l) and preS 1 
fragments are virus-neutralising. 
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The emergence of an escape mutant that has undergone glycine to arginine substitution 
at amino acid 145 in the major protein of the HBsAg, under pressure of an HBV 
vaccine-induced response, indicates that the current vaccines may induce a host 
response that is lacking in some component(s) induced during recovery from natural 
HBV infection. Recently, this escape mutant has been shown to be capable of causing 
hepatitis in chimpanzees inoculated with serum (10 dilution) from the infected 
patient, which contained only the mutant virus detected by PCR (Ogata et al., 1993). 
Waters etal. (1992) demonstrated that immunisation of mice with recombinant HBsAg 
carrying this mutation, although eliciting a high titres of antibody that recognised the 
mutant HBsAg, produced 100-fold lower antibodies recognised the wild-type HBsAg. 
The HBcAg fusion proteins containing g1y 145 mutant sequence of HBs (ll1 . 1S , eg. 
HBcS,4.sR and HBcPreS 1PreS2S 14 , might be useful for evaluation of their efficacy to 
protect against this g1y 145 mutant virus. In addition, an ideal vaccine should induce 
a broader repertoire of protective antibodies against both wild-type and mutant viruses. 
One approach to achieve this goal would be combining various epitopes or different 
sequences of the same epitope, either on the same particle or in a cocktail of particles. 
In this respect, the HBcAg fusion proteins carrying one wild-type and one mutant 
sequence of the HBs (tllls fragment, eg. HBcSPreS 1PreS 2S 14 , HBcSPreS 1PreS2S 14 , 
HBcS 14 PreS 1PreS2S, and HBcS 14 PreS 1PreS 2S, could be evaluated for their efficacy 
to protect chimpanzees against both wild-type and mutant HBV. By cotransformation 
with different plasmids carrying different fusion genes, it is possible to obtain mixed 
HBcAg particles presenting both wild-type and mutant fragments fused to different 
molecules of HBcAg, but assembled into the same particle. With the HBsAg system, 
it has been demonstrated that mixed particles presenting both authentic HB5Ag and 
HBsAg fusion protein carrying poliovirus epitope elicited much higher antibody 
responses to HBsAg and poliovirus epitope than those elicited by the hybrid HBsAg 
particles consisting of the fusion protein only (Delpeyroux et al., 1988). It is tempting 
to speculate that the enhanced immunogenicity of the mixed particles consisting of 
both HBsAg and HB5Ag/polio fusion protein might be partly attributed to the 
"intermolecular-intrastructural" helper mechanism provided by the HBsAg-specific T 
cells. 
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In an attempt to induce a broadly cross-reactive neutralising antibody, another 
approach would be changing the antigenic specificity of the neutralising epitope by 
substitution of amino acid residue(s). However, this approach appears to be quite 
empirical. Ashton-Rickardt and Murray (1989b) demonstrated that the antigenic 
subtype of HBsAg altered from y4d to yd by combining the substitution of serine 1 
by threonine with the replacement of arginine, 22 by lysine, or of tyrosine Lu by 
phenylalanine, or both of these changes in the major protein of HBsAg. Recently, 
broadly cross-reactive CTLs capable of effector function against a wide range of HIV 
isolates have been generated by using substituted peptides within the V3 loop of 
gp160 of HIV-1, which contains an immunodominant determinant for CTLs, as in 
vitro stimulants for the spleen cells from mice immunised with gp160 (Takahashi et 
A, 1992). The competitive binding studies described in this work show that the 
antibodies raised against HBcS, HBcS 14 , HBcS 14 , HBcS14.5K or HBcPreSiPreS2Sl4SR  
recognised a common or overlapping epitope within the HBs (l1l . 15 sequence as 
compared with anti-native BBs antibody. It would be of interest to examine the cross-
reactivity of the antisera raised against HBcAg fusion proteins carrying g1y 145 mutant 
sequence of the HBs(llllS fragment with the gly 145—'arg escape mutant HBsAg. The 
HBcAg fusion proteins carrying g1u 145 or l5 45 mutant HBs(llllS sequences, eg. 
HBcS,45E, HBcS 145K and HBcPreSPreS2SI45E might be exploited in this direction. 
However, whether these HBcAg fusion proteins can induce a broadly cross-reactive 
neutralising antibody remains to be answered. 
The work described here shows the enhanced immunogenicities of the HBV envelope 
epitopes fused to the C-terminus of the truncated HBcAg. The highest anti-HBs 
responses of the HBcAg fusion proteins were seen in rabbits immunised with HBcAg 
fusion protein carrying the HBs (11l fragment accompanied with preS l(120) and 
preS 1 fragments. This HBcAg fusion protein, HBcPreS 1PreS 2S, consists of HBcAg 
as well as three different envelope epitopes from preS 1 , preS 2, and S regions, which 
may induce an immune response that more closely mimics that induced after natural 
HBV infection. The high HBc-specific T-cell response may also augment the 
production of the antibodies against the three envelope epitopes. Although there is 
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no evidence from clinical trials to prove that HBV vaccines containing the S and preS 
regions are superior to those containing only the S protein, the use of HBcAg as a 
carrier for HBV envelope epitopes with or without introducing mutant sequences 
provides a tempting approach for the development of a multivalent vaccine against 
wild-type HBV and its escape mutants. 
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HBcAg is a potent immunogen in terms of T cell activation and antibody production. 
Furthermore, HBcAg can induce antibody production via both T-cell dependent and 
T-cell independent pathways (Millich and McLachlan, 1986). It has been shown that 
HBcAg contains epitopes that stimulate Th cells in mice and that animals primed with 
HBcAg or particular peptides within this sequence when challenged with HBV 
produced antibodies to HBsAg, including the preS epitopes, as well as HBcAg (Milich 
et al., 1987c). This result may well explain the rapid appearance of high levels of 
anti-HBs, which is virus neutralising, and elevated levels of anti-HBe in chimpanzees 
that had been immunised with HBcAg or HBcAg and HBeAg and subsequently 
challenged with HBV (Murray et al., 1984 and 1987). HBcAg-specific Th cells could 
induce anti-S antibody through " intermolecular- intrastructural" Th cell-B cell 
interaction in mice that did not respond to the S protein provided that HBcAg and 
HBsAg be present within the same particle. Therefore, HBcAg may serve as a 
particulate, carrier protein for presentation of peptide epitopes. 
Several gene fusions were constructed in which coding sequences for epitopes from 
the envelope proteins of HBV, including the S, preS and preS 2 regions, were linked 
to those for the C- or both termini of truncated HBcAg. All plasmids expressing 
fusion proteins contain the coding sequence for amino acid residues 3-144 of HBcAg 
fused to C-terminus of the first 8 amino acid residues of -galactosidase via a 
tripeptide linker sequence. The HBcAg fusion proteins carrying the epitopes at the 
C-terminus were expressed efficiently in E. coli and the products assembled to form 
particles morphologically similar to HBcAg itself and were soluble, which allowed 
easy purification. However, when HBcAg carried both the S epitope at the N-
terminus as well as the preS 1 and preS2 or/and the S epitopes at the C-terminus, ie., 
SHBcPreS 1PreS2 or SHBcPreS 1PreS2S, the fusion proteins, although still formed 
particles, were aggregated which hampered their purification. The largest HBcAg 
fusion protein containing 318 amino acid residues, in which 165 residues from the 
sequences of the S, preS 1 and preS2 domains were attached at the C-terminus of 
residue 144 of HBcAg, compared with 183 of the normal HBcAg polypeptide, could 
still be tolerated to form core-like particles. 
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The emergence of an escape mutant with an amino acid substitution from glycine to 
arginine at amino acid residue 145 of HBsAg which cannot be neutralised by vaccine-
induced anti-HBs antibody provided the impetus for constructing the fusions with the 
immunodominant region of the S protein, HBs (lll..l carrying mutations at residue 145 
of HBsAg in which glycine was replaced by arginine, glutamic acid or lysine. On the 
basis of these mutant sequences, fusions were also constructed carrying a dimer of 
HBs(lll.l , one from wild-type and the other from a mutant sequence, accompanied 
by preS 1 and preS2 sequences, with the aim of creating multivalent immunogens based 
on HBcAg which might induce antibody with a wider specificity to confer immunity 
against HBV infection, including antigenic variants. 
All HBcAg fusion proteins retained HBc antigenicity and immunogenicity in terms of 
T-cell activation and antibody response. In all cases animals immunised with the 
fusion proteins mounted strong T-cell-proliferative responses to HBcAg, which may 
provide Th cells for augmentation of antibody production against the inserted epitopes. 
The HBcAg fusion proteins containing HBS(Ill . lS , either wild-type or g1y 145 mutants, 
displayed HBs antigenicity in immunoblot analysis. The HBs antigenicity could also 
be .detected, although weaker than the native HBsAg, within the HEcAg fusion 
particles in the antigen-capture RIA in which the particles were first trapped on the 
solid phase with human anti-HBc antibody and then examined for the presence of anti-
HBs reactive epitopes, ie., the HBs antigenicity, on the surface of the particles using 
rabbit anti-HBs antiserum and radiolabelled second antibody (anti-rabbit 
immunoglobulin) as the probe. However, they showed little HBsAg antigenicity in 
a standard solid-phase RIA in which the HBsAg present on the fusion particles is 
sandwich-captured by two anti-HBs antibodies, one immobilised on the solid phase, 
the other radiolabelled as the probe. 
The weak HBs reactivity of the HBcAg fusion proteins might be due to different 
presentation of the HB5 (111156) segment on the fusion particles from that on the native 
HBsAg. The HBs (111156) segment within the hybrid HBcAg particles, however, could 
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elicit T-cells capable of recognising native HBsAg, although weaker and less 
consistent than those specific to HBcAg. Furthermore, the HBcAg fusion proteins 
carrying HBs(lll..l segment, not only wild-type but also three g1y 145 mutants, induced 
antibody responses cross-reactive with wild-type HBsAg determined by a standard 
solid-phase RIA in which anti-HBs present in the immune serum is sandwich-captured 
by two HBsAg molecules, one immobilised on the solid phase, the other radiolabelled 
as the probe. The competitive RIA demonstrates that polyclonal antibody against the 
HBcAg fusion proteins carrying HBs (lll .lS , either wild-type or g1y 145 mutants, and 
polyclonal antibody against native, intact HBsAg recognise either a common or 
overlapping determinant on the HBs (llllS sequence. It would be of interest, therefore, 
to examine the cross-reactivity of the antibody raised against HBcAg fusion proteins 
carrying wild-type or g1y 145 mutant sequence of the HBs (lll. 156) segment with the 
naturally occurring g1y 145-+arg mutant HBsAg. 
The HBcAg fusion proteins carrying the preS 1 and preS2 or/and the S epitopes also 
elicited antibodies to the corresponding peptides, which might be useful for providing 
a broader repertoire of protective antibodies. Some immunised animals also elicited 
T-cell-proliferative responses to the preS 1 peptide. The HBcAg fusion proteins 
carrying the S as well as preS 1 and preS2 epitopes, ie., HBcPreS 1PreS2S, were superior 
to those carrying only the S domain in terms of the quantity and onset of anti-HBs 
production. Nevertheless, the fusions carrying a dimer of the S domain accompanied 
by the preS 1 and preS2 epitopes, ie., HBcSPreS 1PreS2S, appeared to be relatively poor 
immunogens in terms of antibody production against the inserted epitopes. 
These experiments show that the sequence and position of the epitope fused to HBcAg 
may influence the physical and chemical properties of the hybrid particles as well as 
immunogenicity of the inserted epitope. Attempts to induce a broadly cross-reactive 
neutralising antibody against HBV, the use of HBcAg to present multiple epitopes 
from the 5, preS 1 and preS2 regions or to present altered neutralising epitope of the 
S protein may therefore be a practical approach. .The. results illustrate the potential 
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Appendix: Nucleotide sequence of HBV subtype adyw 
The nucleotide sequence of HBV subtype adyw contained in plasmid pHB Vi 30 (Pasek 
et al., 1979; Gough and Murray, 1982; Pugh et al., 1986) is shown. Both strands of 
the complete genome (3182 nucleotides) are shown with the sense strand on top. 
Numbering is by the convention of Pasek et al. (1979), which set number 1 at the start 
of the core ORF. The amino acid sequence of the viral ORFs is shown in their 
respective translational frames. 
ORFs: 
Proteins 	 nucleotide sequences 	amino acid sequences 
pre-core 3096-3182 frame c 
core 1-549 frame a 
polymerase 407-2903 frame b 
preS 1 948-1271 frame c 
preS2 1272-1436 frame c 
surface 1437-2114 frame c 
X 	 2656-3117 	 frame c 
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ATGGACATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTCTCGTTTTTGCCT 
1 ---------+---------+---------+---------+---------+--------- + 60 
TACCTGTAACTGGGAATATTJCTTAAACCTCGATGACACCTCAATGAGAGCAAAAACGGA 




61 ---------+---------+---------+---------+---------+--------- + 120 
AGACTGAACAAAGGAAGCCATCCTCTAGAAGATCTATGGCGGCCTCGAGACATAGCCCTA 




121 ---------+---------+---------+---------+---------+---------+ 180 
CCGAATCTCAGACGACTCGTAACAAGTGGAGTGGTATGACGTGATCCGTTCGTTAAGAA 










241 ---------+---------+---------+---------+---------+---------+ 300 
AGACCCTGGATCATCAGTCAATACAGTTGTGATTACACCCGGATTTCAAGTCTGTTAT 




301 ---------+---------+---------+---------+---------+--------- + 360 
AACACCAAAGTGTAAAGAACAGAGTGAAAACCTTCTCTTTCCAAGATCTCATAAACCAC 




361 ---------+---------+---------+---------+---------+--------- + 420 
AGAAAACCTCACACCTAAGCGTGAGGACGTCGAATATCTCGTGGTTTACGGCGATAGCAT 
as 	SerPheGlyValTrplleArgThrProProAlaTyrArgProproAsnAlaprolleLeu - 
bs pelymerasesMetProLeuSerTyr - 
Cs 
TCAACMTTCCGGAGACTACTGTTGTTAGACCACGATGCAGCTCCCCTAGAAGAAGAACT 
421 ---------+---------+---------+---------+---------+--------- + 480 
ACTTGTGAAGGCCTCTGATGACAACAATCTGCTGCTACGTCCACGGGATCTTCTTCTTGA 
as 	SerThrLeuProcluThrThrValValArgArgArgcysArgserproArgArgArgmr - 
b s GlnHisPheArgArgLeuLeuLeuLeuAspAspAspAlaclyProLeucluGluGluLeu - 
Cs 
CCCTCGCCTCGCAQACGAAGATCTCAATCCCCGCGTCGCAGAQATcTcAATcTccccA 
481 ---------+---------+---------+---------+---------+---------+ 540 
GGGAGCGGAGCGTCTGCTTCTAGAGTTAGCGGCGCAGCGTCTTCTAGAGTTAGAGCCCTT 
a s 	ProSerProArgArgArgArgSerG1nserProArgArgAxgArgserc1nserga1u - 




541 ---------+---------+---------+---------+---------+--------- + 600 
AGAGTTACAATCATAGGGAACCTGAGTATTCCACCCTTTAAAATGACCCGAAATAAGAAG 
at 	SerGlnCysEndTyrProLeuAspSerEnd(core end) 
bt LeuAsnValSerlleProTrpThrllisLysValGlyAsnPheThrGlyLeuTyrSerSer - 
C: 
TACTGTACCTGTCTTTAACCCTCATTCGAAAACGCCCTCTTTTCCTAATATAcATTTA 
601 ---------+---------+---------+---------+---------+---------+ 660 
ATGACATCGACAGAAATTGGGAGTACTTTTGCGGGAAAACGATTATATGThAAGT 
as 
bt 	ThrValProValPheAanProllisTrpLysThrProSerpheproAsnlleaisLeufijs - 
C: - 
CCAAGATATTATCAAAAAATGTGAACAGTTTGTAGGGCCGCTCACAGTCAATGAGAAAAG 












781 ---------+---------+---------+---------+---------+--------- + 840 
CCTATTCCCATAATTTGGAATAATAGGTCTTGTAGATCAATTAGTAATGAAGGTTTGATC 
a: 
bs 	AspLysGlylleLysProTyrTyrProcluflisLeuValAsnllisTyrPheclnThrArg - 
C: 
ACACTATTTACACACTCTATGGAACCCGCCTGTTTTATATAAGAGAGTATCAACACATAG 
841 ---------+---------+---------+---------+---------+--------- + 900 
TGTGATAAATGTGTGAGATACCTTCCCCCCACAAAATATATTcTcTcATACGTGTATc 
a: 
b: 	HisTyrLeuRisThrLeuTrpLysAlaclyvalLeuTyrLysArgvalserThra laSer - 
C: 
CGCCTCATTTTGTGGGTCACCATATTCTTGGGAACAAGAGCTACAGCATGGGGCAGAATC 




C: 	 preS 1 :MetGlyGlnAsnLeu - 
TTTCCACCACCAATCCTCTGGGATTCTTTCCCGACCACCAGTTGGATCCAGCCTTCAGAG 
961 ---------+---------+---------+---------+---------+---------+ 1020 
AAAGGTGGTCG1rACGAGACCCTAGAGGGCTCGTGGTCAACCTACGTGGTC 
as 
bt 	PheHisGlnGlnSerSerGlyI leLeuSerArgProProValclyserserLeuclnser - 
c: SerThrSersnProLeuG1yPhePheProAspsisc1nLeupproA1aphega - 
CAGACG CA 
1021 ---------+---------+---------+---------+---------+---------+ 1080 
GTTTGTGGTTGTTAGGTCTAACCCTGAAGTTAGGGTTGTTCCTGTGGACCGGTCTGCGGT 
as 
b: 	LysRisG1nG1nSerArgLeuG1yLeuc1nserc1nc1nc1yHjsLeuaJggc1n - 
C: AsnThrAsnAanProAapTrpAspPheAnproAsnLysAspThrTrppropA1n - 
275- 
ACAAGGTAGAGCTGGAGCATTCGGCCTAGGGTTCACCCCACCGCCGGACCCTTTTGG 
1081 	-+ -+- -+ -+ -+ -+1140 
TGTTCCATCCTCGACCTCGTAAGCCCGATCCCAAGTGGGGTGGCGTGCCTCCGGAAAACC 
a: 
GlnGlyArgSerTrpSerl leArgAlaArgValllisProThrAlaArgArgpropheGly - 
C: 	 LysValGlyAlaGlyAlaPheGlyLeuGlyPheThrProProHiaGlyGlyLeuLeuGly - 
GGTGGAGCCCTCACGCTCAGGCCATAATGCAAACCTTGCCAGCAAATCCGCCTCCTGCCT 
1141 ---------+---------+---------+---------+---------+---------+ 1200 
CCACCTCGGGAGTCCGAGTCCCGTATTACGTTTGGAACGGTCGTTAGGCGGAGGACGA 
a: 
bs 	ValGluProSerGlySerGlyllisAsnAlaAsnLeuAlaSerLysSerAlaserCysLeu - 





bt 	TyrGlnSerProValArgThrAlaAlaTyrProAlaValSerThrSerGluAsnHisSer - 
CS ThrAsnArgGlnSerGlyArgGlnProThrProLeuSerProProLeuArgmrThrllis - 
ATCCTCAGGCCATGCACTGGAACTCCACAACCTTCCACCAACTCTGCAAGATCCCAGAG 
1261 ---------+---------+---------+---------+---------+---------+ 1320 
TAGGAGTCCGGTACGTCACCTTGAGGTGTTGCAAGGTGGTTTGAGACGTTCTAGGGTCTC 
a: 
bs 	SerSerGlyHisAlaValGluLeuilisAsnLeuproProAsnSerAlaArgSerclnSer - 
Ct ProGlnAlaMetGlnTrpAsnSerThrThrPheHisGlnThrLeuGlnAspproArgval - 
proS2 : 
TGAGAGGCCTGTATTTCCCTGCTCGTCCCTCCAGTTCAGGGACAGTAAACCCTGTTCCGA 






1381 ---------+---------+---------+---------+---------+---------+ 1440 
GATGCGGAGACGGTATAGCAGTTAGAAGACCTCCTAACCCCTGGGACCCcAcTTGTAcc 
a: 
bt 	TyrcysLeuSerHisl leValAsnLeuLeuCluAspTrpGlyProcysAlaGlullisGly - 
ThrAlaSerProl leSerSerllePheSerArg IleGlyAspProAlaLeuAsnMetGlu - 
surface: 
AGAACATCACATCACGATTCCTAGGACCCCTGCTCGTGTTACAGCCGGGGTTTTTCTTGT 
1441 ---------+---------+---------+---------+---------+---------+ 1500 
TCTTGTAGTGTAGTCCTAAGGATCCTGCGGACGAGCACAATGTCCGCCCCAAAAAGAACA 
a: 
bs 	GluHisHisI leArgI leProArgThrProAlaArgValThrclyGlyValPheLeuva]. - 
CS AsnhleThrSerGlyPheLeuGlyProLeuLeuVaiLeuGlnAiaGiyPhePheLeuLeu - 
TGACAAGAATCCTCACAATACCGCAGAGTCTAGACTCGTGGTGcCTTcTcTcC 




C: 	 ThrArglleLeuThrlleProGlnSerLeuAspSerTrpTrpThrserLeuAsnpheLeu - 
276.... 
TAGGGGAACTACCGTGTGTCTTGGCCAAAA11CGCAGTCCCCAP.TCTCCAATCACTCAC 
1561 ---------+---------+---------+---------+---------+---------+ 1620 
ATCCCCCTrGATGGCACACAGAACCGGTTTTAACCGTCACGCGTTAGAGGTTAGTCAGTG 
as 
bs 	ArgclyAsnTyrArgValSerTrpProLysPheAlaValProAsnLeuclnSerLeuThr - 
C: GlyGlyThrThrValCysLeuGlyGln.AsnSerGlnSerProlleSerAsnllisSerPro - 
CAACCTCCTGTCCTCCACTrGTCCTGGTTATCCCTGGATGTGTCTGCGGCGTTrTATCA 
1621 ---------+---------+---------+---------+---------+---------+ 1680 
GT1GGAGGACAGGAGGTTGAACACGACCAATAGCGACCTACACAGACGCCGCAA.ATAGT 
as 
b: 	A2nLeuLeuSerSerAanLeuSerTrpLeuSerLeuAspValSerAlaAlaPheTyrHis - 
cs ThrSercyaProProThrcysProGlyTyrArgTrpMetCysLeuArgArgPhellelle - 
TCTTCCTCTTCATCCTCCTGCTATGCCTCATCTTC2GTTGGTTCTTCTGGACTATCAAC 
1681 ---------+---------+---------+---------+---------+---------+ 1740 
AGAAGGAGAAGTAGGACGACGATMGGAGTAGAAGAACAACCAAGAAGACCTGATAGTTC 
as 
bz 	LeuProLeuBisProAlaAlaMetprouisLeuLeuValclySerSerGlyLeuSerArg - 






cs 	 MetLeuProValCysProLeulleProGlySerSerThrThrSerThrGlyProcysArg - 
GAACCTCCACGCTCCTGCTCAACCAATCTCTATGTATCCCTCCTGTTCCTGTACAAAAC 
1801 ---------+---------+---------+---------+---------+---------+ 1860 
CTTCGACGTCCTGACGACCAGTTCCTTAGAGATACATAGGCAGGACAACGACATGTTTTC 
as 
b s 	AsnLeullisAspSercysSerArgAsnLeuTyrValSerLeuLeuLeuLeuTyrLyaThr - 
ThrCysThrThrProAlaclnGlyl leSerMetTyrProSercysCysCysThrLyaPro - 
CTTCGATGGAAACTGCACCTGTATTCCCATCCCATCATCCTGCCCTTTCGGAAAATTCC 
1861 ---------+---------+---------+---------+---------+---------+ 1920 
GAAGCCTACCTTTGCGTGACATAAGGGTACGGTAGTAGGACCCGAAGCCTTTTAAGC 
as 
bt 	PheGlyTrpLysLeuflisLeuTyrSeraisProl lelleLeuclyPheArgLys IlePro - 
Cs SerAspGlyABnCysThrcyslleProlleProSerSerTrpAlaPheGlyLysPheLeu - 
TATGGGAGTCGGCCTCACCCCGTTTCTCTTGGCTCAGT'TTACTAGTGCCATTTGTTCAGT 
1921 ---------+---------+---------+---------+---------+---------+ 1980 
ATACCCTCACCCGGAGTCGGGCAAAGAGAACCCAGTCAAATGATCACGGTAAACAAGTCA 
as 
b: 	MetGlyValGlyLeuSerProPheLeuLeuAlaGlnPheThrSerAlallecysSerVal - 
cs TrpGluTrpAlaSerAlaArgPheSerTrpLeuSerLeuLeuValProPheValclnTrp - 
GGTTCGTAGGGCTTTCCCCCATTGTTTCGCTTTCAGTTATATGGATGATGTGGTATTGGG 
1981 ---------+---------+---------+---------+---------+---------+ 2040 
CCAAGCATCCCGAAAGGGGGTACAAACCGAAAGTCAATATACCTACTACACCATAACCC 
as 
b s 	ValArgArgAlaPheProllisCysLeuAlaPheSerTyrMetAspAspValValLeuGly - 
Cs PheVaiGlyLeuSerProl leValTrpLeuSerValI leTrpMetMetTrpTyrTrpGly - 
GGCCAAGTCTGTACAGCATCTTGAGTCCCTTTTTACCGCTGTTACCATTTTCTTTTGTC 
2041 ---------+---------+---------+---------+---------+---------+ 2100 
CCCGTTCAGACATGTCGTAGAACTCAGGGATGGCGACAATGGTTAGAAAAcAG 
as 
b s 	AlaLysSerValGlnliisLeuGluSerLeuPheThrAlaValThrAsnPheLeuLeuser - 
cs ProSerLeuTyrSerlleLeuSerProPheLeuProLeuLeuprol lePhePheCysLeu - 
27.7. 
TTTCGCCATACATT1AACCCTAACAAAACAAAAACATGGGGTTATTCTCTAAATTTCAT 
2101 ---------+--------- 4---------+---------+---------+---------+ 2160 
AAACCCGTATGTAATTTGGGATTGT1TTGTTTTTCTMCCCAATAGAGATTTAAAGTA 
as 
bt 	 LeuclylleEisLeuAsnProAsnLysThrLysArgTrpGlyTyrSerLeuAsnPhel4et - 





b s 	 GlyTyrValI leclycyaTrpGlySerLeuproG].n.AspRis I lel leHiaLyslleLys - 
Cs 
AGAATGTTTTAGAAAACTCCCTGTrCACAGGCCTATTGATTGGAA.AGTGTGTCAACGAAT 
2221 ----------+---------+---------+---------+---------+---------+ 2280 
TCTTAC)ATCTrrTGAGGGACAAGTGTCCGGATAACTAACCrrTCACACAGTTGCTTA 
as 






b * 	 ValGlyLeuLeuGlyPheAlaAlaProPheThrclnCysGlyTyrProAlaLeuMetPro - 
C: 
CTTGTATGCATGTATTCAATCTAAGCAGGCTTTCACTTTTTCGCCAACTTACAAGGCCTT 
2341 ---------+---------+---------+---------+---------+---------+ 2400 
GA?CATACGTACATAAGTTAGATTCGTCCGAAAGTGAAAAAGCGGTTGAATGTTCCGGAA 
a: 
bs 	 LeuTyrAlaCyslleGlnSerLysGlnAlaPheThrPheSerProThrTyrLysAlaPhe — 
Cs 
TCTGTGTAAACAATACCTGAACCTTTACCCCGTTGCCAGCCAACGGCCAGGTCTGTGCCA 
2401 ---------+---------+---------+---------+---------+---------+ 2460 
AGACACATTTGIWrATGGACTTGGAAATGGGGCAACGGTCCGTTGCCGGTCCAGACACGGT 
a: 
bo 	 LeuCysLysGlnTyrLeuAsnLeuTyrProValAlaArgGlnArgproclyLeucysGln - 
C: 
AGTGTTGCTGATGCAACCCCCACTGGCTGGGGCTTGGTCATGCCCCATCAGCGCATGCG 
2461 ---------+---------+---------+---------+---------+---------+ 2520 
TCACAAACGACTACGTTGGGGGTGACCGACCCCGAACCAGTACCCGGTAGTCGCGTACGC 
 
b 	 ValPheA].aAspAlaThrProThrGlyTrpclyLeuValMetGlyHisGln.ArgMetArg - 
C: 
TGGAACCTTTCTGGCTCCTCTGCCGATCCATACTGCGGTCCTAGCCGCTTGTTrTGC 
2521 ---------+---------+---------+---------+---------+---------+ 2580 
ACC1rGGAAAGACCGAGGGACGGCTACGTATGACGCCTTGAGGATCGGCGAACAAAACG 
as 
It 	 GlyThrPheLeuAlaProLeuProllellisThrAlacluLeuLeuAlakLacysphekla — 
C: 
TCGCAGCAGGTCTGGAGCAAACATTCTCGGAACTGACAACTCTGTTGTCCTCTCCCGCAA 






2641 ---------+---------+---------+---------+---------+---------+ 2700 
TATATCTAGCAAACGTACCGACGATCCGACACGACGGTTGACCTAGGACGCGCCCTGCAG 
a 	 Xi MetA1aA1aArgLeuCysCysG1nLeuAspProA1argAspVa1 
b s TyrThrSerPheProTrpLeuLeuGlycysAlaAlaAsnTrplleLeuArgGlyThrSer - 
C: 
CTTTACGTCCCGTCGGCGCTGATCCTCCCGGACCCTTCTCGGGGCCGC1CGG 






2761 ---------+---------+---------+---------+---------+--------- + 2820 
CCGGACAGCAGGAGAAGAGACCGACCCCAAGGCCGGCGGGTGCCCCGCGTGGAGAGAAAT 
a 	AlaLeuSerSerSerSerLeuProAlaValProAlaAlallisGlyAlaflisLeuSerLeu - 





as 	ArgGlyLeuProValCysAlaPheSerSerAlaGlyProCysAlaLeuArgPheThrSer - 






b: HisValAlaTrpArgProProEnd (polysneraae end) 
C: 
AGGACTCTTCGACTCTCTGCAATGTCAACGACCGACCTTGAGGCATACTTCAAAGACTGT 














as 	G1yCysArgHisLysLeuVa1CysA1aProA1aProCysAsnPhePheThrSerA1aEnd(X end) 
bt 
C: 	 pro-core: MetGlnLeuPheflisLeuCysLeulle - 
TCATCTCTTGTTCATGTCCTACTGTTCAAGCCTCCAACCTGTGCCTTGGGTGCCTTTGGG 




c: IleSerCysSercysProThrValGlnAlaSerLysLeuCysLeuGlyTrpLeuTrpGly - 
GC 
3181 -- 3182 
CG 
a: 
C: 	 - 
